drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3 values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00470 | DB00590 | 530 | 1,433 | [
"DDInter601",
"DDInter592"
] | Dronabinol | Doxazosin | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effects of smoking cannabis such as increased appetite, reduced pain, and changes in emotional and cognitive processes. Due to its evidence as an appetite stimulant and an anti-nauseant, Dronabinol is approved for use in anorexia associated with weight loss in patients with AIDS and for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments [FDA Label]. Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most abundant cannabinoids found naturally in | Doxazosin is an alpha-1 antagonist used for the treatment of benign prostatic hypertrophy (BPH) symptoms and hypertension. Other members of this drug class include [Prazosin], [Terazosin], [Tamsulosin], and [Alfuzosin]. Because of its long-lasting effects, doxazosin can be administered once a day. It is marketed by Pfizer and was initially approved by the FDA in 1990. | Moderate | 1 | [
[
[
530,
24,
1433
]
],
[
[
530,
24,
195
],
[
195,
1,
1433
]
],
[
[
530,
63,
1205
],
[
1205,
40,
1433
]
],
[
[
530,
63,
472
],
[
472,
1,
1433
]
],
[
[
530,
6,
4973
],
[
4973,
45,
1433
]
],
[
[
530,
21,
28929
],
[
28929,
60,
1433
]
],
[
[
530,
25,
593
],
[
593,
63,
1433
]
],
[
[
530,
24,
407
],
[
407,
63,
1433
]
],
[
[
530,
63,
475
],
[
475,
24,
1433
]
],
[
[
530,
1,
1614
],
[
1614,
24,
1433
]
]
] | [
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxazosin"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Terazosin"
],
[
"Terazosin",
"{u} (Compound) resembles {v} (Compound)",
"Doxazosin"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prazosin"
],
[
"Prazosin",
"{u} (Compound) resembles {v} (Compound)",
"Doxazosin"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alfuzosin"
],
[
"Alfuzosin",
"{u} (Compound) resembles {v} (Compound)",
"Doxazosin"
]
],
[
[
"Dronabinol",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Doxazosin"
]
],
[
[
"Dronabinol",
"{u} (Compound) causes {v} (Side Effect)",
"Confusional state"
],
[
"Confusional state",
"{u} (Side Effect) is caused by {v} (Compound)",
"Doxazosin"
]
],
[
[
"Dronabinol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxazosin"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxazosin"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxazosin"
]
],
[
[
"Dronabinol",
"{u} (Compound) resembles {v} (Compound)",
"Nabilone"
],
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxazosin"
]
]
] | Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Terazosin and Terazosin (Compound) resembles Doxazosin (Compound)
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Prazosin and Prazosin (Compound) resembles Doxazosin (Compound)
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Alfuzosin and Alfuzosin (Compound) resembles Doxazosin (Compound)
Dronabinol (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Doxazosin (Compound)
Dronabinol (Compound) causes Confusional state (Side Effect) and Confusional state (Side Effect) is caused by Doxazosin (Compound)
Dronabinol may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Doxazosin
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Doxazosin
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Doxazosin
Dronabinol (Compound) resembles Nabilone (Compound) and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Doxazosin |
DB00563 | DB08916 | 663 | 26 | [
"DDInter1174",
"DDInter32"
] | Methotrexate | Afatinib | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma.[A180322,L7144,L7147,L7150,L7180] Due to the toxic effects of methotrexate, it is indicated for treatment of some forms of arthritis and severe psoriasis only if first line treatment has failed or patients are intolerant of those treatments. Methotrexate was granted FDA approval on 7 December 1953. | Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label]. For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test . Gilotrif (afatinib) is the first FDA-approved oncology product from Boehringer Ingelheim . | Moderate | 1 | [
[
[
663,
24,
26
]
],
[
[
663,
63,
883
],
[
883,
40,
26
]
],
[
[
663,
6,
4973
],
[
4973,
45,
26
]
],
[
[
663,
7,
9845
],
[
9845,
46,
26
]
],
[
[
663,
18,
2186
],
[
2186,
46,
26
]
],
[
[
663,
18,
3154
],
[
3154,
57,
26
]
],
[
[
663,
7,
3222
],
[
3222,
57,
26
]
],
[
[
663,
6,
8569
],
[
8569,
57,
26
]
],
[
[
663,
21,
28809
],
[
28809,
60,
26
]
],
[
[
663,
24,
651
],
[
651,
24,
26
]
]
] | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Afatinib"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
],
[
"Gefitinib",
"{u} (Compound) resembles {v} (Compound)",
"Afatinib"
]
],
[
[
"Methotrexate",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Afatinib"
]
],
[
[
"Methotrexate",
"{u} (Compound) upregulates {v} (Gene)",
"AMDHD2"
],
[
"AMDHD2",
"{u} (Gene) is upregulated by {v} (Compound)",
"Afatinib"
]
],
[
[
"Methotrexate",
"{u} (Compound) downregulates {v} (Gene)",
"HSPA1A"
],
[
"HSPA1A",
"{u} (Gene) is upregulated by {v} (Compound)",
"Afatinib"
]
],
[
[
"Methotrexate",
"{u} (Compound) downregulates {v} (Gene)",
"SRSF2"
],
[
"SRSF2",
"{u} (Gene) is downregulated by {v} (Compound)",
"Afatinib"
]
],
[
[
"Methotrexate",
"{u} (Compound) upregulates {v} (Gene)",
"DUSP4"
],
[
"DUSP4",
"{u} (Gene) is downregulated by {v} (Compound)",
"Afatinib"
]
],
[
[
"Methotrexate",
"{u} (Compound) binds {v} (Gene)",
"TYMS"
],
[
"TYMS",
"{u} (Gene) is downregulated by {v} (Compound)",
"Afatinib"
]
],
[
[
"Methotrexate",
"{u} (Compound) causes {v} (Side Effect)",
"Diarrhoea"
],
[
"Diarrhoea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Afatinib"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Afatinib"
]
]
] | Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib (Compound) resembles Afatinib (Compound)
Methotrexate (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Afatinib (Compound)
Methotrexate (Compound) upregulates AMDHD2 (Gene) and AMDHD2 (Gene) is upregulated by Afatinib (Compound)
Methotrexate (Compound) downregulates HSPA1A (Gene) and HSPA1A (Gene) is upregulated by Afatinib (Compound)
Methotrexate (Compound) downregulates SRSF2 (Gene) and SRSF2 (Gene) is downregulated by Afatinib (Compound)
Methotrexate (Compound) upregulates DUSP4 (Gene) and DUSP4 (Gene) is downregulated by Afatinib (Compound)
Methotrexate (Compound) binds TYMS (Gene) and TYMS (Gene) is downregulated by Afatinib (Compound)
Methotrexate (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Afatinib (Compound)
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin and Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Afatinib |
DB00559 | DB08912 | 152 | 1,040 | [
"DDInter223",
"DDInter462"
] | Bosentan | Dabrafenib | Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib), in combination with Mekinist (), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene. | Moderate | 1 | [
[
[
152,
24,
1040
]
],
[
[
152,
6,
8374
],
[
8374,
45,
1040
]
],
[
[
152,
21,
28900
],
[
28900,
60,
1040
]
],
[
[
152,
62,
168
],
[
168,
23,
1040
]
],
[
[
152,
24,
478
],
[
478,
24,
1040
]
],
[
[
152,
24,
466
],
[
466,
63,
1040
]
],
[
[
152,
63,
245
],
[
245,
24,
1040
]
],
[
[
152,
25,
594
],
[
594,
24,
1040
]
],
[
[
152,
25,
760
],
[
760,
63,
1040
]
],
[
[
152,
25,
124
],
[
124,
64,
1040
]
]
] | [
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Bosentan",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Dabrafenib"
]
],
[
[
"Bosentan",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal pain"
],
[
"Abdominal pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dabrafenib"
]
],
[
[
"Bosentan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dabrafenib"
]
],
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Bosentan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bosutinib"
],
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Bosentan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Bosentan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glasdegib"
],
[
"Glasdegib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dabrafenib"
]
]
] | Bosentan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dabrafenib (Compound)
Bosentan (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Dabrafenib (Compound)
Bosentan may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Dabrafenib
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Bosentan may lead to a major life threatening interaction when taken with Bosutinib and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Bosentan may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Bosentan may lead to a major life threatening interaction when taken with Glasdegib and Glasdegib may lead to a major life threatening interaction when taken with Dabrafenib |
DB00539 | DB01268 | 11 | 1,151 | [
"DDInter1837",
"DDInter1731"
] | Toremifene | Sunitinib | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has estrogenic (agonist) activity on the cardiovascular system and on bone tissue and it has weak estrogenic effects on uterine tissue, however, it also has antiestrogenic (estrogen-antagonist) activity on breast tissue. | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3. | Major | 2 | [
[
[
11,
25,
1151
]
],
[
[
11,
6,
4973
],
[
4973,
45,
1151
]
],
[
[
11,
7,
9650
],
[
9650,
46,
1151
]
],
[
[
11,
18,
5497
],
[
5497,
57,
1151
]
],
[
[
11,
21,
29269
],
[
29269,
60,
1151
]
],
[
[
11,
23,
1247
],
[
1247,
23,
1151
]
],
[
[
11,
24,
655
],
[
655,
63,
1151
]
],
[
[
11,
25,
1148
],
[
1148,
24,
1151
]
],
[
[
11,
25,
1250
],
[
1250,
63,
1151
]
],
[
[
11,
64,
215
],
[
215,
24,
1151
]
]
] | [
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sunitinib"
]
],
[
[
"Toremifene",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Sunitinib"
]
],
[
[
"Toremifene",
"{u} (Compound) upregulates {v} (Gene)",
"HMGCS1"
],
[
"HMGCS1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Sunitinib"
]
],
[
[
"Toremifene",
"{u} (Compound) downregulates {v} (Gene)",
"TRAP1"
],
[
"TRAP1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Sunitinib"
]
],
[
[
"Toremifene",
"{u} (Compound) causes {v} (Side Effect)",
"Menopausal symptoms"
],
[
"Menopausal symptoms",
"{u} (Side Effect) is caused by {v} (Compound)",
"Sunitinib"
]
],
[
[
"Toremifene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sunitinib"
]
],
[
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
],
[
"Etravirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pazopanib"
],
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Indinavir"
],
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
]
] | Toremifene (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sunitinib (Compound)
Toremifene (Compound) upregulates HMGCS1 (Gene) and HMGCS1 (Gene) is upregulated by Sunitinib (Compound)
Toremifene (Compound) downregulates TRAP1 (Gene) and TRAP1 (Gene) is downregulated by Sunitinib (Compound)
Toremifene (Compound) causes Menopausal symptoms (Side Effect) and Menopausal symptoms (Side Effect) is caused by Sunitinib (Compound)
Toremifene may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Sunitinib
Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Etravirine and Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Toremifene may lead to a major life threatening interaction when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Toremifene may lead to a major life threatening interaction when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Toremifene may lead to a major life threatening interaction when taken with Indinavir and Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib |
DB00197 | DB15035 | 1,324 | 503 | [
"DDInter1881",
"DDInter1959"
] | Troglitazone | Zanubrutinib | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long-term survival. BTK is an enzyme that plays a role in oncogenic signalling pathways, promoting the survival and proliferation of malignant B cells. Compared to the first-generation BTK inhibitor [ibrutinib], zanubrutinib displays higher potency and selectivity for BTK with fewer off-target effects. Due to this enhanced selectivity towards BTK, zanubrutinib belongs to the second-generation BTK inhibitor drug group that also includes [acalabrutinib], which was approved by the FDA in 2017. Zanubrutinib was granted accelerated approval by the FDA in November 2019 based on clinical trial results that demonstrated an 84% overall response rate from zanubrutinib therapy in patients with MCL, which measures the proportion of patients in a trial whose tumour is entirely or partially destroyed by a drug. It is currently marketed under the trade name BRUKINSA™ and is available as oral capsules. In August 2021, the FDA granted accelerated approval to zanubrutinib for the treatment of adults with Waldenström’s macroglobulinemia. This indication is valid in the US, Europe, and Canada. In September 2021, zanubrutinib was granted another accelerated approval for the treatment of relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20-based regimen. In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended zanubrutinib be granted marketing authorization for the treatment of chronic lymphocytic leukemia. | Moderate | 1 | [
[
[
1324,
24,
503
]
],
[
[
1324,
24,
868
],
[
868,
24,
503
]
],
[
[
1324,
23,
1101
],
[
1101,
24,
503
]
],
[
[
1324,
24,
39
],
[
39,
25,
503
]
],
[
[
1324,
25,
1377
],
[
1377,
25,
503
]
],
[
[
1324,
24,
868
],
[
868,
24,
1094
],
[
1094,
24,
503
]
],
[
[
1324,
24,
1320
],
[
1320,
63,
1094
],
[
1094,
24,
503
]
],
[
[
1324,
24,
1250
],
[
1250,
25,
982
],
[
982,
24,
503
]
],
[
[
1324,
23,
1101
],
[
1101,
23,
982
],
[
982,
24,
503
]
],
[
[
1324,
25,
1377
],
[
1377,
25,
868
],
[
868,
24,
503
]
]
] | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Troglitazone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
],
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Troglitazone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metreleptin"
],
[
"Metreleptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metreleptin"
],
[
"Metreleptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
],
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Troglitazone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Troglitazone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zanubrutinib"
]
]
] | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Zanubrutinib
Troglitazone may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Zanubrutinib
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Metreleptin and Metreleptin may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Metreleptin and Metreleptin may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Troglitazone may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib |
DB01233 | DB06016 | 1,311 | 1,508 | [
"DDInter1197",
"DDInter300"
] | Metoclopramide | Cariprazine | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition to gastroesophageal reflux disease (GERD). It can also be used to prevent nausea or vomiting associated with chemotherapy or certain surgical or diagnostic procedures. One unique property of this drug is that it does not increase gastric acid secretion. It is available in the oral tablet form or in solution, and can also be administered through the intravenous route. Metoclopramide was initially approved by the FDA in 1980. | Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors. Cariprazine has been investigated in a variety of psychiatric disorders, including schizophrenia, bipolar disorders, and major depressive disorder. Cariprazine gained its first global approval in the US in September 2015 and was later approved by Health Canada in April 2022. It is currently used to treat schizophrenia, and manic or mixed episodes and depressive episodes associated with bipolar I disorder.[L41655,L40198] | Major | 2 | [
[
[
1311,
25,
1508
]
],
[
[
1311,
63,
1242
],
[
1242,
24,
1508
]
],
[
[
1311,
24,
868
],
[
868,
63,
1508
]
],
[
[
1311,
24,
649
],
[
649,
24,
1508
]
],
[
[
1311,
25,
820
],
[
820,
24,
1508
]
],
[
[
1311,
64,
999
],
[
999,
24,
1508
]
],
[
[
1311,
24,
760
],
[
760,
64,
1508
]
],
[
[
1311,
63,
475
],
[
475,
25,
1508
]
],
[
[
1311,
25,
497
],
[
497,
25,
1508
]
],
[
[
1311,
64,
593
],
[
593,
25,
1508
]
]
] | [
[
[
"Metoclopramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cariprazine"
]
],
[
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
],
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cariprazine"
]
],
[
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cariprazine"
]
],
[
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cariprazine"
]
],
[
[
"Metoclopramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cariprazine"
]
],
[
[
"Metoclopramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thiethylperazine"
],
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cariprazine"
]
],
[
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cariprazine"
]
],
[
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cariprazine"
]
],
[
[
"Metoclopramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
],
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cariprazine"
]
],
[
[
"Metoclopramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cariprazine"
]
]
] | Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Metoclopramide may lead to a major life threatening interaction when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Metoclopramide may lead to a major life threatening interaction when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat and Cobicistat may lead to a major life threatening interaction when taken with Cariprazine
Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Cariprazine
Metoclopramide may lead to a major life threatening interaction when taken with Iohexol and Iohexol may lead to a major life threatening interaction when taken with Cariprazine
Metoclopramide may lead to a major life threatening interaction when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Cariprazine |
DB01110 | DB06176 | 86 | 1,342 | [
"DDInter1209",
"DDInter1616"
] | Miconazole | Romidepsin | Miconazole is a broad-spectrum azole antifungal with some activity against Gram-positive bacteria as well. It is widely used to treat mucosal yeast infections, including both oral and vaginal infections; although intravenous miconazole is no longer available, a wide variety of suppositories, creams, gels, and tablet-based products are available.[L14021, L14024, L14027, L14033, L14396] Miconazole is thought to act primarily through the inhibition of fungal CYP450 14α-lanosterol demethylase activity.[A203636, A203639] Miconazole was first synthesized in 1969 and first granted FDA approval on January 8, 1974, for sale by INSIGHT Pharmaceuticals as a topical cream.[A214523, L14021] It is currently available as a variety of prescription and over the counter products. Despite having been in clinical use for an extended period, resistance to m | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Moderate | 1 | [
[
[
86,
24,
1342
]
],
[
[
86,
24,
336
],
[
336,
24,
1342
]
],
[
[
86,
24,
1491
],
[
1491,
63,
1342
]
],
[
[
86,
63,
1236
],
[
1236,
24,
1342
]
],
[
[
86,
64,
1557
],
[
1557,
24,
1342
]
],
[
[
86,
62,
1091
],
[
1091,
24,
1342
]
],
[
[
86,
25,
1670
],
[
1670,
63,
1342
]
],
[
[
86,
23,
807
],
[
807,
63,
1342
]
],
[
[
86,
24,
1493
],
[
1493,
25,
1342
]
],
[
[
86,
63,
839
],
[
839,
25,
1342
]
]
] | [
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nifedipine"
],
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
],
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Miconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Astemizole"
],
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Miconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amprenavir"
],
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Miconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eliglustat"
],
[
"Eliglustat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Miconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ulipristal"
],
[
"Ulipristal",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Halofantrine"
],
[
"Halofantrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Romidepsin"
]
],
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Grepafloxacin"
],
[
"Grepafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Romidepsin"
]
]
] | Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine and Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Miconazole may lead to a major life threatening interaction when taken with Astemizole and Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Miconazole may cause a minor interaction that can limit clinical effects when taken with Amprenavir and Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Miconazole may lead to a major life threatening interaction when taken with Eliglustat and Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Miconazole may cause a minor interaction that can limit clinical effects when taken with Ulipristal and Ulipristal may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Halofantrine and Halofantrine may lead to a major life threatening interaction when taken with Romidepsin
Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Grepafloxacin and Grepafloxacin may lead to a major life threatening interaction when taken with Romidepsin |
DB00674 | DB09488 | 1,516 | 103 | [
"DDInter802",
"DDInter23"
] | Galantamine | Acrivastine | Galantamine is a tertiary alkaloid and reversible, competitive inhibitor of the acetylcholinesterase (AChE) enzyme, which is a widely studied therapeutic target used in the treatment of Alzheimer's disease. First characterized in the early 1950s, galantamine is a tertiary alkaloid that was extracted from botanical sources, such as _Galanthus nivalis_. Galantamine was first studied in paralytic and neuropathic conditions, such as myopathies and postpolio paralytic conditions, and for reversal of neuromuscular blockade.[A182993,A201968] Following the discovery of its AChE-inhibiting properties, the cognitive effects of galantamine were studied in a wide variety of psychiatric disorders such as mild cognitive impairment, cognitive impairment in schizophrenia and bipolar disorder, and autism; however, re-development of the drug for Alzheimer’s disease did not commence until the early 1990s due to difficulties in extraction and | Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever. As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension, edema, bronchoconstriction, and tachycardia. Acrivastine is currently available in combination with pseudoephedrine as the FDA-approved product Semprex-D. | Moderate | 1 | [
[
[
1516,
24,
103
]
],
[
[
1516,
63,
85
],
[
85,
24,
103
]
],
[
[
1516,
24,
1264
],
[
1264,
24,
103
]
],
[
[
1516,
63,
85
],
[
85,
24,
1405
],
[
1405,
24,
103
]
],
[
[
1516,
24,
1264
],
[
1264,
64,
1405
],
[
1405,
24,
103
]
],
[
[
1516,
24,
1123
],
[
1123,
24,
1405
],
[
1405,
24,
103
]
],
[
[
1516,
24,
537
],
[
537,
63,
1405
],
[
1405,
24,
103
]
],
[
[
1516,
24,
830
],
[
830,
23,
771
],
[
771,
62,
103
]
],
[
[
1516,
63,
701
],
[
701,
23,
771
],
[
771,
62,
103
]
],
[
[
1516,
63,
1594
],
[
1594,
35,
1405
],
[
1405,
24,
103
]
]
] | [
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
]
],
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atropine"
],
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
]
],
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
]
],
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atropine"
],
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclobenzaprine"
],
[
"Cyclobenzaprine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
]
],
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cyclobenzaprine"
],
[
"Cyclobenzaprine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
]
],
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propantheline"
],
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclobenzaprine"
],
[
"Cyclobenzaprine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
]
],
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclobenzaprine"
],
[
"Cyclobenzaprine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
]
],
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
],
[
"Phenindamine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
],
[
"Hyaluronidase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Acrivastine"
]
],
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
],
[
"Hyaluronidase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Acrivastine"
]
],
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclobenzaprine"
],
[
"Cyclobenzaprine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
]
]
] | Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may cause a moderate interaction that could exacerbate diseases when taken with Cyclobenzaprine and Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may lead to a major life threatening interaction when taken with Cyclobenzaprine and Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Propantheline and Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Cyclobenzaprine and Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Cyclobenzaprine and Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine and Phenindamine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase and Hyaluronidase may cause a minor interaction that can limit clinical effects when taken with Acrivastine
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase and Hyaluronidase may cause a minor interaction that can limit clinical effects when taken with Acrivastine
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine (Compound) resembles Cyclobenzaprine (Compound) and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Cyclobenzaprine and Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine |
DB00712 | DB06605 | 1,274 | 1,409 | [
"DDInter763",
"DDInter108"
] | Flurbiprofen | Apixaban | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically prior to ocular surgery to prevent or reduce intraoperative miosis. Flurbiprofen is structurally and pharmacologically related to fenoprofen, ibuprofen, and ketoprofen. | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012. | Major | 2 | [
[
[
1274,
25,
1409
]
],
[
[
1274,
6,
6017
],
[
6017,
45,
1409
]
],
[
[
1274,
21,
29666
],
[
29666,
60,
1409
]
],
[
[
1274,
23,
297
],
[
297,
62,
1409
]
],
[
[
1274,
63,
109
],
[
109,
24,
1409
]
],
[
[
1274,
25,
990
],
[
990,
63,
1409
]
],
[
[
1274,
24,
655
],
[
655,
24,
1409
]
],
[
[
1274,
24,
1040
],
[
1040,
63,
1409
]
],
[
[
1274,
25,
235
],
[
235,
64,
1409
]
],
[
[
1274,
24,
1047
],
[
1047,
25,
1409
]
]
] | [
[
[
"Flurbiprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
]
],
[
[
"Flurbiprofen",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Apixaban"
]
],
[
[
"Flurbiprofen",
"{u} (Compound) causes {v} (Side Effect)",
"Melaena"
],
[
"Melaena",
"{u} (Side Effect) is caused by {v} (Compound)",
"Apixaban"
]
],
[
[
"Flurbiprofen",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
],
[
"Clove",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Apixaban"
]
],
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
]
],
[
[
"Flurbiprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
],
[
"Lomitapide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
]
],
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
],
[
"Etravirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
]
],
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
]
],
[
[
"Flurbiprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
],
[
"Desirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
]
],
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
],
[
"Trastuzumab emtansine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
]
]
] | Flurbiprofen (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Apixaban (Compound)
Flurbiprofen (Compound) causes Melaena (Side Effect) and Melaena (Side Effect) is caused by Apixaban (Compound)
Flurbiprofen may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Apixaban
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Apixaban
Flurbiprofen may lead to a major life threatening interaction when taken with Lomitapide and Lomitapide may cause a moderate interaction that could exacerbate diseases when taken with Apixaban
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Etravirine and Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Apixaban
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Apixaban
Flurbiprofen may lead to a major life threatening interaction when taken with Desirudin and Desirudin may lead to a major life threatening interaction when taken with Apixaban
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine and Trastuzumab emtansine may lead to a major life threatening interaction when taken with Apixaban |
DB00418 | DB12010 | 536 | 214 | [
"DDInter1650",
"DDInter785"
] | Secobarbital | Fostamatinib | Secobarbital (marketed by Eli Lilly and Company under the brand names Seconal and Tuinal) is a barbiturate derivative drug with anaesthetic, anticonvulsant, sedative and hypnotic properties. It is commonly known as quinalbarbitone in the United Kingdom. | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK kinase.[A235008, A235013, A235018] | Moderate | 1 | [
[
[
536,
24,
214
]
],
[
[
536,
24,
976
],
[
976,
24,
214
]
],
[
[
536,
63,
79
],
[
79,
24,
214
]
],
[
[
536,
40,
1023
],
[
1023,
24,
214
]
],
[
[
536,
25,
126
],
[
126,
24,
214
]
],
[
[
536,
24,
159
],
[
159,
63,
214
]
],
[
[
536,
62,
168
],
[
168,
24,
214
]
],
[
[
536,
23,
752
],
[
752,
24,
214
]
],
[
[
536,
64,
475
],
[
475,
24,
214
]
],
[
[
536,
24,
129
],
[
129,
25,
214
]
]
] | [
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Secobarbital",
"{u} (Compound) resembles {v} (Compound)",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Secobarbital",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Secobarbital",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Secobarbital",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Secobarbital",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostamatinib"
]
]
] | Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Secobarbital (Compound) resembles Pentobarbital (Compound) and Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Secobarbital may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Secobarbital may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Secobarbital may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Secobarbital may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Fostamatinib |
DB01004 | DB01097 | 563 | 1,377 | [
"DDInter806",
"DDInter1033"
] | Ganciclovir | Leflunomide | An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections. | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Moderate | 1 | [
[
[
563,
24,
1377
]
],
[
[
563,
18,
18226
],
[
18226,
57,
1377
]
],
[
[
563,
21,
29062
],
[
29062,
60,
1377
]
],
[
[
563,
63,
597
],
[
597,
24,
1377
]
],
[
[
563,
1,
248
],
[
248,
63,
1377
]
],
[
[
563,
24,
1491
],
[
1491,
64,
1377
]
],
[
[
563,
63,
1001
],
[
1001,
25,
1377
]
],
[
[
563,
24,
1307
],
[
1307,
25,
1377
]
],
[
[
563,
25,
908
],
[
908,
64,
1377
]
],
[
[
563,
64,
1057
],
[
1057,
25,
1377
]
]
] | [
[
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Leflunomide"
]
],
[
[
"Ganciclovir",
"{u} (Compound) downregulates {v} (Gene)",
"GDF15"
],
[
"GDF15",
"{u} (Gene) is downregulated by {v} (Compound)",
"Leflunomide"
]
],
[
[
"Ganciclovir",
"{u} (Compound) causes {v} (Side Effect)",
"Neutropenia"
],
[
"Neutropenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Leflunomide"
]
],
[
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Leflunomide"
]
],
[
[
"Ganciclovir",
"{u} (Compound) resembles {v} (Compound)",
"Valganciclovir"
],
[
"Valganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Leflunomide"
]
],
[
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
],
[
"Midostaurin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mechlorethamine"
],
[
"Mechlorethamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Melphalan"
],
[
"Melphalan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Ganciclovir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
],
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Ganciclovir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
]
] | Ganciclovir (Compound) downregulates GDF15 (Gene) and GDF15 (Gene) is downregulated by Leflunomide (Compound)
Ganciclovir (Compound) causes Neutropenia (Side Effect) and Neutropenia (Side Effect) is caused by Leflunomide (Compound)
Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide
Ganciclovir (Compound) resembles Valganciclovir (Compound) and Val
Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may lead to a major life threatening interaction when taken with Leflunomide
Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Mechlorethamine and Mechlorethamine may lead to a major life threatening interaction when taken with Leflunomide
Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Melphalan and Melphalan may lead to a major life threatening interaction when taken with Leflunomide
Ganciclovir may lead to a major life threatening interaction when taken with Golimumab and Golimumab may lead to a major life threatening interaction when taken with Leflunomide
Ganciclovir may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Leflunomide |
DB00197 | DB00281 | 1,324 | 608 | [
"DDInter1881",
"DDInter1066"
] | Troglitazone | Lidocaine | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication . In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anesthesia for a large variety of surgical procedures [F4349, L5930, L5948]. It ultimately elicits its numbing activity by blocking sodium channels so that the neurons of local tissues that have the medication applied on are transiently incapable of signaling the brain regarding sensations [F4349, L5930, L5948]. In doing so, however, it can block or decrease muscle contractile, resulting in effects like vasodilation, hypotension, and irregular heart rate, among others [F4349, L5930, L5948]. As a result, lidocaine is also considered a class Ib anti-arrhythmic agent [L5930, L5948, F4468]. Nevertheless, lidocaine's local anesthetic action sees its use in many medical situations or circumstances that may benefit from its action, including the treatment of premature ejaculation . Regardless, lidocaine is currently available as a relatively non-expensive generic medication that is written for in millions of prescriptions internationally on a yearly basis. It is even included in the World Health Organization's List of Essential Medicines . | Minor | 0 | [
[
[
1324,
23,
608
]
],
[
[
1324,
23,
1101
],
[
1101,
62,
608
]
],
[
[
1324,
24,
1598
],
[
1598,
62,
608
]
],
[
[
1324,
25,
1510
],
[
1510,
62,
608
]
],
[
[
1324,
24,
362
],
[
362,
23,
608
]
],
[
[
1324,
24,
215
],
[
215,
24,
608
]
],
[
[
1324,
24,
875
],
[
875,
63,
608
]
],
[
[
1324,
63,
966
],
[
966,
24,
608
]
],
[
[
1324,
24,
1091
],
[
1091,
64,
608
]
],
[
[
1324,
23,
228
],
[
228,
25,
608
]
]
] | [
[
[
"Troglitazone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
]
],
[
[
"Troglitazone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tazemetostat"
],
[
"Tazemetostat",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
]
],
[
[
"Troglitazone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indinavir"
],
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
],
[
"Fosaprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Octreotide"
],
[
"Octreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amprenavir"
],
[
"Amprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lidocaine"
]
],
[
[
"Troglitazone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dofetilide"
],
[
"Dofetilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lidocaine"
]
]
] | Troglitazone may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lidocaine
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat and Tazemetostat may cause a minor interaction that can limit clinical effects when taken with Lidocaine
Troglitazone may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a minor interaction that can limit clinical effects when taken with Lidocaine
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin may cause a minor interaction that can limit clinical effects when taken with Lidocaine
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Indinavir and Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Fosaprepitant and Fosaprepitant may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Octreotide and Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Amprenavir and Amprenavir may lead to a major life threatening interaction when taken with Lidocaine
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Dofetilide and Dofetilide may lead to a major life threatening interaction when taken with Lidocaine |
DB00009 | DB01175 | 1,271 | 318 | [
"DDInter56",
"DDInter672"
] | Alteplase | Escitalopram | Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. In the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplase and fibrin.[A252330,L43125] Alteplase is a purified glycoprotein of 527 amino acids expressed in Chinese hamster ovary (CHO) cells.[A252345,L43125] It was first approved by the FDA in 1987 for the management of thromboembolic disease, including acute myocardial infarction (AMI). The use of alteplase to manage AMI has decreased thanks to the availability of safer treatments such as angioplasty and stenting. However, its use for the treatment of acute ischem | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer.[A39738,A185819] Amongst SSRIs, escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in this class. Escitalopram also differentiates itself from other SSRIs via allosteric action on its target - this may be the mechanism responsible for its observed superior efficacy and faster onset compared to other SSRIs.[A185825,A185726,A185822] | Moderate | 1 | [
[
[
1271,
24,
318
]
],
[
[
1271,
24,
1230
],
[
1230,
1,
318
]
],
[
[
1271,
25,
834
],
[
834,
24,
318
]
],
[
[
1271,
24,
714
],
[
714,
24,
318
]
],
[
[
1271,
25,
1564
],
[
1564,
63,
318
]
],
[
[
1271,
24,
885
],
[
885,
63,
318
]
],
[
[
1271,
64,
1578
],
[
1578,
24,
318
]
],
[
[
1271,
24,
1039
],
[
1039,
64,
318
]
],
[
[
1271,
25,
39
],
[
39,
64,
318
]
],
[
[
1271,
24,
222
],
[
222,
25,
318
]
]
] | [
[
[
"Alteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
]
],
[
[
"Alteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Citalopram"
],
[
"Citalopram",
"{u} (Compound) resembles {v} (Compound)",
"Escitalopram"
]
],
[
[
"Alteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Drotrecogin alfa"
],
[
"Drotrecogin alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
]
],
[
[
"Alteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
],
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
]
],
[
[
"Alteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Defibrotide"
],
[
"Defibrotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
]
],
[
[
"Alteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
]
],
[
[
"Alteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
]
],
[
[
"Alteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexfenfluramine"
],
[
"Dexfenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Escitalopram"
]
],
[
[
"Alteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
],
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Escitalopram"
]
],
[
[
"Alteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Escitalopram"
]
]
] | Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram (Compound) resembles Escitalopram (Compound)
Alteplase may lead to a major life threatening interaction when taken with Drotrecogin alfa and Drotrecogin alfa may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram
Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram
Alteplase may lead to a major life threatening interaction when taken with Defibrotide and Defibrotide may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram
Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram
Alteplase may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram
Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfluramine may lead to a major life threatening interaction when taken with Escitalopram
Alteplase may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Escitalopram
Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may lead to a major life threatening interaction when taken with Escitalopram |
DB00204 | DB00860 | 228 | 891 | [
"DDInter580",
"DDInter1513"
] | Dofetilide | Prednisolone | Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter. | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Minor | 0 | [
[
[
228,
23,
891
]
],
[
[
228,
25,
167
],
[
167,
1,
891
]
],
[
[
228,
23,
1220
],
[
1220,
1,
891
]
],
[
[
228,
6,
8374
],
[
8374,
45,
891
]
],
[
[
228,
21,
29196
],
[
29196,
60,
891
]
],
[
[
228,
25,
1674
],
[
1674,
23,
891
]
],
[
[
228,
24,
455
],
[
455,
62,
891
]
],
[
[
228,
25,
1148
],
[
1148,
62,
891
]
],
[
[
228,
24,
384
],
[
384,
63,
891
]
],
[
[
228,
25,
392
],
[
392,
63,
891
]
]
] | [
[
[
"Dofetilide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Prednisolone"
]
],
[
[
"Dofetilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisolone"
]
],
[
[
"Dofetilide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisolone"
]
],
[
[
"Dofetilide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Prednisolone"
]
],
[
[
"Dofetilide",
"{u} (Compound) causes {v} (Side Effect)",
"Paraesthesia"
],
[
"Paraesthesia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Prednisolone"
]
],
[
[
"Dofetilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Orciprenaline"
],
[
"Orciprenaline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Prednisolone"
]
],
[
[
"Dofetilide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
[
"Salmeterol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Prednisolone"
]
],
[
[
"Dofetilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Prednisolone"
]
],
[
[
"Dofetilide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
]
],
[
[
"Dofetilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
]
]
] | Dofetilide may lead to a major life threatening interaction when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Prednisolone (Compound)
Dofetilide may cause a minor interaction that can limit clinical effects when taken with Dexamethasone and Dexamethasone (Compound) resembles Prednisolone (Compound)
Dofetilide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Prednisolone (Compound)
Dofetilide (Compound) causes Paraesthesia (Side Effect) and Paraesthesia (Side Effect) is caused by Prednisolone (Compound)
Dofetilide may lead to a major life threatening interaction when taken with Orciprenaline and Orciprenaline may cause a minor interaction that can limit clinical effects when taken with Prednisolone
Dofetilide may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a minor interaction that can limit clinical effects when taken with Prednisolone
Dofetilide may lead to a major life threatening interaction when taken with Isoprenaline and Isoprenaline may cause a minor interaction that can limit clinical effects when taken with Prednisolone
Dofetilide may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone
Dofetilide may lead to a major life threatening interaction when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone |
DB00749 | DB01222 | 59 | 617 | [
"DDInter699",
"DDInter246"
] | Etodolac | Budesonide | Etodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product with [formoterol]. | Moderate | 1 | [
[
[
59,
24,
617
]
],
[
[
59,
63,
251
],
[
251,
1,
617
]
],
[
[
59,
24,
1220
],
[
1220,
1,
617
]
],
[
[
59,
7,
3727
],
[
3727,
46,
617
]
],
[
[
59,
21,
28719
],
[
28719,
60,
617
]
],
[
[
59,
24,
578
],
[
578,
63,
617
]
],
[
[
59,
63,
1560
],
[
1560,
24,
617
]
],
[
[
59,
25,
4
],
[
4,
63,
617
]
],
[
[
59,
64,
126
],
[
126,
24,
617
]
],
[
[
59,
24,
848
],
[
848,
24,
617
]
]
] | [
[
[
"Etodolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
]
],
[
[
"Etodolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
],
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Budesonide"
]
],
[
[
"Etodolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Budesonide"
]
],
[
[
"Etodolac",
"{u} (Compound) upregulates {v} (Gene)",
"MAL"
],
[
"MAL",
"{u} (Gene) is upregulated by {v} (Compound)",
"Budesonide"
]
],
[
[
"Etodolac",
"{u} (Compound) causes {v} (Side Effect)",
"Pain"
],
[
"Pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Budesonide"
]
],
[
[
"Etodolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
]
],
[
[
"Etodolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
],
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
]
],
[
[
"Etodolac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
]
],
[
[
"Etodolac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
]
],
[
[
"Etodolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
]
]
] | Etodolac may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Budesonide (Compound)
Etodolac may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Budesonide (Compound)
Etodolac (Compound) upregulates MAL (Gene) and MAL (Gene) is upregulated by Budesonide (Compound)
Etodolac (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Budesonide (Compound)
Etodolac may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Budesonide
Etodolac may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Budesonide
Etodolac may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Budesonide
Etodolac may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Budesonide
Etodolac may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Budesonide |
DB00860 | DB10315 | 891 | 1,137 | [
"DDInter1513",
"DDInter1127"
] | Prednisolone | Measles virus vaccine live attenuated | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Measles virus vaccine live attenuated is a live virus vaccine for simultaneous vaccination against measles, which is a common childhood disease. The vaccine is prepared from the attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture. | Major | 2 | [
[
[
891,
25,
1137
]
],
[
[
891,
1,
617
],
[
617,
24,
1137
]
],
[
[
891,
64,
581
],
[
581,
25,
1137
]
],
[
[
891,
24,
384
],
[
384,
25,
1137
]
],
[
[
891,
63,
1101
],
[
1101,
25,
1137
]
],
[
[
891,
40,
1573
],
[
1573,
25,
1137
]
],
[
[
891,
1,
1486
],
[
1486,
25,
1137
]
],
[
[
891,
25,
676
],
[
676,
64,
1137
]
],
[
[
891,
25,
375
],
[
375,
25,
1137
]
],
[
[
891,
24,
1316
],
[
1316,
64,
1137
]
]
] | [
[
[
"Prednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Measles virus vaccine live attenuated"
]
],
[
[
"Prednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Budesonide"
],
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Measles virus vaccine live attenuated"
]
],
[
[
"Prednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Measles virus vaccine live attenuated"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Measles virus vaccine live attenuated"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Measles virus vaccine live attenuated"
]
],
[
[
"Prednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisone"
],
[
"Prednisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Measles virus vaccine live attenuated"
]
],
[
[
"Prednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Measles virus vaccine live attenuated"
]
],
[
[
"Prednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Measles virus vaccine live attenuated"
]
],
[
[
"Prednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Measles virus vaccine live attenuated"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Durvalumab"
],
[
"Durvalumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Measles virus vaccine live attenuated"
]
]
] | Prednisolone (Compound) resembles Budesonide (Compound) and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Measles virus vaccine live attenuated
Prednisolone may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Prednisolone (Compound) resembles Prednisone (Compound) and Prednisone may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Prednisolone (Compound) resembles Methylprednisolone (Compound) and Methyl
Prednisolone may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Prednisolone may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Durvalumab and Durvalumab may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated |
DB01105 | DB01238 | 222 | 673 | [
"DDInter1665",
"DDInter118"
] | Sibutramine | Aripiprazole | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled substance in the United States. In October 2010, Sibutramine was withdrawn from Canadian and U.S. markets due to concerns that the drug increases the risk of heart attack and stroke in patients with a history of heart disease. | Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects through agonism of dopaminergic and 5-HT1A receptors and antagonism of alpha-adrenergic and 5-HT2A receptors.[L45859,A4393] Aripiprazole was given FDA approval on November 15, 2002. | Moderate | 1 | [
[
[
222,
24,
673
]
],
[
[
222,
25,
851
],
[
851,
1,
673
]
],
[
[
222,
64,
827
],
[
827,
40,
673
]
],
[
[
222,
63,
1630
],
[
1630,
1,
673
]
],
[
[
222,
6,
8374
],
[
8374,
45,
673
]
],
[
[
222,
21,
28827
],
[
28827,
60,
673
]
],
[
[
222,
62,
600
],
[
600,
24,
673
]
],
[
[
222,
25,
1039
],
[
1039,
24,
673
]
],
[
[
222,
24,
537
],
[
537,
24,
673
]
],
[
[
222,
24,
649
],
[
649,
63,
673
]
]
] | [
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aripiprazole"
]
],
[
[
"Sibutramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nefazodone"
],
[
"Nefazodone",
"{u} (Compound) resembles {v} (Compound)",
"Aripiprazole"
]
],
[
[
"Sibutramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trazodone"
],
[
"Trazodone",
"{u} (Compound) resembles {v} (Compound)",
"Aripiprazole"
]
],
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perphenazine"
],
[
"Perphenazine",
"{u} (Compound) resembles {v} (Compound)",
"Aripiprazole"
]
],
[
[
"Sibutramine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Aripiprazole"
]
],
[
[
"Sibutramine",
"{u} (Compound) causes {v} (Side Effect)",
"Orthostatic hypotension"
],
[
"Orthostatic hypotension",
"{u} (Side Effect) is caused by {v} (Compound)",
"Aripiprazole"
]
],
[
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aripiprazole"
]
],
[
[
"Sibutramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexfenfluramine"
],
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aripiprazole"
]
],
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aripiprazole"
]
],
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aripiprazole"
]
]
] | Sibutramine may lead to a major life threatening interaction when taken with Nefazodone and Nefazodone (Compound) resembles Aripiprazole (Compound)
Sibutramine may lead to a major life threatening interaction when taken with Trazodone and Trazodone (Compound) resembles Aripiprazole (Compound)
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine and Perphenazine (Compound) resembles Aripiprazole (Compound)
Sibutramine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Aripiprazole (Compound)
Sibutramine (Compound) causes Orthostatic hypotension (Side Effect) and Orthostatic hypotension (Side Effect) is caused by Aripiprazole (Compound)
Sibutramine may cause a minor interaction that can limit clinical effects when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Aripiprazole
Sibutramine may lead to a major life threatening interaction when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Aripiprazole
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Aripiprazole
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Aripiprazole |
DB00586 | DB01172 | 1,512 | 416 | [
"DDInter537",
"DDInter1004"
] | Diclofenac | Kanamycin | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first line therapy for acute and chronic pain and inflammation from a variety of causes. Diclofenac was the product of rational drug design based on the structures of [phenylbutazone], [mefenamic acid], and [indomethacin]. The addition of two chlorine groups in the ortho position of the phenyl ring locks the ring in maximal torsion which appears to be related to increased potency. It is often used in combination with [misoprostol] to prevent NSAID-induced gastric ulcers. Diclofenac was first approved by the | Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate. | Moderate | 1 | [
[
[
1512,
24,
416
]
],
[
[
1512,
6,
7720
],
[
7720,
46,
416
]
],
[
[
1512,
18,
2801
],
[
2801,
57,
416
]
],
[
[
1512,
21,
29196
],
[
29196,
60,
416
]
],
[
[
1512,
63,
1252
],
[
1252,
23,
416
]
],
[
[
1512,
24,
699
],
[
699,
62,
416
]
],
[
[
1512,
63,
831
],
[
831,
24,
416
]
],
[
[
1512,
24,
712
],
[
712,
63,
416
]
],
[
[
1512,
24,
59
],
[
59,
24,
416
]
],
[
[
1512,
64,
663
],
[
663,
24,
416
]
]
] | [
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kanamycin"
]
],
[
[
"Diclofenac",
"{u} (Compound) binds {v} (Gene)",
"PTGS2"
],
[
"PTGS2",
"{u} (Gene) is upregulated by {v} (Compound)",
"Kanamycin"
]
],
[
[
"Diclofenac",
"{u} (Compound) downregulates {v} (Gene)",
"PUF60"
],
[
"PUF60",
"{u} (Gene) is downregulated by {v} (Compound)",
"Kanamycin"
]
],
[
[
"Diclofenac",
"{u} (Compound) causes {v} (Side Effect)",
"Paraesthesia"
],
[
"Paraesthesia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Kanamycin"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
[
"Digoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Kanamycin"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nadolol"
],
[
"Nadolol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Kanamycin"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indomethacin"
],
[
"Indomethacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kanamycin"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olsalazine"
],
[
"Olsalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kanamycin"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etodolac"
],
[
"Etodolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kanamycin"
]
],
[
[
"Diclofenac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kanamycin"
]
]
] | Diclofenac (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Kanamycin (Compound)
Diclofenac (Compound) downregulates PUF60 (Gene) and PUF60 (Gene) is downregulated by Kanamycin (Compound)
Diclofenac (Compound) causes Paraesthesia (Side Effect) and Paraesthesia (Side Effect) is caused by Kanamycin (Compound)
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Kanamycin
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Nadolol and Nadolol may cause a minor interaction that can limit clinical effects when taken with Kanamycin
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin and Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Olsalazine and Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Etodolac and Etodolac may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin
Diclofenac may lead to a major life threatening interaction when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin |
DB00889 | DB12825 | 1,133 | 1,375 | [
"DDInter840",
"DDInter1032"
] | Granisetron | Lefamulin | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. | Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August 2019. This drug is the first semi-synthetic pleuromutilin that has been designed for systemic administration. Lefamulin features a novel mechanism of action that shows benefit against resistant bacteria that cause pneumonia. The chemical structure of lefamulin contains a tricyclic mutilin core that is necessary for some of its antimicrobial activity. | Major | 2 | [
[
[
1133,
25,
1375
]
],
[
[
1133,
23,
112
],
[
112,
23,
1375
]
],
[
[
1133,
24,
159
],
[
159,
63,
1375
]
],
[
[
1133,
63,
1101
],
[
1101,
24,
1375
]
],
[
[
1133,
24,
659
],
[
659,
24,
1375
]
],
[
[
1133,
64,
506
],
[
506,
24,
1375
]
],
[
[
1133,
25,
222
],
[
222,
24,
1375
]
],
[
[
1133,
25,
1069
],
[
1069,
25,
1375
]
],
[
[
1133,
64,
1166
],
[
1166,
25,
1375
]
],
[
[
1133,
24,
609
],
[
609,
25,
1375
]
]
] | [
[
[
"Granisetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lefamulin"
]
],
[
[
"Granisetron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lefamulin"
]
],
[
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Granisetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dextromethorphan"
],
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Granisetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Granisetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
],
[
"Vandetanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lefamulin"
]
],
[
[
"Granisetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolasetron"
],
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lefamulin"
]
],
[
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lefamulin"
]
]
] | Granisetron may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lefamulin
Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Granisetron may lead to a major life threatening interaction when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Granisetron may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Granisetron may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may lead to a major life threatening interaction when taken with Lefamulin
Granisetron may lead to a major life threatening interaction when taken with Dolasetron and Dolasetron may lead to a major life threatening interaction when taken with Lefamulin
Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Lefamulin |
DB00011 | DB15091 | 1,451 | 676 | [
"DDInter944",
"DDInter1901"
] | Interferon alfa-n1 | Upadacitinib | Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes. | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage damage and bone destruction, leading to co-morbidities. Despite a variety of therapeutic agents available for treatment, up to 40% of the patients do not respond to current therapies, including biological therapies. The etiology of the disease is mostly unknown; however, the role of JAK as a driver of immune-mediated conditions was discovered, leading to the use of JAK as therapeutic targets for rheumatoid arthritis. To reduce dose-related toxicity (as seen with some pan-JAK inhibitors) without significantly affecting efficacy, more selective JAK1 inhibitors, upadacitinib and [filgotinib], were developed. The FDA approved upadacitinib in August 2019 and it is used for the treatment of active rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and ankylosing spondylitis. In December 2019, it was additionally approved by the European Commission and Health Canada.[L10899,L42540] Upadacitinib is marketed under the brand name RINVOQ for oral administration. | Major | 2 | [
[
[
1451,
25,
676
]
],
[
[
1451,
24,
1430
],
[
1430,
24,
676
]
],
[
[
1451,
24,
869
],
[
869,
25,
676
]
],
[
[
1451,
25,
1064
],
[
1064,
25,
676
]
],
[
[
1451,
63,
491
],
[
491,
25,
676
]
],
[
[
1451,
23,
450
],
[
450,
25,
676
]
],
[
[
1451,
24,
1430
],
[
1430,
63,
1184
],
[
1184,
25,
676
]
],
[
[
1451,
24,
1593
],
[
1593,
63,
1249
],
[
1249,
24,
676
]
],
[
[
1451,
24,
248
],
[
248,
40,
563
],
[
563,
24,
676
]
],
[
[
1451,
24,
655
],
[
655,
25,
283
],
[
283,
24,
676
]
]
] | [
[
[
"Interferon alfa-n1",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[
"Topotecan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Interferon alfa-n1",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon alfa-2a"
],
[
"Peginterferon alfa-2a",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anakinra"
],
[
"Anakinra",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nafcillin"
],
[
"Nafcillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
],
[
"Valganciclovir",
"{u} (Compound) resembles {v} (Compound)",
"Ganciclovir"
],
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
],
[
"Etravirine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
]
] | Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may lead to a major life threatening interaction when taken with Upadacitinib
Interferon alfa-n1 may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Upadacitinib
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2a and Peginterferon alfa-2a may lead to a major life threatening interaction when taken with Upadacitinib
Interferon alfa-n1 may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide and Cyclophosphamide may lead to a major life threatening interaction when taken with Upadacitinib
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may lead to a major life threatening interaction when taken with Upadacitinib
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Nafcillin and Nafcillin may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir and Valganciclovir (Compound) resembles Ganciclovir (Compound) and Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Etravirine and Etravirine may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib |
DB00619 | DB08873 | 1,419 | 74 | [
"DDInter909",
"DDInter221"
] | Imatinib | Boceprevir | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy".. The discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient. Imatinib was approved on February 1st,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751] | Boceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients . Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) such as Boceprevir. Boceprevir is an inhibitor of NS3/4A, a serine protease enzyme, encoded by HCV genotypes 1 and 4 [synthesis]. These enzymes are essential for viral replication and serve to cleave the virally encoded polyprotein into mature proteins like NS4A, NS4B, NS5A and NS5B [FDA Label]. The barrier for develoment of resistance to NS3/4A inhibitors is lower than that of NS5B inhibitors, another class of DAAs . Subtitutions at amino acid positions 155, 156, or 168 are known to confer resistance. The substitutions of the enzyme's catalytic triad consisting of H58, D82, and S139 are also likely to alter the affinity of the drug for NS3/4A or the activity of the enzyme itself. Despite this disadvantage Boceprevir is still effective against HCV when paired with , , and . In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) do not reccomend Boceprevir in combination with , , and as first line therapy for Hepatitis C . Boceprevir, , , and are used with the intent to cure, or achieve a sustained virologic response (SVR), after 48 weeks of daily therapy. SVR and eradication of HCV infection is associated with significant long-term health benefits including reduced liver-related damage, improved quality of life, reduced incidence of Hepatocellular Carcinoma, and reduced all-cause mortality . Boceprevir is available as a fixed dose product (tradename Victrelis) used for the treatment of chronic Hepatitis C. Approved in May 2011 by the FDA, Victrelis is indicated for the treatment of HCV genotype 1 in combination with , , and [FDA Label]. Victrelis is no longer widely used as interferon-free therapies have been developed. | Moderate | 1 | [
[
[
1419,
24,
74
]
],
[
[
1419,
6,
4973
],
[
4973,
45,
74
]
],
[
[
1419,
21,
28821
],
[
28821,
60,
74
]
],
[
[
1419,
24,
72
],
[
72,
23,
74
]
],
[
[
1419,
24,
310
],
[
310,
24,
74
]
],
[
[
1419,
63,
1424
],
[
1424,
24,
74
]
],
[
[
1419,
24,
466
],
[
466,
63,
74
]
],
[
[
1419,
25,
1634
],
[
1634,
63,
74
]
],
[
[
1419,
25,
126
],
[
126,
24,
74
]
],
[
[
1419,
62,
1101
],
[
1101,
24,
74
]
]
] | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Boceprevir"
]
],
[
[
"Imatinib",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Boceprevir"
]
],
[
[
"Imatinib",
"{u} (Compound) causes {v} (Side Effect)",
"Sepsis"
],
[
"Sepsis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Boceprevir"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eltrombopag"
],
[
"Eltrombopag",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Boceprevir"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Boceprevir"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
],
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Boceprevir"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Boceprevir"
]
],
[
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avatrombopag"
],
[
"Avatrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Boceprevir"
]
],
[
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Boceprevir"
]
],
[
[
"Imatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Boceprevir"
]
]
] | Imatinib (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Boceprevir (Compound)
Imatinib (Compound) causes Sepsis (Side Effect) and Sepsis (Side Effect) is caused by Boceprevir (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Eltrombopag and Eltrombopag may cause a minor interaction that can limit clinical effects when taken with Boceprevir
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Boceprevir
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Boceprevir
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Boceprevir
Imatinib may lead to a major life threatening interaction when taken with Avatrombopag and Avatrombopag may cause a moderate interaction that could exacerbate diseases when taken with Boceprevir
Imatinib may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Boceprevir
Imatinib may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Boceprevir |
DB00261 | DB00675 | 702 | 888 | [
"DDInter93",
"DDInter1744"
] | Anagrelide | Tamoxifen | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythemia treatments (e.g. [busulfan], [hydroxyurea]) and may be better tolerated. | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, side effect profiles, and compliance with [anastrozole]. Tamoxifen was granted FDA approval on 30 December 1977. | Major | 2 | [
[
[
702,
25,
888
]
],
[
[
702,
25,
675
],
[
675,
25,
888
]
],
[
[
702,
24,
543
],
[
543,
63,
888
]
],
[
[
702,
24,
1405
],
[
1405,
40,
888
]
],
[
[
702,
6,
7950
],
[
7950,
45,
888
]
],
[
[
702,
18,
3769
],
[
3769,
45,
888
]
],
[
[
702,
18,
5833
],
[
5833,
46,
888
]
],
[
[
702,
7,
1700
],
[
1700,
46,
888
]
],
[
[
702,
18,
6797
],
[
6797,
57,
888
]
],
[
[
702,
7,
13230
],
[
13230,
57,
888
]
]
] | [
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tamoxifen"
]
],
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dextropropoxyphene"
],
[
"Dextropropoxyphene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tamoxifen"
]
],
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
],
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
]
],
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclobenzaprine"
],
[
"Cyclobenzaprine",
"{u} (Compound) resembles {v} (Compound)",
"Tamoxifen"
]
],
[
[
"Anagrelide",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Tamoxifen"
]
],
[
[
"Anagrelide",
"{u} (Compound) downregulates {v} (Gene)",
"EBP"
],
[
"EBP",
"{u} (Gene) is bound by {v} (Compound)",
"Tamoxifen"
]
],
[
[
"Anagrelide",
"{u} (Compound) downregulates {v} (Gene)",
"ACAT2"
],
[
"ACAT2",
"{u} (Gene) is upregulated by {v} (Compound)",
"Tamoxifen"
]
],
[
[
"Anagrelide",
"{u} (Compound) upregulates {v} (Gene)",
"SIRT3"
],
[
"SIRT3",
"{u} (Gene) is upregulated by {v} (Compound)",
"Tamoxifen"
]
],
[
[
"Anagrelide",
"{u} (Compound) downregulates {v} (Gene)",
"CYCS"
],
[
"CYCS",
"{u} (Gene) is downregulated by {v} (Compound)",
"Tamoxifen"
]
],
[
[
"Anagrelide",
"{u} (Compound) upregulates {v} (Gene)",
"TIPARP"
],
[
"TIPARP",
"{u} (Gene) is downregulated by {v} (Compound)",
"Tamoxifen"
]
]
] | Anagrelide may lead to a major life threatening interaction when taken with Dextropropoxyphene and Dextropropoxyphene may lead to a major life threatening interaction when taken with Tamoxifen
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Cyclobenzaprine and Cyclobenzaprine (Compound) resembles Tamoxifen (Compound)
Anagrelide (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Tamoxifen (Compound)
Anagrelide (Compound) downregulates EBP (Gene) and EBP (Gene) is bound by Tamoxifen (Compound)
Anagrelide (Compound) downregulates ACAT2 (Gene) and ACAT2 (Gene) is upregulated by Tamoxifen (Compound)
Anagrelide (Compound) upregulates SIRT3 (Gene) and SIRT3 (Gene) is upregulated by Tamoxifen (Compound)
Anagrelide (Compound) downregulates CYCS (Gene) and CYCS (Gene) is downregulated by Tamoxifen (Compound)
Anagrelide (Compound) upregulates TIPARP (Gene) and TIPARP (Gene) is downregulated by Tamoxifen (Compound) |
DB01072 | DB11691 | 915 | 1,499 | [
"DDInter129",
"DDInter1258"
] | Atazanavir | Naldemedine | Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses per day) and has lesser effects on the patient's lipid profile (the amounts of cholesterol and other fatty substances in the blood). Like other protease inhibitors, it is used only in combination with other HIV medications. The U.S. Food and Drug Administration (FDA) approved atazanavir on June 20, 2003. | Naldemedine is an opioid receptor antagonist [FDA Label]. It is a modified form of to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier. Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opioid-induced Constipation. | Moderate | 1 | [
[
[
915,
24,
1499
]
],
[
[
915,
63,
723
],
[
723,
24,
1499
]
],
[
[
915,
25,
1670
],
[
1670,
24,
1499
]
],
[
[
915,
25,
1406
],
[
1406,
63,
1499
]
],
[
[
915,
24,
98
],
[
98,
24,
1499
]
],
[
[
915,
40,
1327
],
[
1327,
24,
1499
]
],
[
[
915,
24,
1619
],
[
1619,
63,
1499
]
],
[
[
915,
24,
129
],
[
129,
25,
1499
]
],
[
[
915,
24,
913
],
[
913,
64,
1499
]
],
[
[
915,
63,
723
],
[
723,
23,
307
],
[
307,
23,
1499
]
]
] | [
[
[
"Atazanavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
]
],
[
[
"Atazanavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
]
],
[
[
"Atazanavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eliglustat"
],
[
"Eliglustat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
]
],
[
[
"Atazanavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
],
[
"Neratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
]
],
[
[
"Atazanavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
],
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
]
],
[
[
"Atazanavir",
"{u} (Compound) resembles {v} (Compound)",
"Saquinavir"
],
[
"Saquinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
]
],
[
[
"Atazanavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
]
],
[
[
"Atazanavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naldemedine"
]
],
[
[
"Atazanavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naldemedine"
]
],
[
[
"Atazanavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naldemedine"
]
]
] | Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Atazanavir may lead to a major life threatening interaction when taken with Eliglustat and Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Atazanavir may lead to a major life threatening interaction when taken with Neratinib and Neratinib may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Atazanavir (Compound) resembles Saquinavir (Compound) and Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Naldemedine
Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Naldemedine
Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Naldemedine |
DB00443 | DB00745 | 251 | 307 | [
"DDInter195",
"DDInter1236"
] | Betamethasone | Modafinil | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and negligible mineralocorticoid activity. | Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron activation is associated with psychoactivation and euphoria. The exact mechanism of action is unclear, although in vitro studies have shown it to inhibit the reuptake of dopamine by binding to the dopamine reuptake pump, and lead to an increase in extracellular dopamine. Modafinil activates glutamatergic circuits while inhibiting GABA. | Minor | 0 | [
[
[
251,
23,
307
]
],
[
[
251,
63,
362
],
[
362,
40,
307
]
],
[
[
251,
24,
1236
],
[
1236,
40,
307
]
],
[
[
251,
6,
8374
],
[
8374,
45,
307
]
],
[
[
251,
5,
11594
],
[
11594,
49,
307
]
],
[
[
251,
18,
10375
],
[
10375,
57,
307
]
],
[
[
251,
21,
28748
],
[
28748,
60,
307
]
],
[
[
251,
24,
723
],
[
723,
23,
307
]
],
[
[
251,
24,
761
],
[
761,
62,
307
]
],
[
[
251,
1,
891
],
[
891,
62,
307
]
]
] | [
[
[
"Betamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} (Compound) resembles {v} (Compound)",
"Modafinil"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} (Compound) resembles {v} (Compound)",
"Modafinil"
]
],
[
[
"Betamethasone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Modafinil"
]
],
[
[
"Betamethasone",
"{u} (Compound) treats {v} (Disease)",
"multiple sclerosis"
],
[
"multiple sclerosis",
"{u} (Disease) is palliated by {v} (Compound)",
"Modafinil"
]
],
[
[
"Betamethasone",
"{u} (Compound) downregulates {v} (Gene)",
"RPS4Y1"
],
[
"RPS4Y1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Modafinil"
]
],
[
[
"Betamethasone",
"{u} (Compound) causes {v} (Side Effect)",
"Vertigo"
],
[
"Vertigo",
"{u} (Side Effect) is caused by {v} (Compound)",
"Modafinil"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
],
[
"Saxagliptin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
]
],
[
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
]
]
] | Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Modafinil (Compound)
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine and Carbamazepine (Compound) resembles Modafinil (Compound)
Betamethasone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Modafinil (Compound)
Betamethasone (Compound) treats multiple sclerosis (Disease) and multiple sclerosis (Disease) is palliated by Modafinil (Compound)
Betamethasone (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Modafinil (Compound)
Betamethasone (Compound) causes Vertigo (Side Effect) and Vertigo (Side Effect) is caused by Modafinil (Compound)
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a minor interaction that can limit clinical effects when taken with Modafinil
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a minor interaction that can limit clinical effects when taken with Modafinil
Betamethasone (Compound) resembles Prednisolone (Compound) and Prednisolone may cause a minor interaction that can limit clinical effects when taken with Modafinil |
DB00950 | DB04855 | 1,413 | 540 | [
"DDInter732",
"DDInter602"
] | Fexofenadine | Dronedarone | Fexofenadine is an over-the-counter second-generation antihistamine used in the treatment of various allergic symptoms. It is selective for the H<sub>1</sub> receptor, carries little-to-no activity at off-targets, and does not cross the blood-brain barrier - this is in contrast to previous first-generation antihistamines, such as [diphenhydramine], which readily bind to off-targets that contribute to side effects such as sedation. Fexofenadine is the major active metabolite of [terfenadine] and is administered as a racemic mixture in which both enantiomers display approximately equivalent antihistamine activity. | Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate control, rhythm control, prevention of thromboembolic events, and treatment of the underlying disease. Similar to [amiodarone], dronedarone is a multichannel blocker that works to control rhythm and rate in atrial fibrillation. It meets criteria of all four Vaughan Williams antiarrhythmic drug classes by blocking sodium, potassium, and calcium ion channels and inhibiting β-adrenergic receptors.[A34604,L8699] Dronedarone is a related benzofuran compound to amiodarone but its chemical structure lacks iodine moieties which are associated with amiodarone-induced thyroid problems.[A34604,T28] Additionally, the methyl sulfonyl group in its structure renders dronedarone to be more lipophilic with a shorter half-life than amiodarone. This ultimately leads to reduced tissue accumulation of the drug and decreased risk for organ toxicities, such as thyroid and pulmonary toxicities. Commonly marketed as Multaq®, dronedarone was approved by the FDA in July 2009 and Health Canada in August 2009. A safety concern for the risk of drug-induced hepatocellular injury has been issued following marketing of dronedarone. | Moderate | 1 | [
[
[
1413,
24,
540
]
],
[
[
1413,
6,
12523
],
[
12523,
45,
540
]
],
[
[
1413,
21,
28703
],
[
28703,
60,
540
]
],
[
[
1413,
24,
466
],
[
466,
62,
540
]
],
[
[
1413,
23,
86
],
[
86,
24,
540
]
],
[
[
1413,
24,
214
],
[
214,
63,
540
]
],
[
[
1413,
24,
971
],
[
971,
64,
540
]
],
[
[
1413,
63,
79
],
[
79,
25,
540
]
],
[
[
1413,
62,
600
],
[
600,
25,
540
]
],
[
[
1413,
40,
543
],
[
543,
25,
540
]
]
] | [
[
[
"Fexofenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronedarone"
]
],
[
[
"Fexofenadine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Dronedarone"
]
],
[
[
"Fexofenadine",
"{u} (Compound) causes {v} (Side Effect)",
"Pruritus"
],
[
"Pruritus",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dronedarone"
]
],
[
[
"Fexofenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dronedarone"
]
],
[
[
"Fexofenadine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Miconazole"
],
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronedarone"
]
],
[
[
"Fexofenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronedarone"
]
],
[
[
"Fexofenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dronedarone"
]
],
[
[
"Fexofenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
[
"Sorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dronedarone"
]
],
[
[
"Fexofenadine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dronedarone"
]
],
[
[
"Fexofenadine",
"{u} (Compound) resembles {v} (Compound)",
"Loperamide"
],
[
"Loperamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dronedarone"
]
]
] | Fexofenadine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Dronedarone (Compound)
Fexofenadine (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Dronedarone (Compound)
Fexofenadine may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Dronedarone
Fexofenadine may cause a minor interaction that can limit clinical effects when taken with Miconazole and Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone
Fexofenadine may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone
Fexofenadine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may lead to a major life threatening interaction when taken with Dronedarone
Fexofenadine may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may lead to a major life threatening interaction when taken with Dronedarone
Fexofenadine may cause a minor interaction that can limit clinical effects when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Dronedarone
Fexofenadine (Compound) resembles Loperamide (Compound) and Loperamide may lead to a major life threatening interaction when taken with Dronedarone |
DB01073 | DB11793 | 1,488 | 738 | [
"DDInter745",
"DDInter1297"
] | Fludarabine | Niraparib | Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara. | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, fallopian tube, or primary peritoneal cancer. Niraparib was approved by the European Commission on November 16, 2017 and by Health Canada on June 27, 2019. | Moderate | 1 | [
[
[
1488,
24,
738
]
],
[
[
1488,
63,
1253
],
[
1253,
24,
738
]
],
[
[
1488,
24,
496
],
[
496,
24,
738
]
],
[
[
1488,
64,
1238
],
[
1238,
24,
738
]
],
[
[
1488,
40,
372
],
[
372,
24,
738
]
],
[
[
1488,
24,
385
],
[
385,
63,
738
]
],
[
[
1488,
74,
1224
],
[
1224,
24,
738
]
],
[
[
1488,
64,
1066
],
[
1066,
25,
738
]
],
[
[
1488,
25,
1377
],
[
1377,
25,
738
]
],
[
[
1488,
75,
1064
],
[
1064,
25,
738
]
]
] | [
[
[
"Fludarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Fludarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palifermin"
],
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Fludarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
],
[
"Hepatitis A Vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Fludarabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pentostatin"
],
[
"Pentostatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Fludarabine",
"{u} (Compound) resembles {v} (Compound)",
"Clofarabine"
],
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Fludarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isatuximab"
],
[
"Isatuximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Fludarabine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cytarabine"
],
[
"Cytarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Fludarabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
],
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Niraparib"
]
],
[
[
"Fludarabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Niraparib"
]
],
[
[
"Fludarabine",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Niraparib"
]
]
] | Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Palifermin and Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine and Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Fludarabine may lead to a major life threatening interaction when taken with Pentostatin and Pentostatin may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Fludarabine (Compound) resembles Clofarabine (Compound) and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Isatuximab and Isatuximab may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Fludarabine (Compound) resembles Cytarabine (Compound) and Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Cytarabine and Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Fludarabine may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Niraparib
Fludarabine may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Niraparib
Fludarabine (Compound) resembles Cladribine (Compound) and Fludarabine may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Niraparib |
DB00477 | DB09472 | 216 | 1,383 | [
"DDInter363",
"DDInter1693"
] | Chlorpromazine | Sodium sulfate | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate anhydrous is an electrolyte replenisher and is used in isosmotic solutions so that administration does not disturb normal electrolyte balance and does not lead to absorption or excretion of water and ions. | Moderate | 1 | [
[
[
216,
24,
1383
]
],
[
[
216,
24,
609
],
[
609,
24,
1383
]
],
[
[
216,
1,
146
],
[
146,
24,
1383
]
],
[
[
216,
25,
1311
],
[
1311,
24,
1383
]
],
[
[
216,
63,
521
],
[
521,
24,
1383
]
],
[
[
216,
40,
1178
],
[
1178,
24,
1383
]
],
[
[
216,
24,
971
],
[
971,
63,
1383
]
],
[
[
216,
35,
104
],
[
104,
24,
1383
]
],
[
[
216,
25,
982
],
[
982,
63,
1383
]
],
[
[
216,
64,
475
],
[
475,
24,
1383
]
]
] | [
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Chlorpromazine",
"{u} (Compound) resembles {v} (Compound)",
"Propiomazine"
],
[
"Propiomazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Chlorpromazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Chlorpromazine",
"{u} (Compound) resembles {v} (Compound)",
"Trifluoperazine"
],
[
"Trifluoperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Chlorpromazine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Chlorpromazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Chlorpromazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
]
] | Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Chlorpromazine (Compound) resembles Propiomazine (Compound) and Propiomazine may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Chlorpromazine may lead to a major life threatening interaction when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Chlorpromazine (Compound) resembles Trifluoperazine (Compound) and Trifluoperazine may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Chlorpromazine (Compound) resembles Methdilazine (Compound) and Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Chlorpromazine may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Chlorpromazine may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate |
DB00436 | DB00539 | 323 | 11 | [
"DDInter179",
"DDInter1837"
] | Bendroflumethiazide | Toremifene | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810) | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has estrogenic (agonist) activity on the cardiovascular system and on bone tissue and it has weak estrogenic effects on uterine tissue, however, it also has antiestrogenic (estrogen-antagonist) activity on breast tissue. | Moderate | 1 | [
[
[
323,
24,
11
]
],
[
[
323,
18,
10699
],
[
10699,
57,
11
]
],
[
[
323,
21,
28784
],
[
28784,
60,
11
]
],
[
[
323,
24,
144
],
[
144,
63,
11
]
],
[
[
323,
40,
674
],
[
674,
63,
11
]
],
[
[
323,
23,
126
],
[
126,
63,
11
]
],
[
[
323,
24,
401
],
[
401,
64,
11
]
],
[
[
323,
25,
57
],
[
57,
64,
11
]
],
[
[
323,
18,
10699
],
[
10699,
57,
1661
],
[
1661,
40,
11
]
],
[
[
323,
21,
28784
],
[
28784,
60,
1594
],
[
1594,
40,
11
]
]
] | [
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Toremifene"
]
],
[
[
"Bendroflumethiazide",
"{u} (Compound) downregulates {v} (Gene)",
"KIF20A"
],
[
"KIF20A",
"{u} (Gene) is downregulated by {v} (Compound)",
"Toremifene"
]
],
[
[
"Bendroflumethiazide",
"{u} (Compound) causes {v} (Side Effect)",
"Thrombocytopenia"
],
[
"Thrombocytopenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Toremifene"
]
],
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
],
[
"Olodaterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Toremifene"
]
],
[
[
"Bendroflumethiazide",
"{u} (Compound) resembles {v} (Compound)",
"Trichlormethiazide"
],
[
"Trichlormethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Toremifene"
]
],
[
[
"Bendroflumethiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Toremifene"
]
],
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
]
],
[
[
"Bendroflumethiazide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
],
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
]
],
[
[
"Bendroflumethiazide",
"{u} (Compound) downregulates {v} (Gene)",
"KIF20A"
],
[
"KIF20A",
"{u} (Gene) is downregulated by {v} (Compound)",
"Phenoxybenzamine"
],
[
"Phenoxybenzamine",
"{u} (Compound) resembles {v} (Compound)",
"Toremifene"
]
],
[
[
"Bendroflumethiazide",
"{u} (Compound) causes {v} (Side Effect)",
"Thrombocytopenia"
],
[
"Thrombocytopenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Doxylamine"
],
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound)",
"Toremifene"
]
]
] | Bendroflumethiazide (Compound) downregulates KIF20A (Gene) and KIF20A (Gene) is downregulated by Toremifene (Compound)
Bendroflumethiazide (Compound) causes Thrombocytopenia (Side Effect) and Thrombocytopenia (Side Effect) is caused by Toremifene (Compound)
Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Toremifene
Bendroflumethiazide (Compound) resembles Trichlormethiazide (Compound) and Trichlormethiazide may cause a moderate interaction that could exacerbate diseases when taken with Toremifene
Bendroflumethiazide may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Toremifene
Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may lead to a major life threatening interaction when taken with Toremifene
Bendroflumethiazide may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may lead to a major life threatening interaction when taken with Toremifene
Bendroflumethiazide (Compound) downregulates KIF20A (Gene) and KIF20A (Gene) is downregulated by Phenoxybenzamine (Compound) and Phenoxybenzamine (Compound) resembles Toremifene (Compound)
Bendroflumethiazide (Compound) causes Thrombocytopenia (Side Effect) and Thrombocytopenia (Side Effect) is caused by Doxylamine (Compound) and Doxylamine (Compound) resembles Toremifene (Compound) |
DB01186 | DB01501 | 107 | 1,118 | [
"DDInter1430",
"DDInter549"
] | Pergolide | Difenoxin | Pergolide is a long-acting dopamine agonist approved in 1982 for the treatment of Parkinson’s Disease. It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. It was indicated as adjunct therapy with levodopa/carbidopa in the symptomatic treatment of parkinsonian syndrome. It was later found that pergolide increased the risk of cardiac valvulopathy. The drug was withdrawn from the US market in March 2007 and from the Canadian market in August 2007. While the use of pergolide in humans is still approved in only some countries, pergolide is mainly used for veterinary purposes. | Difenoxin is a 4-phenylpiperidine which is closely related to the opioid analgesic meperidine. Difenoxin alone is a USA Schedule I controlled drug, as it may be habit forming. However, it is listed as a Schedule IV controlled drug if combined with atropine, which is added to decrease deliberate misuse. Motofen(R) is a brand mixture which combines atropine sulfate and difenoxin hydrochloride. It is approved by the FDA to treat acute and chronic diarrhea. Difenoxin is an active metabolite of the anti-diarrheal drug, diphenoxylate, which is also used in combination with atropine in the brand mixture Lomotil(R). It works mostly in the periphery and activates opioid receptors in the intestine rather than the central nervous system (CNS). [3] Difenoxin is also closely related to loperamide, but unlike loperamide it is still capable of crossing the blood brain barrier to produce weak sedative and analgesic effects. However, the antidiarrheal potency of difenoxin is much greater than its CNS effects, which makes it an attractive alternative to other opioids. | Moderate | 1 | [
[
[
107,
24,
1118
]
],
[
[
107,
63,
1688
],
[
1688,
40,
1118
]
],
[
[
107,
63,
506
],
[
506,
24,
1118
]
],
[
[
107,
24,
1609
],
[
1609,
63,
1118
]
],
[
[
107,
63,
1688
],
[
1688,
40,
11264
],
[
11264,
40,
1118
]
],
[
[
107,
63,
506
],
[
506,
63,
576
],
[
576,
1,
1118
]
],
[
[
107,
24,
1609
],
[
1609,
63,
576
],
[
576,
1,
1118
]
],
[
[
107,
24,
649
],
[
649,
1,
11264
],
[
11264,
40,
1118
]
],
[
[
107,
63,
1688
],
[
1688,
40,
576
],
[
576,
1,
1118
]
],
[
[
107,
63,
506
],
[
506,
24,
1688
],
[
1688,
40,
1118
]
]
] | [
[
[
"Pergolide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Difenoxin"
]
],
[
[
"Pergolide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenoxylate"
],
[
"Diphenoxylate",
"{u} (Compound) resembles {v} (Compound)",
"Difenoxin"
]
],
[
[
"Pergolide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
],
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Difenoxin"
]
],
[
[
"Pergolide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
],
[
"Pentoxyverine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Difenoxin"
]
],
[
[
"Pergolide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenoxylate"
],
[
"Diphenoxylate",
"{u} (Compound) resembles {v} (Compound)",
"Diphenidol"
],
[
"Diphenidol",
"{u} (Compound) resembles {v} (Compound)",
"Difenoxin"
]
],
[
[
"Pergolide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
],
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methadone"
],
[
"Methadone",
"{u} (Compound) resembles {v} (Compound)",
"Difenoxin"
]
],
[
[
"Pergolide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
],
[
"Pentoxyverine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methadone"
],
[
"Methadone",
"{u} (Compound) resembles {v} (Compound)",
"Difenoxin"
]
],
[
[
"Pergolide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
"Clofedanol",
"{u} (Compound) resembles {v} (Compound)",
"Diphenidol"
],
[
"Diphenidol",
"{u} (Compound) resembles {v} (Compound)",
"Difenoxin"
]
],
[
[
"Pergolide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenoxylate"
],
[
"Diphenoxylate",
"{u} (Compound) resembles {v} (Compound)",
"Methadone"
],
[
"Methadone",
"{u} (Compound) resembles {v} (Compound)",
"Difenoxin"
]
],
[
[
"Pergolide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
],
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenoxylate"
],
[
"Diphenoxylate",
"{u} (Compound) resembles {v} (Compound)",
"Difenoxin"
]
]
] | Pergolide may cause a moderate interaction that could exacerbate diseases when taken with Diphenoxylate and Diphenoxylate (Compound) resembles Difenoxin (Compound)
Pergolide may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Difenoxin
Pergolide may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Difenoxin
Pergolide may cause a moderate interaction that could exacerbate diseases when taken with Diphenoxylate and Diphenoxylate (Compound) resembles Diphenidol (Compound) and Diphenidol (Compound) resembles Difenoxin (Compound)
Pergolide may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Methadone and Methadone (Compound) resembles Difenoxin (Compound)
Pergolide may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Methadone and Methadone (Compound) resembles Difenoxin (Compound)
Pergolide may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol (Compound) resembles Diphenidol (Compound) and Diphenidol (Compound) resembles Difenoxin (Compound)
Pergolide may cause a moderate interaction that could exacerbate diseases when taken with Diphenoxylate and Diphenoxylate (Compound) resembles Methadone (Compound) and Methadone (Compound) resembles Difenoxin (Compound)
Pergolide may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Diphenoxylate and Diphenoxylate (Compound) resembles Difenoxin (Compound) |
DB01067 | DB01224 | 959 | 623 | [
"DDInter826",
"DDInter1553"
] | Glipizide | Quetiapine | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guidelines by Diabetes Canada, sulfonylurea drugs are considered a second-line glucose-lowering therapy following metformin. Because sulfonylureas require functional pancreatic beta cells for their therapeutic effectiveness, sulfonylureas are more commonly used for early-stage type 2 diabetes when there is no progressed pancreatic failure. Compared to the first-generation sulfonylureas, such as [tolbutamide] and [chlorpropamide], second-generation sulfonylureas contain a more non-polar side chain in their chemical structure, which enhances their hypoglycemic potency. Compared to other members of the sulfonyl | Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable option for some patients with high sensitivity to other drugs, such as [clozapine] and [olanzapine]. | Moderate | 1 | [
[
[
959,
24,
623
]
],
[
[
959,
63,
695
],
[
695,
1,
623
]
],
[
[
959,
6,
8374
],
[
8374,
45,
623
]
],
[
[
959,
18,
6718
],
[
6718,
57,
623
]
],
[
[
959,
21,
28987
],
[
28987,
60,
623
]
],
[
[
959,
63,
752
],
[
752,
23,
623
]
],
[
[
959,
24,
170
],
[
170,
63,
623
]
],
[
[
959,
63,
1179
],
[
1179,
24,
623
]
],
[
[
959,
40,
1411
],
[
1411,
24,
623
]
],
[
[
959,
24,
1532
],
[
1532,
24,
623
]
]
] | [
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quetiapine"
]
],
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clozapine"
],
[
"Clozapine",
"{u} (Compound) resembles {v} (Compound)",
"Quetiapine"
]
],
[
[
"Glipizide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Quetiapine"
]
],
[
[
"Glipizide",
"{u} (Compound) downregulates {v} (Gene)",
"USP22"
],
[
"USP22",
"{u} (Gene) is downregulated by {v} (Compound)",
"Quetiapine"
]
],
[
[
"Glipizide",
"{u} (Compound) causes {v} (Side Effect)",
"Chills"
],
[
"Chills",
"{u} (Side Effect) is caused by {v} (Compound)",
"Quetiapine"
]
],
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Quetiapine"
]
],
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
[
"Sitagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quetiapine"
]
],
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin lispro"
],
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quetiapine"
]
],
[
[
"Glipizide",
"{u} (Compound) resembles {v} (Compound)",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quetiapine"
]
],
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
],
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quetiapine"
]
]
] | Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Clozapine and Clozapine (Compound) resembles Quetiapine (Compound)
Glipizide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Quetiapine (Compound)
Glipizide (Compound) downregulates USP22 (Gene) and USP22 (Gene) is downregulated by Quetiapine (Compound)
Glipizide (Compound) causes Chills (Side Effect) and Chills (Side Effect) is caused by Quetiapine (Compound)
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Quetiapine
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine
Glipizide (Compound) resembles Tolbutamide (Compound) and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine |
DB09104 | DB11986 | 286 | 484 | [
"DDInter1118",
"DDInter648"
] | Magnesium hydroxide | Entrectinib | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used commercially as a fire retardant. It can also be used topically as a deodorant or for the relief of canker sores (aphthous ulcers). | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors. Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval based on early trial data. This therapy offers benefit over similar ALK inhibitors such as [alectinib], [ceritinib], and [lorlatinib] due to a wider range of targets. | Moderate | 1 | [
[
[
286,
24,
484
]
],
[
[
286,
63,
1539
],
[
1539,
24,
484
]
],
[
[
286,
24,
180
],
[
180,
63,
484
]
],
[
[
286,
24,
927
],
[
927,
24,
484
]
],
[
[
286,
62,
1559
],
[
1559,
24,
484
]
],
[
[
286,
25,
627
],
[
627,
24,
484
]
],
[
[
286,
63,
494
],
[
494,
25,
484
]
],
[
[
286,
24,
985
],
[
985,
25,
484
]
],
[
[
286,
24,
1375
],
[
1375,
64,
484
]
],
[
[
286,
63,
1539
],
[
1539,
62,
112
],
[
112,
23,
484
]
]
] | [
[
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ofloxacin"
],
[
"Ofloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
],
[
"Oliceridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Magnesium hydroxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Famotidine"
],
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Magnesium hydroxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bictegravir"
],
[
"Bictegravir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Disopyramide"
],
[
"Disopyramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Entrectinib"
]
],
[
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
],
[
"Osimertinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Entrectinib"
]
],
[
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
],
[
"Lefamulin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Entrectinib"
]
],
[
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ofloxacin"
],
[
"Ofloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Entrectinib"
]
]
] | Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Ofloxacin and Ofloxacin may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine and Oliceridine may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Magnesium hydroxide may cause a minor interaction that can limit clinical effects when taken with Famotidine and Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Magnesium hydroxide may lead to a major life threatening interaction when taken with Bictegravir and Bictegravir may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Disopyramide and Disopyramide may lead to a major life threatening interaction when taken with Entrectinib
Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib and Osimertinib may lead to a major life threatening interaction when taken with Entrectinib
Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin and Lefamulin may lead to a major life threatening interaction when taken with Entrectinib
Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Ofloxacin and Ofloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib |
DB12159 | DB14783 | 12 | 287 | [
"DDInter609",
"DDInter574"
] | Dupilumab | Diroximel fumarate | Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways. As an interleukin-4 receptor alpha antagonist, dupilumab inhibits the signaling of pro-inflammatory cytokines, called interleukins (IL), that induce inflammatory and immunological reactions in several atopic or allergic conditions, such as eczema, allergic reaction, and rhinosinusitis. Dupilumab was generated by recombinant DNA technology in Chinese Hamster Ovary cell suspension culture. Dupilumab is commonly marketed as Dupixent, which is available as a formulation for subcutaneous injection. It was first approved by the FDA in 2017. It is currently used to treat atopic dermatitis, asthma as an add-on maintenance treatment, chronic rhinosinusitis with nasal polyposis, and eosinophilic es | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting forms of MS lead to neurological symptoms that resolve and recur periodically. More than 80% of patients suffering from this disease have relapsing-remitting MS. Diroximel fumarate is a new drug from the fumarate class formulated to treat various relapsing forms of MS. This drug is bioequivalent to [Dimethyl fumarate][A187544,L9626](initially manufactured in 2013), but is less likely to cause gastrointestinal side effects, owing to its unique chemical structure. Diroximel fumarate was formulated by Alkermes in collaboration with Biogen, and was approved by the FDA in October 2019 and by the EMA in November 2021. | Moderate | 1 | [
[
[
12,
24,
287
]
],
[
[
12,
63,
599
],
[
599,
24,
287
]
],
[
[
12,
64,
1510
],
[
1510,
25,
287
]
],
[
[
12,
25,
676
],
[
676,
64,
287
]
],
[
[
12,
63,
713
],
[
713,
25,
287
]
],
[
[
12,
63,
599
],
[
599,
24,
1101
],
[
1101,
24,
287
]
],
[
[
12,
63,
259
],
[
259,
63,
1101
],
[
1101,
24,
287
]
],
[
[
12,
64,
1510
],
[
1510,
64,
1101
],
[
1101,
24,
287
]
],
[
[
12,
64,
1066
],
[
1066,
25,
1101
],
[
1101,
24,
287
]
],
[
[
12,
25,
676
],
[
676,
64,
1101
],
[
1101,
24,
287
]
]
] | [
[
[
"Dupilumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Dupilumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Dupilumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Dupilumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Dupilumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
],
[
"Dimethyl fumarate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Dupilumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Dupilumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
],
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Dupilumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Dupilumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
],
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Dupilumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
]
] | Dupilumab may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Dupilumab may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Diroximel fumarate
Dupilumab may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Diroximel fumarate
Dupilumab may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and Dimethyl fumarate may lead to a major life threatening interaction when taken with Diroximel fumarate
Dupilumab may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Dupilumab may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Dupilumab may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Dupilumab may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Dupilumab may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate |
DB00305 | DB00445 | 377 | 322 | [
"DDInter1232",
"DDInter655"
] | Mitomycin | Epirubicin | Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of _Streptomyces caespitosus_.[L12867,A193419] It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of the DNA double helix. Few other antibiotics have been discovered that work via this alkylating mechanism, making mitomycin relatively unique in the space of microbiota-derived therapies. Mitomycin's cross-linking activity has resulted in its approval for the treatment of a variety of cancers - the most recent of which is an April 2020 approval for its use in low-grade Upper Tract Urothelial Cancer (LG-UTUC) - as well as adjunctly to _ab externo_ glaucoma surgeries. | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Moderate | 1 | [
[
[
377,
24,
322
]
],
[
[
377,
5,
11642
],
[
11642,
44,
322
]
],
[
[
377,
7,
5144
],
[
5144,
46,
322
]
],
[
[
377,
18,
1697
],
[
1697,
57,
322
]
],
[
[
377,
7,
5675
],
[
5675,
57,
322
]
],
[
[
377,
21,
29672
],
[
29672,
60,
322
]
],
[
[
377,
23,
646
],
[
646,
62,
322
]
],
[
[
377,
24,
1307
],
[
1307,
62,
322
]
],
[
[
377,
63,
1648
],
[
1648,
24,
322
]
],
[
[
377,
24,
1224
],
[
1224,
63,
322
]
]
] | [
[
[
"Mitomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
]
],
[
[
"Mitomycin",
"{u} (Compound) treats {v} (Disease)",
"urinary bladder cancer"
],
[
"urinary bladder cancer",
"{u} (Disease) is treated by {v} (Compound)",
"Epirubicin"
]
],
[
[
"Mitomycin",
"{u} (Compound) upregulates {v} (Gene)",
"CXCR4"
],
[
"CXCR4",
"{u} (Gene) is upregulated by {v} (Compound)",
"Epirubicin"
]
],
[
[
"Mitomycin",
"{u} (Compound) downregulates {v} (Gene)",
"KPNA2"
],
[
"KPNA2",
"{u} (Gene) is downregulated by {v} (Compound)",
"Epirubicin"
]
],
[
[
"Mitomycin",
"{u} (Compound) upregulates {v} (Gene)",
"KIAA0907"
],
[
"KIAA0907",
"{u} (Gene) is downregulated by {v} (Compound)",
"Epirubicin"
]
],
[
[
"Mitomycin",
"{u} (Compound) causes {v} (Side Effect)",
"Metastatic disease"
],
[
"Metastatic disease",
"{u} (Side Effect) is caused by {v} (Compound)",
"Epirubicin"
]
],
[
[
"Mitomycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cinoxacin"
],
[
"Cinoxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Epirubicin"
]
],
[
[
"Mitomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Melphalan"
],
[
"Melphalan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Epirubicin"
]
],
[
[
"Mitomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
]
],
[
[
"Mitomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cytarabine"
],
[
"Cytarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
]
]
] | Mitomycin (Compound) treats urinary bladder cancer (Disease) and urinary bladder cancer (Disease) is treated by Epirubicin (Compound)
Mitomycin (Compound) upregulates CXCR4 (Gene) and CXCR4 (Gene) is upregulated by Epirubicin (Compound)
Mitomycin (Compound) downregulates KPNA2 (Gene) and KPNA2 (Gene) is downregulated by Epirubicin (Compound)
Mitomycin (Compound) upregulates KIAA0907 (Gene) and KIAA0907 (Gene) is downregulated by Epirubicin (Compound)
Mitomycin (Compound) causes Metastatic disease (Side Effect) and Metastatic disease (Side Effect) is caused by Epirubicin (Compound)
Mitomycin may cause a minor interaction that can limit clinical effects when taken with Cinoxacin and Cinoxacin may cause a minor interaction that can limit clinical effects when taken with Epirubicin
Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Melphalan and Melphalan may cause a minor interaction that can limit clinical effects when taken with Epirubicin
Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin
Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Cytarabine and Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin |
DB00983 | DB06203 | 480 | 1,002 | [
"DDInter776",
"DDInter51"
] | Formoterol | Alogliptin | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major clinical advantage of formoterol over other inhaled beta-agonists is its rapid onset of action (2-3 minutes), which is at least as fast as [salbutamol], combined with a long duration of action (12 hours) - for this reason, treatment guidelines for asthma recommend its use as both a reliever and maintenance medication. It is available as a single-entity product [L10986,L11223] and in several formulations in combination with both inhaled corticosteroids [L10995,L10619] and long-acting | Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25, 2013. | Moderate | 1 | [
[
[
480,
24,
1002
]
],
[
[
480,
24,
1281
],
[
1281,
40,
1002
]
],
[
[
480,
6,
12523
],
[
12523,
45,
1002
]
],
[
[
480,
21,
28778
],
[
28778,
60,
1002
]
],
[
[
480,
24,
504
],
[
504,
24,
1002
]
],
[
[
480,
63,
1680
],
[
1680,
24,
1002
]
],
[
[
480,
24,
1399
],
[
1399,
63,
1002
]
],
[
[
480,
74,
532
],
[
532,
24,
1002
]
],
[
[
480,
62,
175
],
[
175,
24,
1002
]
],
[
[
480,
23,
708
],
[
708,
24,
1002
]
]
] | [
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
],
[
"Linagliptin",
"{u} (Compound) resembles {v} (Compound)",
"Alogliptin"
]
],
[
[
"Formoterol",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Alogliptin"
]
],
[
[
"Formoterol",
"{u} (Compound) causes {v} (Side Effect)",
"Anaphylactic shock"
],
[
"Anaphylactic shock",
"{u} (Side Effect) is caused by {v} (Compound)",
"Alogliptin"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrochlorothiazide"
],
[
"Hydrochlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etacrynic acid"
],
[
"Etacrynic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
],
[
"Lithium carbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Formoterol",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dobutamine"
],
[
"Dobutamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Formoterol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Formoterol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Corticotropin"
],
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
]
] | Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin (Compound) resembles Alogliptin (Compound)
Formoterol (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Alogliptin (Compound)
Formoterol (Compound) causes Anaphylactic shock (Side Effect) and Anaphylactic shock (Side Effect) is caused by Alogliptin (Compound)
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Hydrochlorothiazide and Hydrochlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Etacrynic acid and Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate and Lithium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin
Formoterol (Compound) resembles Dobutamine (Compound) and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Dobutamine and Dobutamine may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin
Formoterol may cause a minor interaction that can limit clinical effects when taken with Triamcinolone and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin
Formoterol may cause a minor interaction that can limit clinical effects when taken with Corticotropin and Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin |
DB00726 | DB06595 | 1,164 | 1,491 | [
"DDInter1876",
"DDInter1214"
] | Trimipramine | Midostaurin | Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hematopoietic tumors . It was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents. | Moderate | 1 | [
[
[
1164,
24,
1491
]
],
[
[
1164,
23,
112
],
[
112,
23,
1491
]
],
[
[
1164,
63,
888
],
[
888,
24,
1491
]
],
[
[
1164,
24,
1342
],
[
1342,
24,
1491
]
],
[
[
1164,
24,
1662
],
[
1662,
63,
1491
]
],
[
[
1164,
25,
351
],
[
351,
63,
1491
]
],
[
[
1164,
35,
820
],
[
820,
24,
1491
]
],
[
[
1164,
1,
508
],
[
508,
24,
1491
]
],
[
[
1164,
25,
1133
],
[
1133,
24,
1491
]
],
[
[
1164,
64,
1494
],
[
1494,
24,
1491
]
]
] | [
[
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Trimipramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Midostaurin"
]
],
[
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
],
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
],
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Trimipramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Trimipramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Trimipramine",
"{u} (Compound) resembles {v} (Compound)",
"Promazine"
],
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Trimipramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Granisetron"
],
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Trimipramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Palonosetron"
],
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
]
] | Trimipramine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin and Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Trimipramine may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Trimipramine (Compound) resembles Alimemazine (Compound) and Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Trimipramine (Compound) resembles Promazine (Compound) and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Trimipramine may lead to a major life threatening interaction when taken with Granisetron and Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Trimipramine may lead to a major life threatening interaction when taken with Palonosetron and Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin |
DB00526 | DB06699 | 1,555 | 774 | [
"DDInter1355",
"DDInter493"
] | Oxaliplatin | Degarelix | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemical moiety, oxaliplatin readily undergoes non-enzymatic biotransformation, thus complicating oxaliplatin's pharmacokinetics. Like most platinum-based compounds, oxaliplatin's mechanism of action is primarily through DNA damage through DNA crosslinking, particularly intrastrand and interstrand crosslinking. However, due to the structure of oxaliplatin, its adducts make the binding of mismatch repair protein to DNA harder compared to cisplatin or carboplatin's adducts, resulting in greater cytotoxic effects. The | Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH) which ultimately causes testosterone suppression. Reduction in testosterone is important in treating men with advanced prostate cancer. Chemically, it is a synthetic linear decapeptide amide with seven unnatural amino acids, five of which are D-amino acids. FDA approved on December 24, 2008. | Moderate | 1 | [
[
[
1555,
24,
774
]
],
[
[
1555,
63,
521
],
[
521,
1,
774
]
],
[
[
1555,
24,
112
],
[
112,
23,
774
]
],
[
[
1555,
23,
1247
],
[
1247,
23,
774
]
],
[
[
1555,
24,
888
],
[
888,
24,
774
]
],
[
[
1555,
24,
484
],
[
484,
63,
774
]
],
[
[
1555,
63,
1570
],
[
1570,
24,
774
]
],
[
[
1555,
25,
770
],
[
770,
24,
774
]
],
[
[
1555,
25,
33
],
[
33,
25,
774
]
],
[
[
1555,
25,
880
],
[
880,
64,
774
]
]
] | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
"Goserelin",
"{u} (Compound) resembles {v} (Compound)",
"Degarelix"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Degarelix"
]
],
[
[
"Oxaliplatin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Degarelix"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azithromycin"
],
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amiodarone"
],
[
"Amiodarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Degarelix"
]
],
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivabradine"
],
[
"Ivabradine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Degarelix"
]
]
] | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin (Compound) resembles Degarelix (Compound)
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Degarelix
Oxaliplatin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Degarelix
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Degarelix
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Degarelix
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Azithromycin and Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Degarelix
Oxaliplatin may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Degarelix
Oxaliplatin may lead to a major life threatening interaction when taken with Amiodarone and Amiodarone may lead to a major life threatening interaction when taken with Degarelix
Oxaliplatin may lead to a major life threatening interaction when taken with Ivabradine and Ivabradine may lead to a major life threatening interaction when taken with Degarelix |
DB00641 | DB14730 | 467 | 1,412 | [
"DDInter1675",
"DDInter264"
] | Simvastatin | Calaspargase pegol | Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of _Aspergillus terreus_. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid and is the third step in a sequence of metabolic reactions involved in the production of several compounds involved in lipid metabolism and transport including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very low-density lipoprotein (VLDL). Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a | Asparaginase is an important agent used to treat acute lymphoblastic leukemia (ALL) . Asparagine is incorporated into most proteins, and the synthesis of proteins is stopped when asparagine is absent, which inhibits RNA and DNA synthesis, resulting in a halt in cellular proliferation. This forms the basis of asparaginase treatment in ALL , , . Calaspargase pegol, also known as _asparlas_, is an asparagine specific enzyme which is indicated as a part of a multi-agent chemotherapy regimen for the treatment of ALL . The asparagine specific enzyme is derived from Escherichia coli, as a conjugate of L-asparaginase (L-asparagine amidohydrolase) and monomethoxypolyethylene glycol (mPEG) with a succinimidyl carbonate (SC) linker to create a stable molecule which increases the half-life and decreases the dosing frequency [FDA label], . Calaspargase pegol, by _Shire_ pharmaceuticals, was approved by the FDA on December 20, 2018 for acute lymphoblastic anemia (ALL) . | Moderate | 1 | [
[
[
467,
24,
1412
]
],
[
[
467,
24,
1439
],
[
1439,
24,
1412
]
],
[
[
467,
63,
322
],
[
322,
24,
1412
]
],
[
[
467,
64,
1668
],
[
1668,
24,
1412
]
],
[
[
467,
23,
126
],
[
126,
24,
1412
]
],
[
[
467,
25,
384
],
[
384,
24,
1412
]
],
[
[
467,
24,
770
],
[
770,
25,
1412
]
],
[
[
467,
63,
1101
],
[
1101,
25,
1412
]
],
[
[
467,
25,
1377
],
[
1377,
25,
1412
]
],
[
[
467,
24,
1439
],
[
1439,
25,
792
],
[
792,
24,
1412
]
]
] | [
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipilimumab"
],
[
"Ipilimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Simvastatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lenalidomide"
],
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Simvastatin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Simvastatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Simvastatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipilimumab"
],
[
"Ipilimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rivaroxaban"
],
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
]
] | Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab and Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Simvastatin may lead to a major life threatening interaction when taken with Lenalidomide and Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Simvastatin may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Simvastatin may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Calaspargase pegol
Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Calaspargase pegol
Simvastatin may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Calaspargase pegol
Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab and Ipilimumab may lead to a major life threatening interaction when taken with Rivaroxaban and Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol |
DB00501 | DB09039 | 752 | 1,670 | [
"DDInter380",
"DDInter629"
] | Cimetidine | Eliglustat | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy. | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher disease, the accumulation of glucosylceramide leads to the formation of Gaucher cells that infiltrate the liver, spleen, bone marrow and other organs. This leads to complications such as anemia and thrombocytopenia.[L41404,A246384] By inhibiting glucosylceramide synthase, eliglustat reduces the accumulation of glucosylceramide. Eliglustat is mainly metabolized by CYP2D6. Patients selected for eliglustat treatment undergo an FDA-cleared genotyping test to establish if they are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs). The results of this test dictate eliglustat dosing recommendations for each type of patient. There are no dosing recommendations for CYP2D6 ultra-rapid or indeterminate metabolizers.[L41404,A7634] Eliglustat was approved by the FDA in August 2014 as an oral substrate reduction therapy for the first-line treatment of type 1 Gaucher disease.[L41404,A7634] Enzyme replacement continues to be the standard of care for the treatment of type 1 Gaucher disease ([imiglucerase], [velaglucerase alfa], [taliglucerase alfa]); however, oral substrate reduction therapies with favourable safety profiles, such as eliglustat, represent a treatment alternative.[A246389,A7634] | Major | 2 | [
[
[
752,
25,
1670
]
],
[
[
752,
24,
479
],
[
479,
23,
1670
]
],
[
[
752,
23,
1135
],
[
1135,
62,
1670
]
],
[
[
752,
24,
1164
],
[
1164,
24,
1670
]
],
[
[
752,
64,
322
],
[
322,
24,
1670
]
],
[
[
752,
23,
1664
],
[
1664,
24,
1670
]
],
[
[
752,
62,
288
],
[
288,
24,
1670
]
],
[
[
752,
24,
861
],
[
861,
63,
1670
]
],
[
[
752,
63,
88
],
[
88,
24,
1670
]
],
[
[
752,
25,
543
],
[
543,
24,
1670
]
]
] | [
[
[
"Cimetidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eliglustat"
]
],
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
"Donepezil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Eliglustat"
]
],
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Eliglustat"
]
],
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimipramine"
],
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Cimetidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Risperidone"
],
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Butalbital"
],
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ripretinib"
],
[
"Ripretinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoprolol"
],
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Cimetidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Loperamide"
],
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
]
] | Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Eliglustat
Cimetidine may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Eliglustat
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Cimetidine may lead to a major life threatening interaction when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Cimetidine may cause a minor interaction that can limit clinical effects when taken with Risperidone and Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Cimetidine may cause a minor interaction that can limit clinical effects when taken with Butalbital and Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib and Ripretinib may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Metoprolol and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Cimetidine may lead to a major life threatening interaction when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat |
DB00687 | DB06414 | 870 | 655 | [
"DDInter747",
"DDInter703"
] | Fludrocortisone | Etravirine | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to [cortisol], differing only by a fluorine atom at the 9-position of the steroid structure - this fluorination is thought to be crucial to fludrocortisone's significant mineralocorticoid potency. | Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 100mg tablets in the treatment of adult HIV-1 infection documented to be resistant to therapy with other NNRTIs and antiretroviral agents. On March 26, 2012, approval was extended for use in treatment-experienced pediatric patients 6 to 18 years of age, weighing at least 16 kg. Etravarine must always be used in combination with other antiretroviral drugs. Etravirine exerts its effects via direct inhibition of the reverse transcriptase enzyme of human immunodeficiency virus type 1 (HIV-1), and consequently blocks DNA-dependent and RNA-dependent polymerase activity. Etravirine does not inhibit human DNA polymerase alpha, beta or gamma. Common side effects of use include mild to moderate rash within the first 6 weeks of therapy, nausea, diarrhea and peripheral neuropathy. Patients are advised to immediately contact their healthcare provider if a rash develops. In 2009, postmarketing case reports of Stevens-Johnson Syndrome, toxic epidermal necrolysis, erythema multiforme, and other hypersensitivity reactions lead to a revision of etravirine's "Warnings and Precautions," as well as notification of health care providers. In 2013, reports of Autoimmune disorders (such as Graves’ disease, polymyositis, and Guillain-Barré syndrome) in the setting of immune reconstitution, as well as more in depth information about the development of rashes in patients taking etravirine, lead to a modification of etravirine's monograph. | Moderate | 1 | [
[
[
870,
24,
655
]
],
[
[
870,
21,
28936
],
[
28936,
60,
655
]
],
[
[
870,
63,
1101
],
[
1101,
23,
655
]
],
[
[
870,
1,
175
],
[
175,
24,
655
]
],
[
[
870,
64,
1057
],
[
1057,
24,
655
]
],
[
[
870,
63,
245
],
[
245,
24,
655
]
],
[
[
870,
24,
1144
],
[
1144,
24,
655
]
],
[
[
870,
25,
976
],
[
976,
63,
655
]
],
[
[
870,
24,
384
],
[
384,
63,
655
]
],
[
[
870,
62,
1018
],
[
1018,
24,
655
]
]
] | [
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
]
],
[
[
"Fludrocortisone",
"{u} (Compound) causes {v} (Side Effect)",
"Hyperhidrosis"
],
[
"Hyperhidrosis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Etravirine"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Etravirine"
]
],
[
[
"Fludrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
]
],
[
[
"Fludrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
]
],
[
[
"Fludrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
]
],
[
[
"Fludrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
]
]
] | Fludrocortisone (Compound) causes Hyperhidrosis (Side Effect) and Hyperhidrosis (Side Effect) is caused by Etravirine (Compound)
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Etravirine
Fludrocortisone (Compound) resembles Triamcinolone (Compound) and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Etravirine
Fludrocortisone may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Etravirine
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Etravirine
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Etravirine
Fludrocortisone may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Etravirine
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Etravirine
Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with Ticlopidine and Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Etravirine |
DB00731 | DB00867 | 1,144 | 1,052 | [
"DDInter1269",
"DDInter1606"
] | Nateglinide | Ritodrine | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may | Adrenergic beta-agonist used to control premature labor. | Moderate | 1 | [
[
[
1144,
24,
1052
]
],
[
[
1144,
24,
532
],
[
532,
40,
1052
]
],
[
[
1144,
63,
1523
],
[
1523,
40,
1052
]
],
[
[
1144,
63,
870
],
[
870,
23,
1052
]
],
[
[
1144,
24,
708
],
[
708,
62,
1052
]
],
[
[
1144,
24,
167
],
[
167,
23,
1052
]
],
[
[
1144,
24,
1148
],
[
1148,
63,
1052
]
],
[
[
1144,
63,
1466
],
[
1466,
24,
1052
]
],
[
[
1144,
24,
1445
],
[
1445,
24,
1052
]
],
[
[
1144,
63,
11
],
[
11,
25,
1052
]
]
] | [
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ritodrine"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dobutamine"
],
[
"Dobutamine",
"{u} (Compound) resembles {v} (Compound)",
"Ritodrine"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Labetalol"
],
[
"Labetalol",
"{u} (Compound) resembles {v} (Compound)",
"Ritodrine"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ritodrine"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
],
[
"Corticotropin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ritodrine"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ritodrine"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ritodrine"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylpropanolamine"
],
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ritodrine"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pseudoephedrine"
],
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ritodrine"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Toremifene"
],
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ritodrine"
]
]
] | Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Dobutamine and Dobutamine (Compound) resembles Ritodrine (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Labetalol and Labetalol (Compound) resembles Ritodrine (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with Ritodrine
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin and Corticotropin may cause a minor interaction that can limit clinical effects when taken with Ritodrine
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Ritodrine
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Ritodrine
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Phenylpropanolamine and Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Ritodrine
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Ritodrine
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Toremifene and Toremifene may lead to a major life threatening interaction when taken with Ritodrine |
DB00023 | DB01076 | 305 | 700 | [
"DDInter127",
"DDInter133"
] | Asparaginase Escherichia coli | Atorvastatin | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginase from _E. coli_ has clinically shown to exhibit antitumor actions in models of leukaemias [A31996, A31997]. L-asparaginase of _E. coli_ is marketed under several different trade names, including Elspar, for the treatment of acute lymphoblastic leukemia (ALL) as part of a multi-agent chemotherapeutic regimen. It is available as intramuscular or intravenous injections. Therapeutic L-asparaginase from _E. coli_ works by depleting the levels | Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid. This conversion is a critical metabolic reaction involved in the production of several compounds involved in lipid metabolism and transport, including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very-low-density lipoprotein (VLDL). Prescribing statins is considered standard practice for patients following any cardiovascular event, and for people who are at moderate to high risk of developing cardiovascular disease. The evidence supporting statin use, coupled with minimal side effects and long term benefits, has resulted in wide use of this medication in North America.[A181087, A181406] Atorvastatin and other statins including [lovastatin], [pravastatin], [rosuvastatin], [fluvastatin], and [simvastatin] are considered first-line treatment options for dyslipidemia.[A181087, A181406] The increasing use of this class of drugs is largely attributed to the rise in cardiovascular diseases (CVD) (such as heart attack, atherosclerosis, angina, peripheral artery disease, and stroke) in many countries. An elevated cholesterol level (elevated low-density lipoprotein (LDL) levels in particular) is a significant risk factor for the development of CVD.[A181087,A181553] Several landmark studies demonstrate that the use of statins is associated with both a reduction in LDL levels and CVD risk.[A181090,A181093,A181096,A181427,A181475,A181538] Statins were shown to reduce the incidences of all-cause mortality, including fatal and non-fatal CVD, as well as the need for surgical revascularization or angioplasty following a heart attack.[A181087, A181406] Some evidence has shown that even for low-risk individuals (with <10% risk of a major vascular event occurring within five years) statin use leads to a 20%-22% relative reduction in the number of major cardiovascular events (heart attack, stroke, coronary revascularization, and coronary death) for every 1 mmol/L reduction in LDL without any significant side effects or risks.[A181397, A181403] Atorvastatin was first synthesized in 1985 by Dr. Bruce Roth and approved by the FDA in 1996. It is a pentasubstituted pyrrole formed by two contrasting moieties with an achiral heterocyclic core unit and a 3,5-dihydroxypentanoyl side chain identical to its parent compound. Unlike other members of the statin group, atorvastatin is an active compound and therefore does not require activation. | Moderate | 1 | [
[
[
305,
24,
700
]
],
[
[
305,
24,
788
],
[
788,
1,
700
]
],
[
[
305,
24,
303
],
[
303,
23,
700
]
],
[
[
305,
24,
578
],
[
578,
62,
700
]
],
[
[
305,
24,
467
],
[
467,
24,
700
]
],
[
[
305,
25,
770
],
[
770,
24,
700
]
],
[
[
305,
24,
14
],
[
14,
63,
700
]
],
[
[
305,
63,
268
],
[
268,
24,
700
]
],
[
[
305,
25,
908
],
[
908,
63,
700
]
],
[
[
305,
64,
1057
],
[
1057,
24,
700
]
]
] | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atorvastatin"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
],
[
"Pitavastatin",
"{u} (Compound) resembles {v} (Compound)",
"Atorvastatin"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Medroxyprogesterone acetate"
],
[
"Medroxyprogesterone acetate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Atorvastatin"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Atorvastatin"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
],
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atorvastatin"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atorvastatin"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
],
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atorvastatin"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon alfa-2b"
],
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atorvastatin"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
],
[
"Golimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atorvastatin"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atorvastatin"
]
]
] | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin (Compound) resembles Atorvastatin (Compound)
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Medroxyprogesterone acetate and Medroxyprogesterone acetate may cause a minor interaction that can limit clinical effects when taken with Atorvastatin
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Atorvastatin
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Atorvastatin
Asparaginase Escherichia coli may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Atorvastatin
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Atorvastatin
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2b and Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Atorvastatin
Asparaginase Escherichia coli may lead to a major life threatening interaction when taken with Golimumab and Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Atorvastatin
Asparaginase Escherichia coli may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Atorvastatin |
DB00832 | DB01142 | 499 | 1,264 | [
"DDInter1446",
"DDInter593"
] | Phensuximide | Doxepin | Phensuximide is a member of the succinimide class with anticonvulsant properties. It suppresses the paroxysmal three cycle per second spike and wave EEG pattern associated with lapses of consciousness in petit mal seizures. The frequency of attacks is reduced by depression of nerve transmission in the motor cortex. | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepressant but it is commonly associated with the class since it shares a lot of properties with members of the drug family including [amitriptyline], [clomipramine], [desipramine], [imipramine], [nortriptyline], [protriptyline] and [trimipramine]. Doxepin was developed by Pfizer and FDA approved in 1969 as an antidepressant. However, in 2010 it was approved for the treatment of insomnia. The latter indication was presented by Pernix Therapeutics. | Moderate | 1 | [
[
[
499,
24,
1264
]
],
[
[
499,
24,
401
],
[
401,
24,
1264
]
],
[
[
499,
63,
1594
],
[
1594,
24,
1264
]
],
[
[
499,
1,
11305
],
[
11305,
40,
1264
]
],
[
[
499,
6,
10215
],
[
10215,
45,
1264
]
],
[
[
499,
1,
157
],
[
157,
24,
1264
]
],
[
[
499,
24,
407
],
[
407,
63,
1264
]
],
[
[
499,
1,
341
],
[
341,
63,
1264
]
],
[
[
499,
24,
1487
],
[
1487,
64,
1264
]
],
[
[
499,
24,
222
],
[
222,
25,
1264
]
]
] | [
[
[
"Phensuximide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Phensuximide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Phensuximide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Phensuximide",
"{u} (Compound) resembles {v} (Compound)",
"Phenindione"
],
[
"Phenindione",
"{u} (Compound) resembles {v} (Compound)",
"Doxepin"
]
],
[
[
"Phensuximide",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",
"Doxepin"
]
],
[
[
"Phensuximide",
"{u} (Compound) resembles {v} (Compound)",
"Ethotoin"
],
[
"Ethotoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Phensuximide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Phensuximide",
"{u} (Compound) resembles {v} (Compound)",
"Phendimetrazine"
],
[
"Phendimetrazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Phensuximide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
],
[
"Hydroxychloroquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxepin"
]
],
[
[
"Phensuximide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxepin"
]
]
] | Phensuximide may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Phensuximide may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Phensuximide (Compound) resembles Phenindione (Compound) and Phenindione (Compound) resembles Doxepin (Compound)
Phensuximide (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Doxepin (Compound)
Phensuximide (Compound) resembles Ethotoin (Compound) and Ethotoin may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Phensuximide may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Phensuximide (Compound) resembles Phendimetrazine (Compound) and Phendimetrazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Phensuximide may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine and Hydroxychloroquine may lead to a major life threatening interaction when taken with Doxepin
Phensuximide may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may lead to a major life threatening interaction when taken with Doxepin |
DB00912 | DB09043 | 473 | 135 | [
"DDInter1581",
"DDInter36"
] | Repaglinide | Albiglutide | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on April 15, 2014 by the FDA. | Moderate | 1 | [
[
[
473,
24,
135
]
],
[
[
473,
62,
1103
],
[
1103,
23,
135
]
],
[
[
473,
24,
624
],
[
624,
24,
135
]
],
[
[
473,
63,
323
],
[
323,
24,
135
]
],
[
[
473,
64,
646
],
[
646,
24,
135
]
],
[
[
473,
24,
320
],
[
320,
63,
135
]
],
[
[
473,
25,
739
],
[
739,
24,
135
]
],
[
[
473,
25,
255
],
[
255,
63,
135
]
],
[
[
473,
63,
1101
],
[
1101,
25,
135
]
],
[
[
473,
25,
246
],
[
246,
25,
135
]
]
] | [
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Repaglinide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Albiglutide"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liotrix"
],
[
"Liotrix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bendroflumethiazide"
],
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Repaglinide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cinoxacin"
],
[
"Cinoxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thyroid, porcine"
],
[
"Thyroid, porcine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Repaglinide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomefloxacin"
],
[
"Lomefloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Repaglinide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Delafloxacin"
],
[
"Delafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Albiglutide"
]
],
[
[
"Repaglinide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gatifloxacin"
],
[
"Gatifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Albiglutide"
]
]
] | Repaglinide may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Liotrix and Liotrix may cause a moderate interaction that could exacerbate diseases when taken with Albiglutide
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Bendroflumethiazide and Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Albiglutide
Repaglinide may lead to a major life threatening interaction when taken with Cinoxacin and Cinoxacin may cause a moderate interaction that could exacerbate diseases when taken with Albiglutide
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Thyroid, porcine and Thyroid, porcine may cause a moderate interaction that could exacerbate diseases when taken with Albiglutide
Repaglinide may lead to a major life threatening interaction when taken with Lomefloxacin and Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Albiglutide
Repaglinide may lead to a major life threatening interaction when taken with Delafloxacin and Delafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Albiglutide
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Albiglutide
Repaglinide may lead to a major life threatening interaction when taken with Gatifloxacin and Gatifloxacin may lead to a major life threatening interaction when taken with Albiglutide |
DB00115 | DB00736 | 227 | 660 | [
"DDInter451",
"DDInter676"
] | Cyanocobalamin | Esomeprazole | Cyanocobalamin (commonly known as Vitamin B12) is a highly complex, essential vitamin, owing its name to the fact that it contains the mineral, cobalt. This vitamin is produced naturally by bacteria, and is necessary for DNA synthesis and cellular energy production. Vitamin B12 has many forms, including the cyano-, methyl-, deoxyadenosyl- and hydroxy-cobalamin forms. The _cyano_ form, is the most widely used form in supplements and prescription drugs, [FDA label]. Several pharmaceutical forms of cyanocobalamin have been developed, including the tablet, injection, and nasal spray forms [FDA label],,. This drug was initially approved by the FDA in 1942 [FDA label]. | Esomeprazole, sold under the brand name Nexium, is a proton pump inhibitor (PPI) medication used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome. It can also be found in quadruple regimens for the treatment of _H. pylori_ infections along with other antibiotics including , , and , for example.[A177271, F4498] Its efficacy is considered similar to other medications within the PPI class including , , , , and . Esomeprazole is the s-isomer of , which is a racemate of the S- and R-enantiomer. Esomeprazole has been shown to inhibit acid secretion to a similar extent as , without any significant differences between the two compounds _in vitro_. Esomeprazole exerts its stomach acid-suppressing effects by preventing the final step in gastric acid production by covalently binding to sulfhydryl groups of cysteines found on the (H+, K+)-ATPase enzyme at the secretory surface of gastric parietal cells. This effect leads to inhibition of both basal and stimulated gastric acid secretion, irrespective of the stimulus. As the binding of esomeprazole to the (H+, K+)-ATPase enzyme is irreversible and new enzyme needs to be expressed in order to resume acid secretion, esomeprazole's duration of antisecretory effect persists longer than 24 hours.[FDA Label] PPIs such as esomeprazole have also been shown to inhibit the activity of dimethylarginine dimethylaminohydrolase (DDAH), an enzyme necessary for cardiovascular health. DDAH inhibition causes a consequent accumulation of the nitric oxide synthase inhibitor asymmetric dimethylarginie (ADMA), which is thought to cause the association of PPIs with increased risk of cardiovascular events in patients with unstable coronary syndromes.[A177577, A177580] Due to their good safety profile and as several PPIs are available over the counter without a prescription, their current use in North America is widespread. Long term use of PPIs such as esomeprazole has been associated with possible adverse effects, however, including increased susceptibility to bacterial infections (including gastrointestinal _C. difficile_), reduced absorption of micronutrients such as iron and B12, and an increased risk of developing hypomagnesemia and hypocalcemia which may contribute to osteoporosis and bone fractures later in life. Rapid discontinuation of PPIs such as esomeprazole may cause a rebound effect and a short term increase in hypersecretion. Esomeprazole doses should be slowly lowered, or tapered, before discontinuing to prevent this rebound effect. | Minor | 0 | [
[
[
227,
23,
660
]
],
[
[
227,
23,
1215
],
[
1215,
40,
660
]
],
[
[
227,
23,
837
],
[
837,
1,
660
]
],
[
[
227,
23,
1215
],
[
1215,
40,
379
],
[
379,
40,
660
]
],
[
[
227,
23,
379
],
[
379,
1,
1215
],
[
1215,
40,
660
]
],
[
[
227,
1,
204
],
[
204,
21,
28741
],
[
28741,
60,
660
]
],
[
[
227,
23,
1215
],
[
1215,
40,
117
],
[
117,
1,
660
]
],
[
[
227,
6,
10455
],
[
10455,
56,
13230
],
[
13230,
46,
660
]
],
[
[
227,
6,
7289
],
[
7289,
48,
11562
],
[
11562,
49,
660
]
],
[
[
227,
23,
837
],
[
837,
1,
117
],
[
117,
1,
660
]
]
] | [
[
[
"Cyanocobalamin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Esomeprazole"
]
],
[
[
"Cyanocobalamin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lansoprazole"
],
[
"Lansoprazole",
"{u} (Compound) resembles {v} (Compound)",
"Esomeprazole"
]
],
[
[
"Cyanocobalamin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pantoprazole"
],
[
"Pantoprazole",
"{u} (Compound) resembles {v} (Compound)",
"Esomeprazole"
]
],
[
[
"Cyanocobalamin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lansoprazole"
],
[
"Lansoprazole",
"{u} (Compound) resembles {v} (Compound)",
"Rabeprazole"
],
[
"Rabeprazole",
"{u} (Compound) resembles {v} (Compound)",
"Esomeprazole"
]
],
[
[
"Cyanocobalamin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rabeprazole"
],
[
"Rabeprazole",
"{u} (Compound) resembles {v} (Compound)",
"Lansoprazole"
],
[
"Lansoprazole",
"{u} (Compound) resembles {v} (Compound)",
"Esomeprazole"
]
],
[
[
"Cyanocobalamin",
"{u} (Compound) resembles {v} (Compound)",
"Hydroxocobalamin"
],
[
"Hydroxocobalamin",
"{u} (Compound) causes {v} (Side Effect)",
"Agitation"
],
[
"Agitation",
"{u} (Side Effect) is caused by {v} (Compound)",
"Esomeprazole"
]
],
[
[
"Cyanocobalamin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lansoprazole"
],
[
"Lansoprazole",
"{u} (Compound) resembles {v} (Compound)",
"Omeprazole"
],
[
"Omeprazole",
"{u} (Compound) resembles {v} (Compound)",
"Esomeprazole"
]
],
[
[
"Cyanocobalamin",
"{u} (Compound) binds {v} (Gene)",
"MUT"
],
[
"MUT",
"{u} (Gene) is regulated by {v} (Gene)",
"TIPARP"
],
[
"TIPARP",
"{u} (Gene) is upregulated by {v} (Compound)",
"Esomeprazole"
]
],
[
[
"Cyanocobalamin",
"{u} (Compound) binds {v} (Gene)",
"TCN2"
],
[
"TCN2",
"{u} (Gene) is associated with {v} (Disease)",
"prostate cancer"
],
[
"prostate cancer",
"{u} (Disease) is palliated by {v} (Compound)",
"Esomeprazole"
]
],
[
[
"Cyanocobalamin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pantoprazole"
],
[
"Pantoprazole",
"{u} (Compound) resembles {v} (Compound)",
"Omeprazole"
],
[
"Omeprazole",
"{u} (Compound) resembles {v} (Compound)",
"Esomeprazole"
]
]
] | Cyanocobalamin may cause a minor interaction that can limit clinical effects when taken with Lansoprazole and Lansoprazole (Compound) resembles Esomeprazole (Compound)
Cyanocobalamin may cause a minor interaction that can limit clinical effects when taken with Pantoprazole and Pantoprazole (Compound) resembles Esomeprazole (Compound)
Cyanocobalamin may cause a minor interaction that can limit clinical effects when taken with Lansoprazole and Lansoprazole (Compound) resembles Rabeprazole (Compound) and Rabeprazole (Compound) resembles Esomeprazole (Compound)
Cyanocobalamin may cause a minor interaction that can limit clinical effects when taken with Rabeprazole and Rabeprazole (Compound) resembles Lansoprazole (Compound) and Lansoprazole (Compound) resembles Esomeprazole (Compound)
Cyanocobalamin (Compound) resembles Hydroxocobalamin (Compound) and Hydroxocobalamin (Compound) causes Agitation (Side Effect) and Agitation (Side Effect) is caused by Esomeprazole (Compound)
Cyanocobalamin may cause a minor interaction that can limit clinical effects when taken with Lansoprazole and Lansoprazole (Compound) resembles Omeprazole (Compound) and Omeprazole (Compound) resembles Esomeprazole (Compound)
Cyanocobalamin (Compound) binds MUT (Gene) and MUT (Gene) is regulated by TIPARP (Gene) and TIPARP (Gene) is upregulated by Esomeprazole (Compound)
Cyanocobalamin (Compound) binds TCN2 (Gene) and TCN2 (Gene) is associated with prostate cancer (Disease) and prostate cancer (Disease) is palliated by Esomeprazole (Compound)
Cyanocobalamin may cause a minor interaction that can limit clinical effects when taken with Pantoprazole and Pantoprazole (Compound) resembles Omeprazole (Compound) and Omeprazole (Compound) resembles Esomeprazole (Compound) |
DB00747 | DB01036 | 1,442 | 211 | [
"DDInter1647",
"DDInter1832"
] | Scopolamine | Tolterodine | Scopolamine is a tropane alkaloid isolated from members of the _Solanaceae_ family of plants, similar to [atropine] and [hyoscyamine], all of which structurally mimic the natural neurotransmitter [acetylcholine].[A228423, A228763] Scopolamine was first synthesized in 1959, but to date, synthesis remains less efficient than extracting scopolamine from plants. As an acetylcholine analogue, scopolamine can antagonize muscarinic acetylcholine receptors (mAChRs) in the central nervous system and throughout the body, inducing several therapeutic and adverse effects related to alteration of parasympathetic nervous system and cholinergic signalling.[A228758, L31578] Due to its dose-dependent adverse effects, scopolamine was the first drug to be offered commercially as a transdermal delivery system, Scopoderm TTS®, in 1981.[A228423, | Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors. | Moderate | 1 | [
[
[
1442,
24,
211
]
],
[
[
1442,
24,
358
],
[
358,
40,
211
]
],
[
[
1442,
63,
1523
],
[
1523,
40,
211
]
],
[
[
1442,
63,
128
],
[
128,
24,
211
]
],
[
[
1442,
24,
100
],
[
100,
24,
211
]
],
[
[
1442,
6,
4304
],
[
4304,
45,
211
]
],
[
[
1442,
21,
28779
],
[
28779,
60,
211
]
],
[
[
1442,
74,
85
],
[
85,
24,
211
]
],
[
[
1442,
24,
1264
],
[
1264,
63,
211
]
],
[
[
1442,
25,
1621
],
[
1621,
25,
211
]
]
] | [
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolterodine"
]
],
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
],
[
"Orphenadrine",
"{u} (Compound) resembles {v} (Compound)",
"Tolterodine"
]
],
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Labetalol"
],
[
"Labetalol",
"{u} (Compound) resembles {v} (Compound)",
"Tolterodine"
]
],
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
],
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolterodine"
]
],
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolterodine"
]
],
[
[
"Scopolamine",
"{u} (Compound) binds {v} (Gene)",
"CHRM2"
],
[
"CHRM2",
"{u} (Gene) is bound by {v} (Compound)",
"Tolterodine"
]
],
[
[
"Scopolamine",
"{u} (Compound) causes {v} (Side Effect)",
"Dry mouth"
],
[
"Dry mouth",
"{u} (Side Effect) is caused by {v} (Compound)",
"Tolterodine"
]
],
[
[
"Scopolamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atropine"
],
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolterodine"
]
],
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolterodine"
]
],
[
[
"Scopolamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium chloride"
],
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tolterodine"
]
]
] | Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine and Orphenadrine (Compound) resembles Tolterodine (Compound)
Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Labetalol and Labetalol (Compound) resembles Tolterodine (Compound)
Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine
Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine
Scopolamine (Compound) binds CHRM2 (Gene) and CHRM2 (Gene) is bound by Tolterodine (Compound)
Scopolamine (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Tolterodine (Compound)
Scopolamine (Compound) resembles Atropine (Compound) and Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine
Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine
Scopolamine may lead to a major life threatening interaction when taken with Potassium chloride and Potassium chloride may lead to a major life threatening interaction when taken with Tolterodine |
DB00176 | DB00604 | 529 | 1,425 | [
"DDInter770",
"DDInter385"
] | Fluvoxamine | Cisapride | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised of approximately 35,000 patients. It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine. | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | Major | 2 | [
[
[
529,
25,
1425
]
],
[
[
529,
24,
1311
],
[
1311,
1,
1425
]
],
[
[
529,
6,
21998
],
[
21998,
45,
1425
]
],
[
[
529,
24,
475
],
[
475,
23,
1425
]
],
[
[
529,
24,
1362
],
[
1362,
63,
1425
]
],
[
[
529,
24,
971
],
[
971,
64,
1425
]
],
[
[
529,
25,
477
],
[
477,
64,
1425
]
],
[
[
529,
24,
702
],
[
702,
25,
1425
]
],
[
[
529,
23,
1424
],
[
1424,
25,
1425
]
],
[
[
529,
25,
1494
],
[
1494,
25,
1425
]
]
] | [
[
[
"Fluvoxamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisapride"
]
],
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} (Compound) resembles {v} (Compound)",
"Cisapride"
]
],
[
[
"Fluvoxamine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A7-CYP3A51P"
],
[
"CYP3A7-CYP3A51P",
"{u} (Gene) is bound by {v} (Compound)",
"Cisapride"
]
],
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cisapride"
]
],
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisapride"
]
],
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisapride"
]
],
[
[
"Fluvoxamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cilostazol"
],
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisapride"
]
],
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisapride"
]
],
[
[
"Fluvoxamine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Quinine"
],
[
"Quinine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisapride"
]
],
[
[
"Fluvoxamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Palonosetron"
],
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisapride"
]
]
] | Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide (Compound) resembles Cisapride (Compound)
Fluvoxamine (Compound) binds CYP3A7-CYP3A51P (Gene) and CYP3A7-CYP3A51P (Gene) is bound by Cisapride (Compound)
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a minor interaction that can limit clinical effects when taken with Cisapride
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Cisapride
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may lead to a major life threatening interaction when taken with Cisapride
Fluvoxamine may lead to a major life threatening interaction when taken with Cilostazol and Cilostazol may lead to a major life threatening interaction when taken with Cisapride
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Cisapride
Fluvoxamine may cause a minor interaction that can limit clinical effects when taken with Quinine and Quinine may lead to a major life threatening interaction when taken with Cisapride
Fluvoxamine may lead to a major life threatening interaction when taken with Palonosetron and Palonosetron may lead to a major life threatening interaction when taken with Cisapride |
DB00033 | DB15091 | 342 | 676 | [
"DDInter949",
"DDInter1901"
] | Interferon gamma-1b | Upadacitinib | Human Interferon gamma-1b (140 residues), produced from E. coli. Production of Actimmune is achieved by fermentation of a genetically engineered Escherichia coli bacterium containing the DNA which encodes for the human protein. Purification of the product is achieved by conventional column chromatography. The sequence displayed is a cDNA sequence which codes for human interferon gamma, as described by Gray et. al. and not specifically interferon gamma 1b. | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage damage and bone destruction, leading to co-morbidities. Despite a variety of therapeutic agents available for treatment, up to 40% of the patients do not respond to current therapies, including biological therapies. The etiology of the disease is mostly unknown; however, the role of JAK as a driver of immune-mediated conditions was discovered, leading to the use of JAK as therapeutic targets for rheumatoid arthritis. To reduce dose-related toxicity (as seen with some pan-JAK inhibitors) without significantly affecting efficacy, more selective JAK1 inhibitors, upadacitinib and [filgotinib], were developed. The FDA approved upadacitinib in August 2019 and it is used for the treatment of active rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and ankylosing spondylitis. In December 2019, it was additionally approved by the European Commission and Health Canada.[L10899,L42540] Upadacitinib is marketed under the brand name RINVOQ for oral administration. | Major | 2 | [
[
[
342,
25,
676
]
],
[
[
342,
24,
1430
],
[
1430,
24,
676
]
],
[
[
342,
24,
869
],
[
869,
25,
676
]
],
[
[
342,
25,
1064
],
[
1064,
25,
676
]
],
[
[
342,
63,
305
],
[
305,
25,
676
]
],
[
[
342,
24,
1430
],
[
1430,
63,
1184
],
[
1184,
25,
676
]
],
[
[
342,
24,
597
],
[
597,
24,
1249
],
[
1249,
24,
676
]
],
[
[
342,
24,
810
],
[
810,
63,
248
],
[
248,
24,
676
]
],
[
[
342,
24,
869
],
[
869,
63,
1461
],
[
1461,
23,
676
]
],
[
[
342,
24,
270
],
[
270,
62,
1193
],
[
1193,
23,
676
]
]
] | [
[
[
"Interferon gamma-1b",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Interferon gamma-1b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
],
[
[
"Interferon gamma-1b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[
"Topotecan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Interferon gamma-1b",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Interferon gamma-1b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparaginase Escherichia coli",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Interferon gamma-1b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anakinra"
],
[
"Anakinra",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Interferon gamma-1b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nafcillin"
],
[
"Nafcillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
],
[
[
"Interferon gamma-1b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
],
[
"Strontium chloride Sr-89",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
],
[
"Valganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
],
[
[
"Interferon gamma-1b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Upadacitinib"
]
],
[
[
"Interferon gamma-1b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Upadacitinib"
]
]
] | Interferon gamma-1b may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Interferon gamma-1b may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may lead to a major life threatening interaction when taken with Upadacitinib
Interferon gamma-1b may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Upadacitinib
Interferon gamma-1b may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may lead to a major life threatening interaction when taken with Upadacitinib
Interferon gamma-1b may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may lead to a major life threatening interaction when taken with Upadacitinib
Interferon gamma-1b may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Nafcillin and Nafcillin may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Interferon gamma-1b may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89 and Strontium chloride Sr-89 may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir and Valganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Interferon gamma-1b may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Upadacitinib
Interferon gamma-1b may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Upadacitinib |
DB11613 | DB12364 | 1,519 | 1,421 | [
"DDInter1924",
"DDInter200"
] | Velpatasvir | Betrixaban | Velpatasvir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients. Velpatasvir acts as a defective substrate for NS5A (Non-Structural Protein 5A), a non-enzymatic viral protein that plays a key role in Hepatitis C Virus replication, assembly, and modulation of host immune responses. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) such as velpatasvir. Notably, velpatasvir has a significantly higher barrier to resistance than the first generation NS5A | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals Inc., is prescribed as a venous thromboembolism (VTE) prophylactic for adult patients with moderate to severe restricted motility or with other risks for VTE . VTE can be manifested as deep vein thrombosis or pulmonary embolism and it is a leading cause of preventable death in hospitalized patients . | Moderate | 1 | [
[
[
1519,
24,
1421
]
],
[
[
1519,
24,
971
],
[
971,
24,
1421
]
],
[
[
1519,
64,
129
],
[
129,
24,
1421
]
],
[
[
1519,
64,
498
],
[
498,
25,
1421
]
],
[
[
1519,
63,
868
],
[
868,
25,
1421
]
],
[
[
1519,
24,
971
],
[
971,
64,
1091
],
[
1091,
24,
1421
]
],
[
[
1519,
64,
129
],
[
129,
63,
1091
],
[
1091,
24,
1421
]
],
[
[
1519,
64,
498
],
[
498,
23,
297
],
[
297,
23,
1421
]
],
[
[
1519,
63,
868
],
[
868,
63,
1091
],
[
1091,
24,
1421
]
],
[
[
1519,
62,
1135
],
[
1135,
62,
807
],
[
807,
24,
1421
]
]
] | [
[
[
"Velpatasvir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Velpatasvir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Velpatasvir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Velpatasvir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Edoxaban"
],
[
"Edoxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Velpatasvir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Velpatasvir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amprenavir"
],
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Velpatasvir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amprenavir"
],
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Velpatasvir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Edoxaban"
],
[
"Edoxaban",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
],
[
"Clove",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Betrixaban"
]
],
[
[
"Velpatasvir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amprenavir"
],
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Velpatasvir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ulipristal"
],
[
"Ulipristal",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
]
] | Velpatasvir may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Velpatasvir may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Velpatasvir may lead to a major life threatening interaction when taken with Edoxaban and Edoxaban may lead to a major life threatening interaction when taken with Betrixaban
Velpatasvir may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may lead to a major life threatening interaction when taken with Betrixaban
Velpatasvir may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may lead to a major life threatening interaction when taken with Amprenavir and Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Velpatasvir may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Amprenavir and Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Velpatasvir may lead to a major life threatening interaction when taken with Edoxaban and Edoxaban may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Betrixaban
Velpatasvir may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Amprenavir and Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Velpatasvir may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Ulipristal and Ulipristal may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban |
DB01159 | DB09082 | 419 | 659 | [
"DDInter854",
"DDInter1934"
] | Halothane | Vilanterol | A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required. (From AMA Drug Evaluations Annual, 1994, p178) | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug administration). Vilanterol was designed based on the salmeterol molecular scaffold, particularly as a antedrug analog of salmeterol modification by modifying the salmeterol molecule to create homochiral compounds with the (R)-configuration. Vilanterol is 1000 and 400 fold more selective for β2 than β1 and β3 adrenoceptors, respectively, with a faster onset of action than salmeterol. Additionally, vilanterol demonstrated a significantly longer duration of action than salmeterol, with the bronchodilator effect still apparent at 22h. Vilanterol's pharmacological effect is attributable to stimulation of intracellular adenylyl cyclase which catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). Increases in cyclic AMP are associated with the relaxation of bronchial smooth muscle and inhibition of the release of hypersensitivity mediators from mast cells in the lungs.[A7738,A259961] Vilanterol is approved for use in several combination products such as with [fluticasone furoate] under the tradename BREO ELLIPTA, with [umeclidinium bromide] as ANORO ELLIPTA, and with both [fluticasone furoate] and [umeclidinium bromide] under the trade name TRELEGY ELLIPTA.[L46481,L44461,L44456] BREO ELLIPTA is the first vilanterol-containing product to be approved by the FDA in May 2013, followed by ANORO ELLIPTA in December 2013 and TRELEGY ELLIPTA in September 2020.[L46876,L46881,L46886] Although all 3 products are approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD), only TRELEGY ELLIPTA and BREO ELLIPTA are approved for maintenance treatments of asthma in patients aged 18 years and older and 5 years and older respectively.[L46481,L44461,L44456] | Moderate | 1 | [
[
[
419,
24,
659
]
],
[
[
419,
24,
927
],
[
927,
63,
659
]
],
[
[
419,
25,
1069
],
[
1069,
24,
659
]
],
[
[
419,
63,
485
],
[
485,
24,
659
]
],
[
[
419,
24,
1151
],
[
1151,
24,
659
]
],
[
[
419,
64,
702
],
[
702,
24,
659
]
],
[
[
419,
25,
982
],
[
982,
63,
659
]
],
[
[
419,
25,
877
],
[
877,
64,
659
]
],
[
[
419,
24,
927
],
[
927,
64,
1220
],
[
1220,
23,
659
]
],
[
[
419,
25,
1069
],
[
1069,
63,
1220
],
[
1220,
23,
659
]
]
] | [
[
[
"Halothane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Halothane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Halothane",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
],
[
"Vandetanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Halothane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
],
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Halothane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
],
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Halothane",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Halothane",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Halothane",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
],
[
"Macimorelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vilanterol"
]
],
[
[
"Halothane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vilanterol"
]
],
[
[
"Halothane",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
],
[
"Vandetanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vilanterol"
]
]
] | Halothane may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Halothane may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Halothane may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Halothane may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Halothane may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Halothane may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Halothane may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may lead to a major life threatening interaction when taken with Vilanterol
Halothane may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may lead to a major life threatening interaction when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Halothane may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vilanterol |
DB00196 | DB00620 | 600 | 175 | [
"DDInter743",
"DDInter1855"
] | Fluconazole | Triamcinolone | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole has many advantages over the other antifungal drugs including the option of oral administration. The side effect profile of this drug is minimal. It has been demonstrated as an efficacious treatment for vaginal yeast infections in one single dose. | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermatoses. Triamcinolone is more commonly seen in the forms triamcinolone hexacetonide, triamcinolone acetonide, and triamcinolone diacetate.[L8246,L8249,L8252,L8255,L8258,L8261,L8264] Triamcinolone was granted FDA approval on 3 December 1957. In October 2021, a suspension of triamcinolone acetonide was approved for suprachoroidal injection - the first suprachoroidal injection to receive FDA approval - for the treatment of patients with macular edema associated with uveitis. | Moderate | 1 | [
[
[
600,
24,
175
]
],
[
[
600,
24,
1573
],
[
1573,
1,
175
]
],
[
[
600,
24,
617
],
[
617,
40,
175
]
],
[
[
600,
6,
8374
],
[
8374,
45,
175
]
],
[
[
600,
18,
7847
],
[
7847,
46,
175
]
],
[
[
600,
21,
28762
],
[
28762,
60,
175
]
],
[
[
600,
24,
455
],
[
455,
62,
175
]
],
[
[
600,
23,
307
],
[
307,
62,
175
]
],
[
[
600,
24,
1017
],
[
1017,
63,
175
]
],
[
[
600,
24,
789
],
[
789,
24,
175
]
]
] | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
],
[
"Prednisone",
"{u} (Compound) resembles {v} (Compound)",
"Triamcinolone"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
],
[
"Budesonide",
"{u} (Compound) resembles {v} (Compound)",
"Triamcinolone"
]
],
[
[
"Fluconazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Triamcinolone"
]
],
[
[
"Fluconazole",
"{u} (Compound) downregulates {v} (Gene)",
"BAG3"
],
[
"BAG3",
"{u} (Gene) is upregulated by {v} (Compound)",
"Triamcinolone"
]
],
[
[
"Fluconazole",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Compound)",
"Triamcinolone"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
[
"Salmeterol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Triamcinolone"
]
],
[
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Triamcinolone"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Foscarnet"
],
[
"Foscarnet",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
]
]
] | Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone (Compound) resembles Triamcinolone (Compound)
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide (Compound) resembles Triamcinolone (Compound)
Fluconazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Triamcinolone (Compound)
Fluconazole (Compound) downregulates BAG3 (Gene) and BAG3 (Gene) is upregulated by Triamcinolone (Compound)
Fluconazole (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Triamcinolone (Compound)
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a minor interaction that can limit clinical effects when taken with Triamcinolone
Fluconazole may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Triamcinolone
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Foscarnet and Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone |
DB00810 | DB09488 | 456 | 103 | [
"DDInter211",
"DDInter23"
] | Biperiden | Acrivastine | A muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine. | Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever. As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension, edema, bronchoconstriction, and tachycardia. Acrivastine is currently available in combination with pseudoephedrine as the FDA-approved product Semprex-D. | Moderate | 1 | [
[
[
456,
24,
103
]
],
[
[
456,
63,
85
],
[
85,
24,
103
]
],
[
[
456,
24,
1264
],
[
1264,
24,
103
]
],
[
[
456,
1,
1105
],
[
1105,
24,
103
]
],
[
[
456,
64,
1621
],
[
1621,
25,
103
]
],
[
[
456,
63,
85
],
[
85,
24,
1405
],
[
1405,
24,
103
]
],
[
[
456,
24,
1264
],
[
1264,
64,
1405
],
[
1405,
24,
103
]
],
[
[
456,
24,
537
],
[
537,
63,
1405
],
[
1405,
24,
103
]
],
[
[
456,
24,
830
],
[
830,
23,
771
],
[
771,
62,
103
]
],
[
[
456,
63,
832
],
[
832,
23,
771
],
[
771,
62,
103
]
]
] | [
[
[
"Biperiden",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
]
],
[
[
"Biperiden",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atropine"
],
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
]
],
[
[
"Biperiden",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
]
],
[
[
"Biperiden",
"{u} (Compound) resembles {v} (Compound)",
"Trihexyphenidyl"
],
[
"Trihexyphenidyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
]
],
[
[
"Biperiden",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium chloride"
],
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acrivastine"
]
],
[
[
"Biperiden",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atropine"
],
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclobenzaprine"
],
[
"Cyclobenzaprine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
]
],
[
[
"Biperiden",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cyclobenzaprine"
],
[
"Cyclobenzaprine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
]
],
[
[
"Biperiden",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclobenzaprine"
],
[
"Cyclobenzaprine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
]
],
[
[
"Biperiden",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
],
[
"Phenindamine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
],
[
"Hyaluronidase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Acrivastine"
]
],
[
[
"Biperiden",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
],
[
"Tripelennamine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
],
[
"Hyaluronidase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Acrivastine"
]
]
] | Biperiden may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine
Biperiden may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine
Biperiden (Compound) resembles Trihexyphenidyl (Compound) and Trihexyphenidyl may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine
Biperiden may lead to a major life threatening interaction when taken with Potassium chloride and Potassium chloride may lead to a major life threatening interaction when taken with Acrivastine
Biperiden may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may cause a moderate interaction that could exacerbate diseases when taken with Cyclobenzaprine and Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine
Biperiden may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may lead to a major life threatening interaction when taken with Cyclobenzaprine and Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine
Biperiden may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Cyclobenzaprine and Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine
Biperiden may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine and Phenindamine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase and Hyaluronidase may cause a minor interaction that can limit clinical effects when taken with Acrivastine
Biperiden may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase and Hyaluronidase may cause a minor interaction that can limit clinical effects when taken with Acrivastine |
DB01278 | DB06016 | 1,021 | 1,508 | [
"DDInter1506",
"DDInter300"
] | Pramlintide | Cariprazine | Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes. | Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors. Cariprazine has been investigated in a variety of psychiatric disorders, including schizophrenia, bipolar disorders, and major depressive disorder. Cariprazine gained its first global approval in the US in September 2015 and was later approved by Health Canada in April 2022. It is currently used to treat schizophrenia, and manic or mixed episodes and depressive episodes associated with bipolar I disorder.[L41655,L40198] | Moderate | 1 | [
[
[
1021,
24,
1508
]
],
[
[
1021,
63,
176
],
[
176,
24,
1508
]
],
[
[
1021,
24,
1254
],
[
1254,
24,
1508
]
],
[
[
1021,
24,
98
],
[
98,
63,
1508
]
],
[
[
1021,
63,
609
],
[
609,
25,
1508
]
],
[
[
1021,
63,
176
],
[
176,
24,
1450
],
[
1450,
63,
1508
]
],
[
[
1021,
63,
1507
],
[
1507,
63,
1123
],
[
1123,
24,
1508
]
],
[
[
1021,
63,
245
],
[
245,
64,
600
],
[
600,
24,
1508
]
],
[
[
1021,
63,
1123
],
[
1123,
24,
1507
],
[
1507,
24,
1508
]
],
[
[
1021,
24,
1254
],
[
1254,
24,
1450
],
[
1450,
63,
1508
]
]
] | [
[
[
"Pramlintide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cariprazine"
]
],
[
[
"Pramlintide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
],
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cariprazine"
]
],
[
[
"Pramlintide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
],
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cariprazine"
]
],
[
[
"Pramlintide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
],
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cariprazine"
]
],
[
[
"Pramlintide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cariprazine"
]
],
[
[
"Pramlintide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
],
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
],
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cariprazine"
]
],
[
[
"Pramlintide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dicyclomine"
],
[
"Dicyclomine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propantheline"
],
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cariprazine"
]
],
[
[
"Pramlintide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cariprazine"
]
],
[
[
"Pramlintide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propantheline"
],
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dicyclomine"
],
[
"Dicyclomine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cariprazine"
]
],
[
[
"Pramlintide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
],
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
],
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cariprazine"
]
]
] | Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Cariprazine
Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Dicyclomine and Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Propantheline and Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Propantheline and Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Dicyclomine and Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine |
DB00574 | DB12887 | 121 | 1,598 | [
"DDInter717",
"DDInter1750"
] | Fenfluramine | Tazemetostat | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients typically display delayed development and neurocognitive impairment.[A214694, A214709, A214712, A214715] Fenfluramine is a serotonergic phenethylamine originally used as an appetite suppressant until concerns regarding cardiotoxicity in obese patients lead to its withdrawal from the market in 1997.[A214694, A214718, A11906] Through its ability to modulate neurotransmission, fenfluramine has reemerged as an effective therapy against pharmacoresistant seizures, such as those involved in Dravet syndrome.[A214688, A214691, A214700] Fenfluramine was granted initial FDA approval in 1973 prior to its withdrawal | Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438. Tazemetaostat was granted FDA approval on 23 January 2020. | Moderate | 1 | [
[
[
121,
24,
1598
]
],
[
[
121,
25,
1039
],
[
1039,
24,
1598
]
],
[
[
121,
63,
1324
],
[
1324,
24,
1598
]
],
[
[
121,
24,
578
],
[
578,
24,
1598
]
],
[
[
121,
24,
1046
],
[
1046,
25,
1598
]
],
[
[
121,
63,
273
],
[
273,
25,
1598
]
],
[
[
121,
25,
1039
],
[
1039,
64,
888
],
[
888,
24,
1598
]
],
[
[
121,
25,
888
],
[
888,
24,
594
],
[
594,
24,
1598
]
],
[
[
121,
63,
1324
],
[
1324,
23,
608
],
[
608,
23,
1598
]
],
[
[
121,
24,
578
],
[
578,
24,
985
],
[
985,
24,
1598
]
]
] | [
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tazemetostat"
]
],
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexfenfluramine"
],
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tazemetostat"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tazemetostat"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tazemetostat"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Caplacizumab"
],
[
"Caplacizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tazemetostat"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tositumomab"
],
[
"Tositumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tazemetostat"
]
],
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexfenfluramine"
],
[
"Dexfenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tazemetostat"
]
],
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
],
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tazemetostat"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tazemetostat"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
],
[
"Osimertinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tazemetostat"
]
]
] | Fenfluramine may lead to a major life threatening interaction when taken with Dexfenfluramine and Dex
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Caplacizumab and Caplacizumab may lead to a major life threatening interaction when taken with Tazemetostat
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Tositumomab and Tositumomab may lead to a major life threatening interaction when taken with Tazemetostat
Fenfluramine may lead to a major life threatening interaction when taken with Dexfenfluramine and Dexfenfluramine may lead to a major life threatening interaction when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Fenfluramine may lead to a major life threatening interaction when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Tazemetostat
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib and Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat |
DB00848 | DB09074 | 281 | 1,362 | [
"DDInter1044",
"DDInter1327"
] | Levamisole | Olaparib | Levamisole is an antihelminthic drug that was commonly used for the treatment of parasitic, viral, and bacterial infections. It was manufactured by _Janssen_ and first used in 1969 as an agent to treat worm infestations Levamisole was approved by the FDA in 1990 as an adjuvant treatment for colon cancer. Prior to this, levamisole was used as an antirheumatic therapy in the 1970s and 1980s for patients with rheumatoid arthritis. Because of its immunomodulatory effects, this drug has been studied in the treatment of various immune-mediated diseases, with some studies showing positive results. This drug has also been used in combination with other drugs for the treatment of various cancers. [A178117, A178123] Levamisole was withdrawn from the American market in 2000 due to its ability to cause serious adverse effects, including agranul | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Olaparib is used to treat a number of BRCA-associated tumours, including ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer.[L41100, L40908, L43792] It was first approved by the FDA and EU in December 2014, and by Health Canada in April 2016. | Moderate | 1 | [
[
[
281,
24,
1362
]
],
[
[
281,
24,
1683
],
[
1683,
24,
1362
]
],
[
[
281,
63,
139
],
[
139,
24,
1362
]
],
[
[
281,
24,
151
],
[
151,
63,
1362
]
],
[
[
281,
64,
1066
],
[
1066,
25,
1362
]
],
[
[
281,
63,
362
],
[
362,
25,
1362
]
],
[
[
281,
25,
1011
],
[
1011,
25,
1362
]
],
[
[
281,
25,
676
],
[
676,
64,
1362
]
],
[
[
281,
24,
651
],
[
651,
25,
1362
]
],
[
[
281,
24,
1683
],
[
1683,
25,
725
],
[
725,
63,
1362
]
]
] | [
[
[
"Levamisole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Levamisole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Levamisole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zidovudine"
],
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Levamisole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
],
[
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Levamisole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
],
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
]
],
[
[
"Levamisole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
]
],
[
[
"Levamisole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
]
],
[
[
"Levamisole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
]
],
[
[
"Levamisole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
]
],
[
[
"Levamisole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Satralizumab"
],
[
"Satralizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
]
] | Levamisole may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Levamisole may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Levamisole may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) and Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Levamisole may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Olaparib
Levamisole may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin may lead to a major life threatening interaction when taken with Olaparib
Levamisole may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Olaparib
Levamisole may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Olaparib
Levamisole may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin and Fosphenytoin may lead to a major life threatening interaction when taken with Olaparib
Levamisole may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may lead to a major life threatening interaction when taken with Satralizumab and Satralizumab may cause a moderate interaction that could exacerbate diseases when taken with Olaparib |
DB00470 | DB00962 | 530 | 1,639 | [
"DDInter601",
"DDInter1957"
] | Dronabinol | Zaleplon | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effects of smoking cannabis such as increased appetite, reduced pain, and changes in emotional and cognitive processes. Due to its evidence as an appetite stimulant and an anti-nauseant, Dronabinol is approved for use in anorexia associated with weight loss in patients with AIDS and for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments [FDA Label]. Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most abundant cannabinoids found naturally in | Zaleplon is a sedative/hypnotic, mainly used for insomnia. It is known as a nonbenzodiazepine hypnotic. Zaleplon interacts with the GABA receptor complex and shares some of the pharmacological properties of the benzodiazepines. Zaleplon is a schedule IV drug in the United States. | Moderate | 1 | [
[
[
530,
24,
1639
]
],
[
[
530,
6,
8374
],
[
8374,
45,
1639
]
],
[
[
530,
21,
29316
],
[
29316,
60,
1639
]
],
[
[
530,
63,
13
],
[
13,
24,
1639
]
],
[
[
530,
24,
1609
],
[
1609,
63,
1639
]
],
[
[
530,
24,
1219
],
[
1219,
24,
1639
]
],
[
[
530,
1,
1614
],
[
1614,
24,
1639
]
],
[
[
530,
25,
593
],
[
593,
63,
1639
]
],
[
[
530,
63,
475
],
[
475,
25,
1639
]
],
[
[
530,
6,
8374
],
[
8374,
45,
891
],
[
891,
23,
1639
]
]
] | [
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zaleplon"
]
],
[
[
"Dronabinol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Zaleplon"
]
],
[
[
"Dronabinol",
"{u} (Compound) causes {v} (Side Effect)",
"Sweating"
],
[
"Sweating",
"{u} (Side Effect) is caused by {v} (Compound)",
"Zaleplon"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zaleplon"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
],
[
"Pentoxyverine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zaleplon"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azatadine"
],
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zaleplon"
]
],
[
[
"Dronabinol",
"{u} (Compound) resembles {v} (Compound)",
"Nabilone"
],
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zaleplon"
]
],
[
[
"Dronabinol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zaleplon"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zaleplon"
]
],
[
[
"Dronabinol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zaleplon"
]
]
] | Dronabinol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Zaleplon (Compound)
Dronabinol (Compound) causes Sweating (Side Effect) and Sweating (Side Effect) is caused by Zaleplon (Compound)
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Zaleplon
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Zaleplon
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Azatadine and Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Zaleplon
Dronabinol (Compound) resembles Nabilone (Compound) and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Zaleplon
Dronabinol may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Zaleplon
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Zaleplon
Dronabinol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Prednisolone (Compound) and Prednisolone may cause a minor interaction that can limit clinical effects when taken with Zaleplon |
DB01177 | DB04953 | 77 | 495 | [
"DDInter904",
"DDInter708"
] | Idarubicin | Ezogabine | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients with refractory epilepsy. FDA approved in June 10, 2011 under the name of ezogabine. | Moderate | 1 | [
[
[
77,
24,
495
]
],
[
[
77,
21,
28787
],
[
28787,
60,
495
]
],
[
[
77,
62,
112
],
[
112,
23,
495
]
],
[
[
77,
63,
1494
],
[
1494,
24,
495
]
],
[
[
77,
24,
927
],
[
927,
63,
495
]
],
[
[
77,
74,
51
],
[
51,
24,
495
]
],
[
[
77,
24,
1151
],
[
1151,
24,
495
]
],
[
[
77,
64,
770
],
[
770,
24,
495
]
],
[
[
77,
25,
478
],
[
478,
25,
495
]
],
[
[
77,
25,
1593
],
[
1593,
64,
495
]
]
] | [
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ezogabine"
]
],
[
[
"Idarubicin",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ezogabine"
]
],
[
[
"Idarubicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ezogabine"
]
],
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palonosetron"
],
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ezogabine"
]
],
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ezogabine"
]
],
[
[
"Idarubicin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daunorubicin"
],
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ezogabine"
]
],
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
],
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ezogabine"
]
],
[
[
"Idarubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ezogabine"
]
],
[
[
"Idarubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ezogabine"
]
],
[
[
"Idarubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ezogabine"
]
]
] | Idarubicin (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Ezogabine (Compound)
Idarubicin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ezogabine
Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Palonosetron and Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Ezogabine
Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Ezogabine
Idarubicin (Compound) resembles Daunorubicin (Compound) and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Ezogabine
Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Ezogabine
Idarubicin may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Ezogabine
Idarubicin may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may lead to a major life threatening interaction when taken with Ezogabine
Idarubicin may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may lead to a major life threatening interaction when taken with Ezogabine |
DB01128 | DB06603 | 918 | 39 | [
"DDInter204",
"DDInter1387"
] | Bicalutamide | Panobinostat | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Panobinostat is marketed by Novartis under the brand name Farydak. Panobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market. | Major | 2 | [
[
[
918,
25,
39
]
],
[
[
918,
62,
1247
],
[
1247,
23,
39
]
],
[
[
918,
63,
211
],
[
211,
23,
39
]
],
[
[
918,
63,
912
],
[
912,
24,
39
]
],
[
[
918,
24,
1627
],
[
1627,
63,
39
]
],
[
[
918,
24,
673
],
[
673,
24,
39
]
],
[
[
918,
25,
880
],
[
880,
64,
39
]
],
[
[
918,
24,
859
],
[
859,
25,
39
]
],
[
[
918,
63,
1056
],
[
1056,
25,
39
]
],
[
[
918,
24,
594
],
[
594,
64,
39
]
]
] | [
[
[
"Bicalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Bicalutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Panobinostat"
]
],
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolterodine"
],
[
"Tolterodine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Panobinostat"
]
],
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon beta-1a"
],
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
],
[
"Cannabidiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aripiprazole"
],
[
"Aripiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Bicalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivabradine"
],
[
"Ivabradine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Posaconazole"
],
[
"Posaconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telithromycin"
],
[
"Telithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
],
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
]
] | Bicalutamide may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine and Tolterodine may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Aripiprazole and Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Bicalutamide may lead to a major life threatening interaction when taken with Ivabradine and Ivabradine may lead to a major life threatening interaction when taken with Panobinostat
Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Posaconazole and Posaconazole may lead to a major life threatening interaction when taken with Panobinostat
Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Telithromycin and Telithromycin may lead to a major life threatening interaction when taken with Panobinostat
Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may lead to a major life threatening interaction when taken with Panobinostat |
DB00524 | DB05351 | 811 | 101 | [
"DDInter1199",
"DDInter519"
] | Metolazone | Dexlansoprazole | A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss. | Dexlansoprazole is a new-generation proton pump inhibitor (PPI) used for the management of symptoms associated with gastroesophageal reflux disease (GERD) and erosive esophagitis. Dexlansoprazole is the R-enantiomer of , which is composed of a racemic mixture of the R- and S-enantiomers. Compared to the older generation of PPIs (which includes , , and ), dexlansoprazole has a unique pharmacokinetic profile due to its delayed-release and dual-delivery release system: This aims to address some limitations of the older-generation PPIs, such as short plasma half-life and the need for meal-associated dosing.[A19566, A19568, A178084, A174244] Dexlansoprazole inhibits the final step in gastric acid production by blocking the (H+, K+)-ATPase enzyme. | Moderate | 1 | [
[
[
811,
24,
101
]
],
[
[
811,
40,
1014
],
[
1014,
24,
101
]
],
[
[
811,
1,
1605
],
[
1605,
24,
101
]
],
[
[
811,
23,
126
],
[
126,
24,
101
]
],
[
[
811,
24,
1287
],
[
1287,
24,
101
]
],
[
[
811,
24,
663
],
[
663,
25,
101
]
],
[
[
811,
40,
1014
],
[
1014,
40,
178
],
[
178,
24,
101
]
],
[
[
811,
1,
1605
],
[
1605,
62,
126
],
[
126,
24,
101
]
],
[
[
811,
23,
126
],
[
126,
25,
256
],
[
256,
62,
101
]
],
[
[
811,
24,
1287
],
[
1287,
63,
589
],
[
589,
24,
101
]
]
] | [
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexlansoprazole"
]
],
[
[
"Metolazone",
"{u} (Compound) resembles {v} (Compound)",
"Benzthiazide"
],
[
"Benzthiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexlansoprazole"
]
],
[
[
"Metolazone",
"{u} (Compound) resembles {v} (Compound)",
"Indapamide"
],
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexlansoprazole"
]
],
[
[
"Metolazone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexlansoprazole"
]
],
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amphotericin B"
],
[
"Amphotericin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexlansoprazole"
]
],
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexlansoprazole"
]
],
[
[
"Metolazone",
"{u} (Compound) resembles {v} (Compound)",
"Benzthiazide"
],
[
"Benzthiazide",
"{u} (Compound) resembles {v} (Compound)",
"Polythiazide"
],
[
"Polythiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexlansoprazole"
]
],
[
[
"Metolazone",
"{u} (Compound) resembles {v} (Compound)",
"Indapamide"
],
[
"Indapamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexlansoprazole"
]
],
[
[
"Metolazone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prasugrel"
],
[
"Prasugrel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexlansoprazole"
]
],
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amphotericin B"
],
[
"Amphotericin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
],
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexlansoprazole"
]
]
] | Metolazone (Compound) resembles Benzthiazide (Compound) and Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole
Metolazone (Compound) resembles Indapamide (Compound) and Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole
Metolazone may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole
Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Amphotericin B and Amphotericin B may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole
Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may lead to a major life threatening interaction when taken with Dexlansoprazole
Metolazone (Compound) resembles Benzthiazide (Compound) and Benzthiazide (Compound) resembles Polythiazide (Compound) and Polythiazide may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole
Metolazone (Compound) resembles Indapamide (Compound) and Indapamide may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole
Metolazone may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may lead to a major life threatening interaction when taken with Prasugrel and Prasugrel may cause a minor interaction that can limit clinical effects when taken with Dexlansoprazole
Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Amphotericin B and Amphotericin B may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole |
DB00031 | DB11071 | 20 | 1,004 | [
"DDInter1764",
"DDInter1449"
] | Tenecteplase | Phenyl salicylate | Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at amino acids 296-299 in the protease domain. | Phenyl salicylate is a 2-hydroxybenzoic acid phenyl ester. It is utilized in some manufacturing processes of polymers, lacquers, adhesives, waxes, as well as polishes. It is an active ingredient in some pharmaceutical products as a mild analgesic for pain relief by releasing salicylate (found in ). Phenyl salicylate may also be found in some antiseptic agents . It is synthesized by heating salicylic acid with phenol , [MSDS]. Phenyl salicylate is used as a food additive in the USA . This compound belongs to the class of organic compounds known as depsides and depsidones. These are polycyclic compounds that is either a polyphenolic compound composed of two or more monocyclic aromatic units linked by an ester bond (depside), or a compound containing the depsidone structure (depsidone) . | Moderate | 1 | [
[
[
20,
24,
1004
]
],
[
[
20,
25,
500
],
[
500,
24,
1004
]
],
[
[
20,
25,
235
],
[
235,
63,
1004
]
],
[
[
20,
24,
885
],
[
885,
24,
1004
]
],
[
[
20,
64,
942
],
[
942,
24,
1004
]
],
[
[
20,
25,
330
],
[
330,
25,
1004
]
],
[
[
20,
25,
500
],
[
500,
25,
498
],
[
498,
24,
1004
]
],
[
[
20,
25,
498
],
[
498,
64,
500
],
[
500,
24,
1004
]
],
[
[
20,
24,
885
],
[
885,
64,
500
],
[
500,
24,
1004
]
],
[
[
20,
24,
1061
],
[
1061,
25,
500
],
[
500,
24,
1004
]
]
] | [
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyl salicylate"
]
],
[
[
"Tenecteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enoxaparin"
],
[
"Enoxaparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyl salicylate"
]
],
[
[
"Tenecteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
],
[
"Desirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyl salicylate"
]
],
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyl salicylate"
]
],
[
[
"Tenecteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bivalirudin"
],
[
"Bivalirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyl salicylate"
]
],
[
[
"Tenecteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ramucirumab"
],
[
"Ramucirumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenyl salicylate"
]
],
[
[
"Tenecteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enoxaparin"
],
[
"Enoxaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Edoxaban"
],
[
"Edoxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyl salicylate"
]
],
[
[
"Tenecteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Edoxaban"
],
[
"Edoxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enoxaparin"
],
[
"Enoxaparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyl salicylate"
]
],
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enoxaparin"
],
[
"Enoxaparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyl salicylate"
]
],
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[
"Treprostinil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enoxaparin"
],
[
"Enoxaparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyl salicylate"
]
]
] | Tenecteplase may lead to a major life threatening interaction when taken with Enoxaparin and Enoxaparin may cause a moderate interaction that could exacerbate diseases when taken with Phenyl salicylate
Tenecteplase may lead to a major life threatening interaction when taken with Desirudin and Desirudin may cause a moderate interaction that could exacerbate diseases when taken with Phenyl salicylate
Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Phenyl salicylate
Tenecteplase may lead to a major life threatening interaction when taken with Bivalirudin and Bivalirudin may cause a moderate interaction that could exacerbate diseases when taken with Phenyl salicylate
Tenecteplase may lead to a major life threatening interaction when taken with Ramucirumab and Ramucirumab may lead to a major life threatening interaction when taken with Phenyl salicylate
Tenecteplase may lead to a major life threatening interaction when taken with Enoxaparin and Enoxaparin may lead to a major life threatening interaction when taken with Edoxaban and Edoxaban may cause a moderate interaction that could exacerbate diseases when taken with Phenyl salicylate
Tenecteplase may lead to a major life threatening interaction when taken with Edoxaban and Edoxaban may lead to a major life threatening interaction when taken with Enoxaparin and Enoxaparin may cause a moderate interaction that could exacerbate diseases when taken with Phenyl salicylate
Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may lead to a major life threatening interaction when taken with Enoxaparin and Enoxaparin may cause a moderate interaction that could exacerbate diseases when taken with Phenyl salicylate
Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may lead to a major life threatening interaction when taken with Enoxaparin and Enoxaparin may cause a moderate interaction that could exacerbate diseases when taken with Phenyl salicylate |
DB06616 | DB12245 | 594 | 823 | [
"DDInter224",
"DDInter1863"
] | Bosutinib | Triclabendazole | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR-ABL fusion protein.[A6902,A261796,A261801] The first BCR-ABL inhibitor, [imatinib], was introduced over a decade ago as a breakthrough in CML management; however, emerging resistance to [imatinib] poses challenges in achieving remission. Second-generation BCR-ABL inhibitors like bosutinib inhibit most resistance-conferring BCR-ABL mutations except V299L and T315, thus providing more therapeutic options for patients.[A6901,A17961] Bosutinib was first approved by the FDA in | Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common liver fluke” or “the sheep liver fluke” or by _Fasciola gigantica_, another helminth. These parasites can infect humans following ingestion of larvae in contaminated water or food. Triclabendazole was previously used in the treatment of fascioliasis in livestock, but is now approved for human use. This drug is currently the only FDA-approved drug for individuals with fascioliasis, which affects 2.4 million people worldwide.[A174988,L5452] | Moderate | 1 | [
[
[
594,
24,
823
]
],
[
[
594,
62,
1247
],
[
1247,
23,
823
]
],
[
[
594,
24,
1612
],
[
1612,
24,
823
]
],
[
[
594,
63,
1010
],
[
1010,
24,
823
]
],
[
[
594,
64,
1622
],
[
1622,
24,
823
]
],
[
[
594,
24,
1619
],
[
1619,
63,
823
]
],
[
[
594,
25,
129
],
[
129,
24,
823
]
],
[
[
594,
25,
868
],
[
868,
25,
823
]
],
[
[
594,
64,
702
],
[
702,
25,
823
]
],
[
[
594,
63,
478
],
[
478,
25,
823
]
]
] | [
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Bosutinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Triclabendazole"
]
],
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
[
"Fostemsavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mefloquine"
],
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Voriconazole"
],
[
"Voriconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triclabendazole"
]
],
[
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triclabendazole"
]
],
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triclabendazole"
]
]
] | Bosutinib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Bosutinib may lead to a major life threatening interaction when taken with Voriconazole and Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Bosutinib may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Bosutinib may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may lead to a major life threatening interaction when taken with Triclabendazole
Bosutinib may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Triclabendazole
Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may lead to a major life threatening interaction when taken with Triclabendazole |
DB01114 | DB01215 | 272 | 1,418 | [
"DDInter362",
"DDInter677"
] | Chlorpheniramine | Estazolam | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | A benzodiazepine with anticonvulsant, hypnotic, and muscle relaxant properties. It has been shown in some cases to be more potent than diazepam or nitrazepam. | Moderate | 1 | [
[
[
272,
24,
1418
]
],
[
[
272,
63,
523
],
[
523,
1,
1418
]
],
[
[
272,
63,
1216
],
[
1216,
40,
1418
]
],
[
[
272,
24,
481
],
[
481,
40,
1418
]
],
[
[
272,
6,
8374
],
[
8374,
45,
1418
]
],
[
[
272,
21,
28956
],
[
28956,
60,
1418
]
],
[
[
272,
24,
537
],
[
537,
24,
1418
]
],
[
[
272,
63,
13
],
[
13,
24,
1418
]
],
[
[
272,
74,
100
],
[
100,
24,
1418
]
],
[
[
272,
24,
649
],
[
649,
63,
1418
]
]
] | [
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estazolam"
]
],
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alprazolam"
],
[
"Alprazolam",
"{u} (Compound) resembles {v} (Compound)",
"Estazolam"
]
],
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurazepam"
],
[
"Flurazepam",
"{u} (Compound) resembles {v} (Compound)",
"Estazolam"
]
],
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quazepam"
],
[
"Quazepam",
"{u} (Compound) resembles {v} (Compound)",
"Estazolam"
]
],
[
[
"Chlorpheniramine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Estazolam"
]
],
[
[
"Chlorpheniramine",
"{u} (Compound) causes {v} (Side Effect)",
"Palpitations"
],
[
"Palpitations",
"{u} (Side Effect) is caused by {v} (Compound)",
"Estazolam"
]
],
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estazolam"
]
],
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estazolam"
]
],
[
[
"Chlorpheniramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estazolam"
]
],
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estazolam"
]
]
] | Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Alprazolam and Alprazolam (Compound) resembles Estazolam (Compound)
Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Flurazepam and Flurazepam (Compound) resembles Estazolam (Compound)
Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Quazepam and Quazepam (Compound) resembles Estazolam (Compound)
Chlorpheniramine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Estazolam (Compound)
Chlorpheniramine (Compound) causes Palpitations (Side Effect) and Palpitations (Side Effect) is caused by Estazolam (Compound)
Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Estazolam
Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Estazolam
Chlorpheniramine (Compound) resembles Brompheniramine (Compound) and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Estazolam
Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Estazolam |
DB00284 | DB01577 | 1,647 | 1,529 | [
"DDInter11",
"DDInter1161"
] | Acarbose | Metamfetamine | Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal glucoamylase, sucrase, maltase, and isomaltase - which are responsible for the metabolism of complex starches and oligo-, tri-, and disaccharides into absorbable simple sugars.[L31633,A37868] By inhibiting the activity of these enzymes, acarbose limits the absorption of dietary carbohydrates and the subsequent postprandial increase in blood glucose and insulin levels. Acarbose is therefore used in conjunction with diet, exercise, and other pharmacotherapies for the management of blood sugar levels in patients with type 2 diabetes.[L31628,L31633] Acarbose is one of only two approved alpha-glucosidase inhibitors (the other being | Metamfetamine (methamphetamine) is a psychostimulant and sympathomimetic drug, and a member of the amphetamine group of sympathomimetic amines. Methamphetamine can induce effects such as euphoria, increased alertness and energy, and enhanced self-esteem. It is a scheduled drug in most countries due to its high potential for addiction and abuse. The FDA withdrew its approval for the use of all parenteral drug products containing methamphetamine hydrochloride, a metamfetamine salt. | Moderate | 1 | [
[
[
1647,
24,
1529
]
],
[
[
1647,
24,
939
],
[
939,
40,
1529
]
],
[
[
1647,
24,
22
],
[
22,
24,
1529
]
],
[
[
1647,
24,
1039
],
[
1039,
25,
1529
]
],
[
[
1647,
21,
28898
],
[
28898,
60,
1529
]
],
[
[
1647,
23,
1645
],
[
1645,
24,
1529
]
],
[
[
1647,
24,
659
],
[
659,
63,
1529
]
],
[
[
1647,
23,
135
],
[
135,
63,
1529
]
],
[
[
1647,
63,
1152
],
[
1152,
24,
1529
]
],
[
[
1647,
24,
1445
],
[
1445,
35,
1529
]
]
] | [
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metamfetamine"
]
],
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzphetamine"
],
[
"Benzphetamine",
"{u} (Compound) resembles {v} (Compound)",
"Metamfetamine"
]
],
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ephedrine"
],
[
"Ephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metamfetamine"
]
],
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexfenfluramine"
],
[
"Dexfenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metamfetamine"
]
],
[
[
"Acarbose",
"{u} (Compound) causes {v} (Side Effect)",
"Constipation"
],
[
"Constipation",
"{u} (Side Effect) is caused by {v} (Compound)",
"Metamfetamine"
]
],
[
[
"Acarbose",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metformin"
],
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metamfetamine"
]
],
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metamfetamine"
]
],
[
[
"Acarbose",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Albiglutide"
],
[
"Albiglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metamfetamine"
]
],
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liothyronine"
],
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metamfetamine"
]
],
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pseudoephedrine"
],
[
"Pseudoephedrine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metamfetamine"
]
]
] | Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Benzphetamine and Benzphetamine (Compound) resembles Metamfetamine (Compound)
Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine
Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfluramine may lead to a major life threatening interaction when taken with Metamfetamine
Acarbose (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Metamfetamine (Compound)
Acarbose may cause a minor interaction that can limit clinical effects when taken with Metformin and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine
Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine
Acarbose may cause a minor interaction that can limit clinical effects when taken with Albiglutide and Albiglutide may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine
Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine and Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine
Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine (Compound) resembles Metamfetamine (Compound) and Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine |
DB00072 | DB09054 | 550 | 384 | [
"DDInter1846",
"DDInter905"
] | Trastuzumab | Idelalisib | Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2). It is used as a treatment of human epidermal growth factor receptor (HER)-2+ metastatic breast cancer, where there is a proven amplification of the HER-2 oncogene or over-expression of the HER-2 protein in tumours. It is suggested that the overexpression or gene amplification of HER2 has been found in about 20–30% of breast cancers and elevated activation of HER2 triggers multiple downstream pathways leading to abnormal proliferation of cancer cells. Trastuzumab binds to HER2 and suppresses cancer cell growth, proliferation, and survival directly and indirectly. In December 2017, FDA approved OGIVRI ( | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. In contrast to the other class IA PI3Ks p110α and p110β, p110δ is principally expressed in leukocytes (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils. By inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and type 4 signalling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Treatment of lymphoma cells with idelalisib has been shown to result in inhibition of chemotaxis and adhesion, and reduced cell viability. | Moderate | 1 | [
[
[
550,
24,
384
]
],
[
[
550,
24,
58
],
[
58,
24,
384
]
],
[
[
550,
24,
287
],
[
287,
63,
384
]
],
[
[
550,
25,
322
],
[
322,
24,
384
]
],
[
[
550,
63,
1257
],
[
1257,
24,
384
]
],
[
[
550,
25,
1259
],
[
1259,
64,
384
]
],
[
[
550,
25,
1066
],
[
1066,
25,
384
]
],
[
[
550,
64,
581
],
[
581,
25,
384
]
],
[
[
550,
24,
1362
],
[
1362,
64,
384
]
],
[
[
550,
24,
58
],
[
58,
24,
725
],
[
725,
63,
384
]
]
] | [
[
[
"Trastuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Trastuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
],
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Trastuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
],
[
"Diroximel fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Trastuzumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Trastuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegfilgrastim"
],
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Trastuzumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
]
],
[
[
"Trastuzumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
],
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
]
],
[
[
"Trastuzumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
]
],
[
[
"Trastuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
]
],
[
[
"Trastuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
],
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Satralizumab"
],
[
"Satralizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
]
] | Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate and Diroximel fumarate may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Trastuzumab may lead to a major life threatening interaction when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Pegfilgrastim and Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Trastuzumab may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Idelalisib
Trastuzumab may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Idelalisib
Trastuzumab may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Idelalisib
Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may lead to a major life threatening interaction when taken with Idelalisib
Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Satralizumab and Satralizumab may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib |
DB00860 | DB01165 | 891 | 1,539 | [
"DDInter1513",
"DDInter1325"
] | Prednisolone | Ofloxacin | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. | Major | 2 | [
[
[
891,
25,
1539
]
],
[
[
891,
64,
1467
],
[
1467,
1,
1539
]
],
[
[
891,
25,
945
],
[
945,
40,
1539
]
],
[
[
891,
25,
739
],
[
739,
1,
1539
]
],
[
[
891,
5,
11566
],
[
11566,
49,
1539
]
],
[
[
891,
21,
29378
],
[
29378,
60,
1539
]
],
[
[
891,
63,
1648
],
[
1648,
23,
1539
]
],
[
[
891,
24,
1021
],
[
1021,
63,
1539
]
],
[
[
891,
63,
355
],
[
355,
24,
1539
]
],
[
[
891,
24,
848
],
[
848,
24,
1539
]
]
] | [
[
[
"Prednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ofloxacin"
]
],
[
[
"Prednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enoxacin"
],
[
"Enoxacin",
"{u} (Compound) resembles {v} (Compound)",
"Ofloxacin"
]
],
[
[
"Prednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sparfloxacin"
],
[
"Sparfloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Ofloxacin"
]
],
[
[
"Prednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomefloxacin"
],
[
"Lomefloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Ofloxacin"
]
],
[
[
"Prednisolone",
"{u} (Compound) treats {v} (Disease)",
"chronic obstructive pulmonary disease"
],
[
"chronic obstructive pulmonary disease",
"{u} (Disease) is palliated by {v} (Compound)",
"Ofloxacin"
]
],
[
[
"Prednisolone",
"{u} (Compound) causes {v} (Side Effect)",
"Petechiae"
],
[
"Petechiae",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ofloxacin"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ofloxacin"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
],
[
"Pramlintide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ofloxacin"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
],
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ofloxacin"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ofloxacin"
]
]
] | Prednisolone may lead to a major life threatening interaction when taken with Enoxacin and Enoxacin (Compound) resembles Ofloxacin (Compound)
Prednisolone may lead to a major life threatening interaction when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Ofloxacin (Compound)
Prednisolone may lead to a major life threatening interaction when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Ofloxacin (Compound)
Prednisolone (Compound) treats chronic obstructive pulmonary disease (Disease) and chronic obstructive pulmonary disease (Disease) is palliated by Ofloxacin (Compound)
Prednisolone (Compound) causes Petechiae (Side Effect) and Petechiae (Side Effect) is caused by Ofloxacin (Compound)
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a minor interaction that can limit clinical effects when taken with Ofloxacin
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide and Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Ofloxacin
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Ofloxacin
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Ofloxacin |
DB01263 | DB12245 | 859 | 823 | [
"DDInter1494",
"DDInter1863"
] | Posaconazole | Triclabendazole | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common liver fluke” or “the sheep liver fluke” or by _Fasciola gigantica_, another helminth. These parasites can infect humans following ingestion of larvae in contaminated water or food. Triclabendazole was previously used in the treatment of fascioliasis in livestock, but is now approved for human use. This drug is currently the only FDA-approved drug for individuals with fascioliasis, which affects 2.4 million people worldwide.[A174988,L5452] | Moderate | 1 | [
[
[
859,
24,
823
]
],
[
[
859,
62,
112
],
[
112,
23,
823
]
],
[
[
859,
63,
1010
],
[
1010,
24,
823
]
],
[
[
859,
24,
28
],
[
28,
24,
823
]
],
[
[
859,
64,
543
],
[
543,
24,
823
]
],
[
[
859,
25,
971
],
[
971,
24,
823
]
],
[
[
859,
24,
1619
],
[
1619,
63,
823
]
],
[
[
859,
25,
868
],
[
868,
25,
823
]
],
[
[
859,
64,
702
],
[
702,
25,
823
]
],
[
[
859,
25,
982
],
[
982,
64,
823
]
]
] | [
[
[
"Posaconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Posaconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Triclabendazole"
]
],
[
[
"Posaconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mefloquine"
],
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Posaconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
],
[
"Bisacodyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Posaconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Loperamide"
],
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Posaconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Posaconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Posaconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triclabendazole"
]
],
[
[
"Posaconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triclabendazole"
]
],
[
[
"Posaconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triclabendazole"
]
]
] | Posaconazole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl and Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Posaconazole may lead to a major life threatening interaction when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Posaconazole may lead to a major life threatening interaction when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Posaconazole may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may lead to a major life threatening interaction when taken with Triclabendazole
Posaconazole may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Triclabendazole
Posaconazole may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Triclabendazole |
DB00023 | DB01004 | 305 | 563 | [
"DDInter127",
"DDInter806"
] | Asparaginase Escherichia coli | Ganciclovir | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginase from _E. coli_ has clinically shown to exhibit antitumor actions in models of leukaemias [A31996, A31997]. L-asparaginase of _E. coli_ is marketed under several different trade names, including Elspar, for the treatment of acute lymphoblastic leukemia (ALL) as part of a multi-agent chemotherapeutic regimen. It is available as intramuscular or intravenous injections. Therapeutic L-asparaginase from _E. coli_ works by depleting the levels | An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections. | Moderate | 1 | [
[
[
305,
24,
563
]
],
[
[
305,
24,
248
],
[
248,
40,
563
]
],
[
[
305,
24,
552
],
[
552,
24,
563
]
],
[
[
305,
25,
770
],
[
770,
63,
563
]
],
[
[
305,
25,
1101
],
[
1101,
24,
563
]
],
[
[
305,
63,
1451
],
[
1451,
24,
563
]
],
[
[
305,
24,
478
],
[
478,
63,
563
]
],
[
[
305,
25,
375
],
[
375,
64,
563
]
],
[
[
305,
25,
581
],
[
581,
25,
563
]
],
[
[
305,
64,
1057
],
[
1057,
25,
563
]
]
] | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
],
[
"Valganciclovir",
"{u} (Compound) resembles {v} (Compound)",
"Ganciclovir"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carmustine"
],
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon alfa-n1"
],
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ganciclovir"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ganciclovir"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ganciclovir"
]
]
] | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir and Valganciclovir (Compound) resembles Ganciclovir (Compound)
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir
Asparaginase Escherichia coli may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir
Asparaginase Escherichia coli may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Interferon alfa-n1 and Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir
Asparaginase Escherichia coli may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Ganciclovir
Asparaginase Escherichia coli may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Ganciclovir
Asparaginase Escherichia coli may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Ganciclovir |
DB06589 | DB10343 | 1,250 | 962 | [
"DDInter1400",
"DDInter160"
] | Pazopanib | Bacillus calmette-guerin substrain tice live antigen | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Bacillus calmette-guerin substrain tice live antigen is a vaccine containing attenuated live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of *Mycobacterium bovis* for percutaneous use. It is administered to prevent the development of tuberculosis. | Major | 2 | [
[
[
1250,
25,
962
]
],
[
[
1250,
63,
617
],
[
617,
24,
962
]
],
[
[
1250,
64,
1057
],
[
1057,
25,
962
]
],
[
[
1250,
63,
1342
],
[
1342,
25,
962
]
],
[
[
1250,
24,
270
],
[
270,
64,
962
]
],
[
[
1250,
24,
1362
],
[
1362,
25,
962
]
],
[
[
1250,
25,
976
],
[
976,
25,
962
]
],
[
[
1250,
25,
1259
],
[
1259,
64,
962
]
],
[
[
1250,
63,
617
],
[
617,
64,
1057
],
[
1057,
25,
962
]
],
[
[
1250,
64,
1057
],
[
1057,
25,
617
],
[
617,
24,
962
]
]
] | [
[
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
],
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
]
],
[
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
],
[
"Romidepsin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
]
],
[
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
]
],
[
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
],
[
"Budesonide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
]
],
[
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Budesonide"
],
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
]
]
] | Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Bacillus calmette-guerin substrain tice live antigen
Pazopanib may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin and Romidepsin may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen
Pazopanib may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen
Pazopanib may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen
Pazopanib may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Budesonide and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Bacillus calmette-guerin substrain tice live antigen |
DB00414 | DB01284 | 590 | 1,042 | [
"DDInter16",
"DDInter1782"
] | Acetohexamide | Tetracosactide | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticosteroids in the adrenal cortex. Tetracosactide exhibits the same activity as natural ACTH with regard to all its biological activities. The complex results in a product whose absorption in man is effected over a longer period of time as compared to corticotropin. Therefore, therapy may be maintained with less frequent administration. | Moderate | 1 | [
[
[
590,
24,
1042
]
],
[
[
590,
24,
688
],
[
688,
23,
1042
]
],
[
[
590,
63,
461
],
[
461,
24,
1042
]
],
[
[
590,
24,
811
],
[
811,
24,
1042
]
],
[
[
590,
24,
761
],
[
761,
63,
1042
]
],
[
[
590,
23,
1551
],
[
1551,
24,
1042
]
],
[
[
590,
24,
1377
],
[
1377,
25,
1042
]
],
[
[
590,
24,
688
],
[
688,
24,
209
],
[
209,
62,
1042
]
],
[
[
590,
63,
461
],
[
461,
25,
455
],
[
455,
23,
1042
]
],
[
[
590,
24,
811
],
[
811,
24,
455
],
[
455,
23,
1042
]
]
] | [
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
[
"Salbutamol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetracosactide"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"
],
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metolazone"
],
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
],
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Acetohexamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Methyldopa"
],
[
"Methyldopa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tetracosactide"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Racepinephrine"
],
[
"Racepinephrine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetracosactide"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"
],
[
"Timolol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Salmeterol"
],
[
"Salmeterol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetracosactide"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metolazone"
],
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
[
"Salmeterol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetracosactide"
]
]
] | Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a minor interaction that can limit clinical effects when taken with Tetracosactide
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Metolazone and Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Acetohexamide may cause a minor interaction that can limit clinical effects when taken with Methyldopa and Methyldopa may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Tetracosactide
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Racepinephrine and Racepinephrine may cause a minor interaction that can limit clinical effects when taken with Tetracosactide
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol may lead to a major life threatening interaction when taken with Salmeterol and Salmeterol may cause a minor interaction that can limit clinical effects when taken with Tetracosactide
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Metolazone and Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a minor interaction that can limit clinical effects when taken with Tetracosactide |
DB00927 | DB01319 | 1,559 | 34 | [
"DDInter712",
"DDInter777"
] | Famotidine | Fosamprenavir | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</sub> receptor antagonists, famotidine displays high selectivity towards this receptor; in a study consisting of healthy volunteers and patients with acid hypersecretory disease, famotidine was about 20 to 50 times more potent at inhibiting gastric acid secretion than [cimetidine] and eight times more potent than [ranitidine] on a weight basis. Famotidine is used in various over-the-counter and off-label uses. While oral formulations of famotidine are more commonly used, the intravenous solution of the drug is available for use in hospital settings. | Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease. | Moderate | 1 | [
[
[
1559,
24,
34
]
],
[
[
1559,
21,
29062
],
[
29062,
60,
34
]
],
[
[
1559,
24,
609
],
[
609,
23,
34
]
],
[
[
1559,
24,
1374
],
[
1374,
62,
34
]
],
[
[
1559,
63,
245
],
[
245,
24,
34
]
],
[
[
1559,
24,
1151
],
[
1151,
24,
34
]
],
[
[
1559,
24,
868
],
[
868,
63,
34
]
],
[
[
1559,
24,
455
],
[
455,
25,
34
]
],
[
[
1559,
63,
1557
],
[
1557,
25,
34
]
],
[
[
1559,
24,
1297
],
[
1297,
64,
34
]
]
] | [
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosamprenavir"
]
],
[
[
"Famotidine",
"{u} (Compound) causes {v} (Side Effect)",
"Neutropenia"
],
[
"Neutropenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Fosamprenavir"
]
],
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fosamprenavir"
]
],
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
],
[
"Abiraterone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fosamprenavir"
]
],
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosamprenavir"
]
],
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
],
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosamprenavir"
]
],
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosamprenavir"
]
],
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
[
"Salmeterol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fosamprenavir"
]
],
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Astemizole"
],
[
"Astemizole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fosamprenavir"
]
],
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
],
[
"Osilodrostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fosamprenavir"
]
]
] | Famotidine (Compound) causes Neutropenia (Side Effect) and Neutropenia (Side Effect) is caused by Fosamprenavir (Compound)
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Fosamprenavir
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a minor interaction that can limit clinical effects when taken with Fosamprenavir
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Fosamprenavir
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Fosamprenavir
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Fosamprenavir
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may lead to a major life threatening interaction when taken with Fosamprenavir
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Astemizole and Astemizole may lead to a major life threatening interaction when taken with Fosamprenavir
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may lead to a major life threatening interaction when taken with Fosamprenavir |
DB00569 | DB14357 | 553 | 944 | [
"DDInter775",
"DDInter347"
] | Fondaparinux | Chamomile | Fondaparinux (Arixtra) is a synthetic anticoagulant agent consisting of five monomeric sugar units and a O-methyl group at the reducing end of the molecule. It is structurally similar to polymeric glycosaminoglycan heparin and heparan sulfate (HS) when they are cleaved into monomeric units. The monomeric sequence in heparin and HS is thought to form the high affinity binding site for the natural anti-coagulant factor, antithrombin III (ATIII). Once bound to heparin or HS, the anticoagulant activity of ATIII is potentiated by 1000-fold. Fondaparinux potentiates the neutralizing action of ATIII on activated Factor X 300-fold. Fondaparinux may be used: to prevent venous thromboembolism in patients who have undergone orthopedic surgery of the lower limbs (e.g. hip fracture | Chamomile is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug. | Minor | 0 | [
[
[
553,
23,
944
]
],
[
[
553,
25,
256
],
[
256,
23,
944
]
],
[
[
553,
64,
582
],
[
582,
23,
944
]
],
[
[
553,
25,
256
],
[
256,
64,
582
],
[
582,
23,
944
]
],
[
[
553,
64,
582
],
[
582,
25,
256
],
[
256,
23,
944
]
],
[
[
553,
25,
126
],
[
126,
25,
256
],
[
256,
23,
944
]
],
[
[
553,
64,
1061
],
[
1061,
24,
256
],
[
256,
23,
944
]
],
[
[
553,
25,
1347
],
[
1347,
36,
256
],
[
256,
23,
944
]
],
[
[
553,
25,
714
],
[
714,
24,
256
],
[
256,
23,
944
]
],
[
[
553,
21,
28681
],
[
28681,
60,
256
],
[
256,
23,
944
]
]
] | [
[
[
"Fondaparinux",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
]
],
[
[
"Fondaparinux",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prasugrel"
],
[
"Prasugrel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
]
],
[
[
"Fondaparinux",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Reteplase"
],
[
"Reteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
]
],
[
[
"Fondaparinux",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prasugrel"
],
[
"Prasugrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Reteplase"
],
[
"Reteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
]
],
[
[
"Fondaparinux",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Reteplase"
],
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prasugrel"
],
[
"Prasugrel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
]
],
[
[
"Fondaparinux",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prasugrel"
],
[
"Prasugrel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
]
],
[
[
"Fondaparinux",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Treprostinil"
],
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prasugrel"
],
[
"Prasugrel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
]
],
[
[
"Fondaparinux",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clopidogrel"
],
[
"Clopidogrel",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Prasugrel"
],
[
"Prasugrel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
]
],
[
[
"Fondaparinux",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iloprost"
],
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prasugrel"
],
[
"Prasugrel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
]
],
[
[
"Fondaparinux",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused by {v} (Compound)",
"Prasugrel"
],
[
"Prasugrel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
]
]
] | Fondaparinux may lead to a major life threatening interaction when taken with Prasugrel and Prasugrel may cause a minor interaction that can limit clinical effects when taken with Chamomile
Fondaparinux may lead to a major life threatening interaction when taken with Reteplase and Reteplase may cause a minor interaction that can limit clinical effects when taken with Chamomile
Fondaparinux may lead to a major life threatening interaction when taken with Prasugrel and Prasugrel may lead to a major life threatening interaction when taken with Reteplase and Reteplase may cause a minor interaction that can limit clinical effects when taken with Chamomile
Fondaparinux may lead to a major life threatening interaction when taken with Reteplase and Reteplase may lead to a major life threatening interaction when taken with Prasugrel and Prasugrel may cause a minor interaction that can limit clinical effects when taken with Chamomile
Fondaparinux may lead to a major life threatening interaction when taken with Warfarin and Warfarin may lead to a major life threatening interaction when taken with Prasugrel and Prasugrel may cause a minor interaction that can limit clinical effects when taken with Chamomile
Fondaparinux may lead to a major life threatening interaction when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel and Prasugrel may cause a minor interaction that can limit clinical effects when taken with Chamomile
Fondaparinux may lead to a major life threatening interaction when taken with Clopidogrel and Clopidogrel (Compound) resembles Prasugrel (Compound) and Clopidogrel may lead to a major life threatening interaction when taken with Prasugrel and Prasugrel may cause a minor interaction that can limit clinical effects when taken with Chamomile
Fondaparinux may lead to a major life threatening interaction when taken with Iloprost and Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel and Prasugrel may cause a minor interaction that can limit clinical effects when taken with Chamomile
Fondaparinux (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Prasugrel (Compound) and Prasugrel may cause a minor interaction that can limit clinical effects when taken with Chamomile |
DB00563 | DB00881 | 663 | 954 | [
"DDInter1174",
"DDInter1554"
] | Methotrexate | Quinapril | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma.[A180322,L7144,L7147,L7150,L7180] Due to the toxic effects of methotrexate, it is indicated for treatment of some forms of arthritis and severe psoriasis only if first line treatment has failed or patients are intolerant of those treatments. Methotrexate was granted FDA approval on 7 December 1953. | Quinapril is the ethyl ester prodrug of the non-sulfhydryl angiotensin converting enzyme inhibitor quinaprilat.[L8420,L8423] It is used to treat hypertension and heart failure.[L8420,L8423] ACE inhibitors are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta blockers. Quinapril was granted FDA approval on 19 November 1991. A combination tablet with [hydrochlorothiazide] was also approved on 28 December 1999. | Moderate | 1 | [
[
[
663,
24,
954
]
],
[
[
663,
63,
1638
],
[
1638,
1,
954
]
],
[
[
663,
24,
610
],
[
610,
1,
954
]
],
[
[
663,
24,
1523
],
[
1523,
40,
954
]
],
[
[
663,
21,
28828
],
[
28828,
60,
954
]
],
[
[
663,
23,
1117
],
[
1117,
62,
954
]
],
[
[
663,
63,
251
],
[
251,
24,
954
]
],
[
[
663,
23,
1487
],
[
1487,
63,
954
]
],
[
[
663,
24,
891
],
[
891,
24,
954
]
],
[
[
663,
25,
1512
],
[
1512,
24,
954
]
]
] | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinapril"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trandolapril"
],
[
"Trandolapril",
"{u} (Compound) resembles {v} (Compound)",
"Quinapril"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enalapril"
],
[
"Enalapril",
"{u} (Compound) resembles {v} (Compound)",
"Quinapril"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Labetalol"
],
[
"Labetalol",
"{u} (Compound) resembles {v} (Compound)",
"Quinapril"
]
],
[
[
"Methotrexate",
"{u} (Compound) causes {v} (Side Effect)",
"Photosensitivity reaction"
],
[
"Photosensitivity reaction",
"{u} (Side Effect) is caused by {v} (Compound)",
"Quinapril"
]
],
[
[
"Methotrexate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium bicarbonate"
],
[
"Sodium bicarbonate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Quinapril"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
],
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinapril"
]
],
[
[
"Methotrexate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hydroxychloroquine"
],
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinapril"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinapril"
]
],
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinapril"
]
]
] | Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Trandolapril and Trandolapril (Compound) resembles Quinapril (Compound)
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Enalapril and Enalapril (Compound) resembles Quinapril (Compound)
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Labetalol and Labetalol (Compound) resembles Quinapril (Compound)
Methotrexate (Compound) causes Photosensitivity reaction (Side Effect) and Photosensitivity reaction (Side Effect) is caused by Quinapril (Compound)
Methotrexate may cause a minor interaction that can limit clinical effects when taken with Sodium bicarbonate and Sodium bicarbonate may cause a minor interaction that can limit clinical effects when taken with Quinapril
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Quinapril
Methotrexate may cause a minor interaction that can limit clinical effects when taken with Hydroxychloroquine and Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Quinapril
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Quinapril
Methotrexate may lead to a major life threatening interaction when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Quinapril |
DB09488 | DB14740 | 103 | 771 | [
"DDInter23",
"DDInter881"
] | Acrivastine | Hyaluronidase | Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever. As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension, edema, bronchoconstriction, and tachycardia. Acrivastine is currently available in combination with pseudoephedrine as the FDA-approved product Semprex-D. | Hyaluronidase is an enzyme used to improve the absorption and dispersion of parenterally administered fluids, drugs, and contrast agents. The action of hyaluronidase was first described in 1936, and named in 1939. Early research into hyaluronidase identified it as a "spreading factor" which allowed for increased permeability of the connective tissue. Hyaluronidase has been used in surgical settings for at least the past 60 years to improve the diffusion of local anesthetics. Hyaluronidase was first used in prescription products in the United States on 5 May 2004. | Minor | 0 | [
[
[
103,
23,
771
]
],
[
[
103,
63,
849
],
[
849,
23,
771
]
],
[
[
103,
24,
337
],
[
337,
23,
771
]
],
[
[
103,
63,
849
],
[
849,
24,
337
],
[
337,
23,
771
]
],
[
[
103,
24,
337
],
[
337,
63,
849
],
[
849,
23,
771
]
],
[
[
103,
63,
662
],
[
662,
35,
849
],
[
849,
23,
771
]
],
[
[
103,
63,
849
],
[
849,
63,
1242
],
[
1242,
23,
771
]
],
[
[
103,
63,
252
],
[
252,
74,
1242
],
[
1242,
23,
771
]
],
[
[
103,
63,
104
],
[
104,
40,
820
],
[
820,
23,
771
]
],
[
[
103,
63,
820
],
[
820,
1,
104
],
[
104,
23,
771
]
]
] | [
[
[
"Acrivastine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
]
],
[
[
"Acrivastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
[
"Mepyramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
]
],
[
[
"Acrivastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyltoloxamine"
],
[
"Phenyltoloxamine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
]
],
[
[
"Acrivastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyltoloxamine"
],
[
"Phenyltoloxamine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
]
],
[
[
"Acrivastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyltoloxamine"
],
[
"Phenyltoloxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
[
"Mepyramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
]
],
[
[
"Acrivastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
[
"Mepyramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
]
],
[
[
"Acrivastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
],
[
"Cetirizine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
]
],
[
[
"Acrivastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyzine"
],
[
"Hydroxyzine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
],
[
"Cetirizine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
]
],
[
[
"Acrivastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} (Compound) resembles {v} (Compound)",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
]
],
[
[
"Acrivastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} (Compound) resembles {v} (Compound)",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
]
]
] | Acrivastine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase
Acrivastine may cause a moderate interaction that could exacerbate diseases when taken with Phenyltoloxamine and Phenyltoloxamine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase
Acrivastine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Phenyltoloxamine and Phenyltoloxamine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase
Acrivastine may cause a moderate interaction that could exacerbate diseases when taken with Phenyltoloxamine and Phenyltoloxamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase
Acrivastine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine (Compound) resembles Mepyramine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase
Acrivastine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase
Acrivastine may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyzine and Hydroxyzine (Compound) resembles Cetirizine (Compound) and Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase
Acrivastine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Alimemazine (Compound) and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase
Acrivastine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine (Compound) resembles Methdilazine (Compound) and Methdilazine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase |
DB00366 | DB00996 | 1,594 | 1,198 | [
"DDInter600",
"DDInter791"
] | Doxylamine | Gabapentin | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | Gabapentin is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid ([GABA]) that was first approved for use in the United States in 1993. It was originally developed as a novel anti-epileptic for the treatment of certain types of seizures[A186277,A186143] - today it is also widely used to treat neuropathic pain.[A14097,A186179] Gabapentin has some stark advantages as compared with other anti-epileptics, such as a relatively benign adverse effect profile, wide therapeutic index, and lack of appreciable metabolism making it unlikely to participate in pharmacokinetic drug interactions.[A186143,A185981,L8717]. It is structurally and functionally related to another GABA derivative, [pregabalin]. | Moderate | 1 | [
[
[
1594,
24,
1198
]
],
[
[
1594,
18,
18226
],
[
18226,
57,
1198
]
],
[
[
1594,
21,
29034
],
[
29034,
60,
1198
]
],
[
[
1594,
24,
1311
],
[
1311,
63,
1198
]
],
[
[
1594,
24,
530
],
[
530,
24,
1198
]
],
[
[
1594,
35,
128
],
[
128,
24,
1198
]
],
[
[
1594,
63,
1242
],
[
1242,
24,
1198
]
],
[
[
1594,
74,
701
],
[
701,
24,
1198
]
],
[
[
1594,
35,
272
],
[
272,
63,
1198
]
],
[
[
1594,
63,
475
],
[
475,
25,
1198
]
]
] | [
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gabapentin"
]
],
[
[
"Doxylamine",
"{u} (Compound) downregulates {v} (Gene)",
"GDF15"
],
[
"GDF15",
"{u} (Gene) is downregulated by {v} (Compound)",
"Gabapentin"
]
],
[
[
"Doxylamine",
"{u} (Compound) causes {v} (Side Effect)",
"Urinary tract disorder"
],
[
"Urinary tract disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Gabapentin"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gabapentin"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
],
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gabapentin"
]
],
[
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
],
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gabapentin"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
],
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gabapentin"
]
],
[
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gabapentin"
]
],
[
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gabapentin"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gabapentin"
]
]
] | Doxylamine (Compound) downregulates GDF15 (Gene) and GDF15 (Gene) is downregulated by Gabapentin (Compound)
Doxylamine (Compound) causes Urinary tract disorder (Side Effect) and Urinary tract disorder (Side Effect) is caused by Gabapentin (Compound)
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Gabapentin
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Gabapentin
Doxylamine (Compound) resembles Dexbrompheniramine (Compound) and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Gabapentin
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Gabapentin
Doxylamine (Compound) resembles Clemastine (Compound) and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Gabapentin
Doxylamine (Compound) resembles Chlorpheniramine (Compound) and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Gabapentin
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Gabapentin |
DB01211 | DB01410 | 609 | 423 | [
"DDInter393",
"DDInter375"
] | Clarithromycin | Ciclesonide | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration. | Ciclesonide is a glucocorticoid used to treat obstructive airway diseases. It is marketed under the brand name Alvesco. | Moderate | 1 | [
[
[
609,
24,
423
]
],
[
[
609,
63,
1573
],
[
1573,
1,
423
]
],
[
[
609,
63,
1351
],
[
1351,
40,
423
]
],
[
[
609,
64,
1486
],
[
1486,
40,
423
]
],
[
[
609,
25,
617
],
[
617,
40,
423
]
],
[
[
609,
6,
8374
],
[
8374,
45,
423
]
],
[
[
609,
21,
28850
],
[
28850,
60,
423
]
],
[
[
609,
63,
1148
],
[
1148,
23,
423
]
],
[
[
609,
24,
659
],
[
659,
62,
423
]
],
[
[
609,
64,
455
],
[
455,
23,
423
]
]
] | [
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ciclesonide"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
],
[
"Prednisone",
"{u} (Compound) resembles {v} (Compound)",
"Ciclesonide"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flunisolide"
],
[
"Flunisolide",
"{u} (Compound) resembles {v} (Compound)",
"Ciclesonide"
]
],
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Ciclesonide"
]
],
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Budesonide"
],
[
"Budesonide",
"{u} (Compound) resembles {v} (Compound)",
"Ciclesonide"
]
],
[
[
"Clarithromycin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Ciclesonide"
]
],
[
[
"Clarithromycin",
"{u} (Compound) causes {v} (Side Effect)",
"Back pain"
],
[
"Back pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ciclesonide"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ciclesonide"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ciclesonide"
]
],
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Salmeterol"
],
[
"Salmeterol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ciclesonide"
]
]
] | Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone (Compound) resembles Ciclesonide (Compound)
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Flunisolide and Flunisolide (Compound) resembles Ciclesonide (Compound)
Clarithromycin may lead to a major life threatening interaction when taken with Methylprednisolone and Methylprednisolone (Compound) resembles Ciclesonide (Compound)
Clarithromycin may lead to a major life threatening interaction when taken with Budesonide and Budesonide (Compound) resembles Ciclesonide (Compound)
Clarithromycin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ciclesonide (Compound)
Clarithromycin (Compound) causes Back pain (Side Effect) and Back pain (Side Effect) is caused by Ciclesonide (Compound)
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a minor interaction that can limit clinical effects when taken with Ciclesonide
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a minor interaction that can limit clinical effects when taken with Ciclesonide
Clarithromycin may lead to a major life threatening interaction when taken with Salmeterol and Salmeterol may cause a minor interaction that can limit clinical effects when taken with Ciclesonide |
DB00204 | DB01254 | 228 | 1,213 | [
"DDInter580",
"DDInter484"
] | Dofetilide | Dasatinib | Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter. | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein BCR-ABL. BCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the pathogenesis of CML and 15-30% of ALL cases.[A11377,A33432] Dasatinib also inhibits a spectrum of kinases involved in cancer, including several SRC-family kinases. Unlike [imatinib], another tyrosine kinase used for the treatment of CML and Ph-positive ALL, dasatinib inhibits the active and inactive conformations of the ABL kinase domain.[A2226,A11377] Also, mutations in the kinase domain of BCR-ABL may lead to relapse during imatinib treatment. Since dasatinib does not interact with some of the residues involved in those mutations, the use of this drug represents a therapeutic alternative for patients with cancers that have developed imatinib-resistance. The use of dasatinib was first approved by the FDA in 2006.[L45171,L45186] | Major | 2 | [
[
[
228,
25,
1213
]
],
[
[
228,
6,
8374
],
[
8374,
45,
1213
]
],
[
[
228,
18,
6448
],
[
6448,
46,
1213
]
],
[
[
228,
18,
10182
],
[
10182,
57,
1213
]
],
[
[
228,
21,
28956
],
[
28956,
60,
1213
]
],
[
[
228,
23,
112
],
[
112,
23,
1213
]
],
[
[
228,
25,
1133
],
[
1133,
24,
1213
]
],
[
[
228,
24,
543
],
[
543,
24,
1213
]
],
[
[
228,
25,
1619
],
[
1619,
63,
1213
]
],
[
[
228,
64,
618
],
[
618,
24,
1213
]
]
] | [
[
[
"Dofetilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
]
],
[
[
"Dofetilide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Dasatinib"
]
],
[
[
"Dofetilide",
"{u} (Compound) downregulates {v} (Gene)",
"CTSD"
],
[
"CTSD",
"{u} (Gene) is upregulated by {v} (Compound)",
"Dasatinib"
]
],
[
[
"Dofetilide",
"{u} (Compound) downregulates {v} (Gene)",
"CDCA4"
],
[
"CDCA4",
"{u} (Gene) is downregulated by {v} (Compound)",
"Dasatinib"
]
],
[
[
"Dofetilide",
"{u} (Compound) causes {v} (Side Effect)",
"Palpitations"
],
[
"Palpitations",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dasatinib"
]
],
[
[
"Dofetilide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dasatinib"
]
],
[
[
"Dofetilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Granisetron"
],
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
],
[
[
"Dofetilide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
],
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
],
[
[
"Dofetilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
],
[
[
"Dofetilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abarelix"
],
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
]
] | Dofetilide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dasatinib (Compound)
Dofetilide (Compound) downregulates CTSD (Gene) and CTSD (Gene) is upregulated by Dasatinib (Compound)
Dofetilide (Compound) downregulates CDCA4 (Gene) and CDCA4 (Gene) is downregulated by Dasatinib (Compound)
Dofetilide (Compound) causes Palpitations (Side Effect) and Palpitations (Side Effect) is caused by Dasatinib (Compound)
Dofetilide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Dasatinib
Dofetilide may lead to a major life threatening interaction when taken with Granisetron and Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
Dofetilide may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
Dofetilide may lead to a major life threatening interaction when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
Dofetilide may lead to a major life threatening interaction when taken with Abarelix and Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib |
DB00798 | DB01331 | 1,132 | 1,558 | [
"DDInter815",
"DDInter325"
] | Gentamicin | Cefoxitin | Gentamicin is a bactericidal aminoglycoside that was discovered and isolated from _Micromonospora purpurea_ in 1963. It is one of the most frequently prescribed aminoglycosides due to its spectrum of activity, low cost, and availability.[A234339,A234354] Gentamicin is effective against both gram-positive and gram-negative organisms but is particularly useful for the treatment of severe gram-negative infections including those caused by _Pseudomonas aeruginosa_.[A233325,A234359,A234364] There is the added benefit of synergy when gentamicin is co-administered with other antibacterials such as beta-lactams. This synergistic activity is not only important for the treatment of complex infections, but can also contribute to dose optimization and reduced adverse effects.[A234359,A234364] Although gentamicin is well-established and may be used in a variety of clinical applications, | Cefoxitin is a semi-synthetic, broad-spectrum cepha antibiotic for intravenous administration. It is derived from cephamycin C, which is produced by <i>Streptomyces lactamdurans</i>. | Moderate | 1 | [
[
[
1132,
24,
1558
]
],
[
[
1132,
24,
665
],
[
665,
40,
1558
]
],
[
[
1132,
24,
1402
],
[
1402,
1,
1558
]
],
[
[
1132,
63,
277
],
[
277,
1,
1558
]
],
[
[
1132,
63,
164
],
[
164,
40,
1558
]
],
[
[
1132,
21,
28775
],
[
28775,
60,
1558
]
],
[
[
1132,
24,
1662
],
[
1662,
63,
1558
]
],
[
[
1132,
24,
1448
],
[
1448,
24,
1558
]
],
[
[
1132,
35,
416
],
[
416,
24,
1558
]
],
[
[
1132,
24,
665
],
[
665,
40,
11239
],
[
11239,
1,
1558
]
]
] | [
[
[
"Gentamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefoxitin"
]
],
[
[
"Gentamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefuroxime"
],
[
"Cefuroxime",
"{u} (Compound) resembles {v} (Compound)",
"Cefoxitin"
]
],
[
[
"Gentamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefotetan"
],
[
"Cefotetan",
"{u} (Compound) resembles {v} (Compound)",
"Cefoxitin"
]
],
[
[
"Gentamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefmetazole"
],
[
"Cefmetazole",
"{u} (Compound) resembles {v} (Compound)",
"Cefoxitin"
]
],
[
[
"Gentamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefalotin"
],
[
"Cefalotin",
"{u} (Compound) resembles {v} (Compound)",
"Cefoxitin"
]
],
[
[
"Gentamicin",
"{u} (Compound) causes {v} (Side Effect)",
"Phlebitis"
],
[
"Phlebitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Cefoxitin"
]
],
[
[
"Gentamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
],
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefoxitin"
]
],
[
[
"Gentamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Streptomycin"
],
[
"Streptomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefoxitin"
]
],
[
[
"Gentamicin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kanamycin"
],
[
"Kanamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefoxitin"
]
],
[
[
"Gentamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefuroxime"
],
[
"Cefuroxime",
"{u} (Compound) resembles {v} (Compound)",
"Cephaloglycin"
],
[
"Cephaloglycin",
"{u} (Compound) resembles {v} (Compound)",
"Cefoxitin"
]
]
] | Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Cefuroxime and Cefuroxime (Compound) resembles Cefoxitin (Compound)
Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Cefotetan and Cefotetan (Compound) resembles Cefoxitin (Compound)
Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Cefmetazole and Cefmetazole (Compound) resembles Cefoxitin (Compound)
Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Cefalotin and Cefalotin (Compound) resembles Cefoxitin (Compound)
Gentamicin (Compound) causes Phlebitis (Side Effect) and Phlebitis (Side Effect) is caused by Cefoxitin (Compound)
Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Cefoxitin
Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Streptomycin and Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Cefoxitin
Gentamicin (Compound) resembles Kanamycin (Compound) and Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin and Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Cefoxitin
Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Cefuroxime and Cefuroxime (Compound) resembles Cephaloglycin (Compound) and Cephaloglycin (Compound) resembles Cefoxitin (Compound) |
DB01166 | DB11915 | 477 | 1,293 | [
"DDInter379",
"DDInter1909"
] | Cilostazol | Valbenazine | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions. | Valbenazine is a modified metabolite of [tetrabenazine], and it is currently being approved for the treatment of various movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's disease.[L47885,A261135] Tardive dyskinesia has long been regarded as a consequence of anti-dopamine receptor therapy, and until 2008 with the advent of [tetrabenazine], most treatments were ineffective. However, challenges in using [tetrabenazine] as a treatment of tardive dyskinesia included frequent dosing and safety and tolerability concerns. On April 2017, valbenazine was approved by the FDA under the brand name INGREZZA as the first and only approved treatment for adults with Tardive Dyskinesia (TD). On August 2023, valbenazine was again approved by the FDA for the treatment of chorea associated with Huntington's disease respectively. This approval was supported by positive results in multiple trials, including the KINECT-HD Phase 3 study and the ongoing KINECT-HD2 open-label extension trial. The reduction in chorea severity was observed as early as 2 weeks after starting treatment with an initial dose of 40 mg. | Moderate | 1 | [
[
[
477,
24,
1293
]
],
[
[
477,
62,
112
],
[
112,
23,
1293
]
],
[
[
477,
63,
521
],
[
521,
24,
1293
]
],
[
[
477,
25,
283
],
[
283,
63,
1293
]
],
[
[
477,
24,
392
],
[
392,
24,
1293
]
],
[
[
477,
24,
159
],
[
159,
63,
1293
]
],
[
[
477,
25,
1213
],
[
1213,
24,
1293
]
],
[
[
477,
64,
600
],
[
600,
24,
1293
]
],
[
[
477,
24,
129
],
[
129,
25,
1293
]
],
[
[
477,
25,
384
],
[
384,
25,
1293
]
]
] | [
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valbenazine"
]
],
[
[
"Cilostazol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Valbenazine"
]
],
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valbenazine"
]
],
[
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valbenazine"
]
],
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valbenazine"
]
],
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valbenazine"
]
],
[
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valbenazine"
]
],
[
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valbenazine"
]
],
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Valbenazine"
]
],
[
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Valbenazine"
]
]
] | Cilostazol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Valbenazine
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Valbenazine
Cilostazol may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Valbenazine
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Valbenazine
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Valbenazine
Cilostazol may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Valbenazine
Cilostazol may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Valbenazine
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Valbenazine
Cilostazol may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Valbenazine |
DB04868 | DB05528 | 478 | 1,070 | [
"DDInter1293",
"DDInter1228"
] | Nilotinib | Mipomersen | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor used as a first-line treatment for CML. | Mipomersen sodium, which was known as the investigational drug, isis-301012, is the salt form of a synthetic phosphorothioate oligonucleotide. Mipomersen sodium prevents the formation of apo B-100, resulting in a decrease in the levels of apolipoprotein B (apo B), low density lipoprotein (LDL), and total cholesterol. Mipomersen is indicated in patients with homozygous familial hypercholesterolemia as an adjunct to diet and other lipid-lowering medications. It is marketed under the brand name Kynamro in the United States, and the FDA label includes a black box warning of hepatoxicity. Specifically, elevations in the liver enzymes, i.e. transaminases, and in liver fat (hepatic steatosis) have been reported. Due to this serious risk of liver toxicity, mipomersen sodium is only available to patients under the restricted program called Kynamro Risk Evaluation and Mitigation Strategy program. | Major | 2 | [
[
[
478,
25,
1070
]
],
[
[
478,
63,
1512
],
[
1512,
25,
1070
]
],
[
[
478,
25,
1250
],
[
1250,
64,
1070
]
],
[
[
478,
24,
594
],
[
594,
64,
1070
]
],
[
[
478,
64,
1151
],
[
1151,
25,
1070
]
],
[
[
478,
24,
866
],
[
866,
25,
1070
]
],
[
[
478,
74,
1419
],
[
1419,
25,
1070
]
],
[
[
478,
63,
1512
],
[
1512,
25,
292
],
[
292,
64,
1070
]
],
[
[
478,
25,
1250
],
[
1250,
63,
14
],
[
14,
25,
1070
]
],
[
[
478,
63,
1195
],
[
1195,
24,
1320
],
[
1320,
64,
1070
]
]
] | [
[
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mipomersen"
]
],
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mipomersen"
]
],
[
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pazopanib"
],
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mipomersen"
]
],
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
],
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mipomersen"
]
],
[
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sunitinib"
],
[
"Sunitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mipomersen"
]
],
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobimetinib"
],
[
"Cobimetinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mipomersen"
]
],
[
[
"Nilotinib",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mipomersen"
]
],
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Regorafenib"
],
[
"Regorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mipomersen"
]
],
[
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pazopanib"
],
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
],
[
"Rosuvastatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mipomersen"
]
],
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erlotinib"
],
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
"Elagolix",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mipomersen"
]
]
] | Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may lead to a major life threatening interaction when taken with Mipomersen
Nilotinib may lead to a major life threatening interaction when taken with Pazopanib and Pazopanib may lead to a major life threatening interaction when taken with Mipomersen
Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may lead to a major life threatening interaction when taken with Mipomersen
Nilotinib may lead to a major life threatening interaction when taken with Sunitinib and Sunitinib may lead to a major life threatening interaction when taken with Mipomersen
Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib and Cobimetinib may lead to a major life threatening interaction when taken with Mipomersen
Nilotinib (Compound) resembles Imatinib (Compound) and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may lead to a major life threatening interaction when taken with Mipomersen
Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may lead to a major life threatening interaction when taken with Regorafenib and Regorafenib may lead to a major life threatening interaction when taken with Mipomersen
Nilotinib may lead to a major life threatening interaction when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may lead to a major life threatening interaction when taken with Mipomersen
Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Erlotinib and Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may lead to a major life threatening interaction when taken with Mipomersen |
DB01276 | DB05260 | 123 | 1,329 | [
"DDInter706",
"DDInter804"
] | Exenatide | Gallium nitrate | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulations.[L42685,L42690] Bydureon, the brand name product of extended-release exenatide in an injectable suspension, was discontinued in 2021. Bydureon BCise, an auto-injector extended-release formulation, remains available. | Gallium nitrate is a nitrate salt of , a heavy metal that has been used as a diagnostic agent. Gallium nitrate is reported to possess antiresorptive and hypocalcemic effects on bone. GANITE, a product of gallium nitrate previously used to treat cancer-related hypercalcemia, was discontinued from marketing in the US for reasons other than safety or effectiveness. Apart from cancer-related hypercalcemia, gallium nitrate has been studied in arthritis, autoimmune disorders, and tumours. | Moderate | 1 | [
[
[
123,
24,
1329
]
],
[
[
123,
63,
712
],
[
712,
24,
1329
]
],
[
[
123,
63,
361
],
[
361,
25,
1329
]
],
[
[
123,
63,
712
],
[
712,
63,
1555
],
[
1555,
24,
1329
]
],
[
[
123,
63,
361
],
[
361,
21,
28746
],
[
28746,
60,
1329
]
],
[
[
123,
63,
684
],
[
684,
18,
6896
],
[
6896,
45,
1329
]
],
[
[
123,
63,
712
],
[
712,
1,
50
],
[
50,
24,
1329
]
],
[
[
123,
63,
50
],
[
50,
40,
712
],
[
712,
24,
1329
]
],
[
[
123,
63,
874
],
[
874,
7,
2675
],
[
2675,
45,
1329
]
],
[
[
123,
63,
50
],
[
50,
24,
1272
],
[
1272,
24,
1329
]
]
] | [
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gallium nitrate"
]
],
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olsalazine"
],
[
"Olsalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gallium nitrate"
]
],
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neomycin"
],
[
"Neomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gallium nitrate"
]
],
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olsalazine"
],
[
"Olsalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gallium nitrate"
]
],
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neomycin"
],
[
"Neomycin",
"{u} (Compound) causes {v} (Side Effect)",
"Erythema"
],
[
"Erythema",
"{u} (Side Effect) is caused by {v} (Compound)",
"Gallium nitrate"
]
],
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thioridazine"
],
[
"Thioridazine",
"{u} (Compound) downregulates {v} (Gene)",
"RRM2"
],
[
"RRM2",
"{u} (Gene) is bound by {v} (Compound)",
"Gallium nitrate"
]
],
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olsalazine"
],
[
"Olsalazine",
"{u} (Compound) resembles {v} (Compound)",
"Sulfasalazine"
],
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gallium nitrate"
]
],
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfasalazine"
],
[
"Sulfasalazine",
"{u} (Compound) resembles {v} (Compound)",
"Olsalazine"
],
[
"Olsalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gallium nitrate"
]
],
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epinephrine"
],
[
"Epinephrine",
"{u} (Compound) upregulates {v} (Gene)",
"TF"
],
[
"TF",
"{u} (Gene) is bound by {v} (Compound)",
"Gallium nitrate"
]
],
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfasalazine"
],
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flucytosine"
],
[
"Flucytosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gallium nitrate"
]
]
] | Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Olsalazine and Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Gallium nitrate
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Neomycin and Neomycin may lead to a major life threatening interaction when taken with Gallium nitrate
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Olsalazine and Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Gallium nitrate
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Neomycin and Neomycin (Compound) causes Erythema (Side Effect) and Erythema (Side Effect) is caused by Gallium nitrate (Compound)
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Thioridazine and Thioridazine (Compound) downregulates RRM2 (Gene) and RRM2 (Gene) is bound by Gallium nitrate (Compound)
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Olsalazine and Olsalazine (Compound) resembles Sulfasalazine (Compound) and Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Gallium nitrate
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine and Sulfasalazine (Compound) resembles Olsalazine (Compound) and Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Gallium nitrate
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine (Compound) upregulates TF (Gene) and TF (Gene) is bound by Gallium nitrate (Compound)
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine and Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Flucytosine and Flucytosine may cause a moderate interaction that could exacerbate diseases when taken with Gallium nitrate |
DB00962 | DB01181 | 1,639 | 1,532 | [
"DDInter1957",
"DDInter906"
] | Zaleplon | Ifosfamide | Zaleplon is a sedative/hypnotic, mainly used for insomnia. It is known as a nonbenzodiazepine hypnotic. Zaleplon interacts with the GABA receptor complex and shares some of the pharmacological properties of the benzodiazepines. Zaleplon is a schedule IV drug in the United States. | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Moderate | 1 | [
[
[
1639,
24,
1532
]
],
[
[
1639,
6,
7524
],
[
7524,
45,
1532
]
],
[
[
1639,
21,
28956
],
[
28956,
60,
1532
]
],
[
[
1639,
63,
1648
],
[
1648,
24,
1532
]
],
[
[
1639,
24,
401
],
[
401,
24,
1532
]
],
[
[
1639,
24,
849
],
[
849,
63,
1532
]
],
[
[
1639,
62,
1324
],
[
1324,
24,
1532
]
],
[
[
1639,
64,
475
],
[
475,
24,
1532
]
],
[
[
1639,
24,
770
],
[
770,
25,
1532
]
],
[
[
1639,
6,
7524
],
[
7524,
45,
307
],
[
307,
23,
1532
]
]
] | [
[
[
"Zaleplon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Zaleplon",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)",
"Ifosfamide"
]
],
[
[
"Zaleplon",
"{u} (Compound) causes {v} (Side Effect)",
"Palpitations"
],
[
"Palpitations",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ifosfamide"
]
],
[
[
"Zaleplon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Zaleplon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Zaleplon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Zaleplon",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Zaleplon",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Zaleplon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ifosfamide"
]
],
[
[
"Zaleplon",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ifosfamide"
]
]
] | Zaleplon (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Ifosfamide (Compound)
Zaleplon (Compound) causes Palpitations (Side Effect) and Palpitations (Side Effect) is caused by Ifosfamide (Compound)
Zaleplon may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Zaleplon may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Zaleplon may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Zaleplon may cause a minor interaction that can limit clinical effects when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Zaleplon may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Zaleplon may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Ifosfamide
Zaleplon (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Ifosfamide |
DB00549 | DB06448 | 522 | 171 | [
"DDInter1955",
"DDInter1087"
] | Zafirlukast | Lonafarnib | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), which is usually taken just once daily. Zafirlukast blocks the action of the cysteinyl leukotrienes on the CysLT1 receptors, thus reducing constriction of the airways, build-up of mucus in the lungs and inflammation of the breathing passages. | Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cutaneous effects, lipoatrophy, alopecia, and a severe failure to thrive; HGPS is uniformly fatal.[A224379, A224384, A224389, A224394, A224399] Mechanistically, HGPS is underpinned by a single heterozygous C-to-T mutation at position 1824 of the _LMNA_ gene, which results in the accumulation of an aberrant farnesylated form of lamin A called progerin in the inner nuclear membrane.[A224379, A224394] Lonafarnib is a farnesyl transferase (FTase) inhibitor (FTI), which reduces the farnesylation of numerous cellular proteins, including progerin; as progerin farnesylation is important for localization to the nuclear membrane, lonafarnib inhibits progerin accumulation and improves symptoms in HGPS patients.[A224379, A224414, A224419, L23414] Merck originally developed Lonafarnib and subsequently licensed it to Eiger Biopharmaceuticals Inc., which currently markets it under the trademark ZOKINVY™.[L23414, L23544] Lonafarnib was granted FDA approval on November 20, 2020, and is the first FDA-approved treatment for HGPS and other related progeroid laminopathies.[L23414, L23549] | Major | 2 | [
[
[
522,
25,
171
]
],
[
[
522,
23,
222
],
[
222,
23,
171
]
],
[
[
522,
63,
254
],
[
254,
24,
171
]
],
[
[
522,
24,
112
],
[
112,
24,
171
]
],
[
[
522,
24,
310
],
[
310,
63,
171
]
],
[
[
522,
23,
1347
],
[
1347,
24,
171
]
],
[
[
522,
25,
1377
],
[
1377,
24,
171
]
],
[
[
522,
24,
129
],
[
129,
64,
171
]
],
[
[
522,
25,
1493
],
[
1493,
25,
171
]
],
[
[
522,
24,
723
],
[
723,
25,
171
]
]
] | [
[
[
"Zafirlukast",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lonafarnib"
]
],
[
[
"Zafirlukast",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lonafarnib"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitisinone"
],
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
]
],
[
[
"Zafirlukast",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clopidogrel"
],
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
]
],
[
[
"Zafirlukast",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lonafarnib"
]
],
[
[
"Zafirlukast",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Halofantrine"
],
[
"Halofantrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lonafarnib"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lonafarnib"
]
]
] | Zafirlukast may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Lonafarnib
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Nitisinone and Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Zafirlukast may cause a minor interaction that can limit clinical effects when taken with Clopidogrel and Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Zafirlukast may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Lonafarnib
Zafirlukast may lead to a major life threatening interaction when taken with Halofantrine and Halofantrine may lead to a major life threatening interaction when taken with Lonafarnib
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may lead to a major life threatening interaction when taken with Lonafarnib |
DB00471 | DB01097 | 201 | 1,377 | [
"DDInter1242",
"DDInter1033"
] | Montelukast | Leflunomide | Montelukast was first approved for clinical use by the US FDA in 1998 as Merck's brand name Singulair. The medication is a member of the leukotriene receptor antagonist (LTRA) category of drugs.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] Although capable of demonstrating effectiveness, the use of such LTRAs like montelukast is typically in addition to or complementary with the use of inhaled corticosteroids or other agents in asthma step therapy. Regardless, in 2008-2009, there were FDA-led investigations into the possibility of montelukast to elicit neuropsychiatric effects like agitation, hallucinations, suicidal behaviour, and others in individuals who used the medication. And although these kinds of effects are currently included in the official prescribing information for montelukast,[L6301,L6304,L6307,L6310,L6325,L632 | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Moderate | 1 | [
[
[
201,
24,
1377
]
],
[
[
201,
6,
6017
],
[
6017,
45,
1377
]
],
[
[
201,
21,
29231
],
[
29231,
60,
1377
]
],
[
[
201,
24,
1144
],
[
1144,
24,
1377
]
],
[
[
201,
24,
655
],
[
655,
63,
1377
]
],
[
[
201,
24,
1622
],
[
1622,
25,
1377
]
],
[
[
201,
24,
392
],
[
392,
64,
1377
]
],
[
[
201,
63,
362
],
[
362,
25,
1377
]
],
[
[
201,
6,
6017
],
[
6017,
45,
240
],
[
240,
24,
1377
]
],
[
[
201,
21,
29231
],
[
29231,
60,
1005
],
[
1005,
24,
1377
]
]
] | [
[
[
"Montelukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Leflunomide"
]
],
[
[
"Montelukast",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Leflunomide"
]
],
[
[
"Montelukast",
"{u} (Compound) causes {v} (Side Effect)",
"Cardiac disorder"
],
[
"Cardiac disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Leflunomide"
]
],
[
[
"Montelukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Leflunomide"
]
],
[
[
"Montelukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
],
[
"Etravirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Leflunomide"
]
],
[
[
"Montelukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voriconazole"
],
[
"Voriconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Montelukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Montelukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Montelukast",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Losartan"
],
[
"Losartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Leflunomide"
]
],
[
[
"Montelukast",
"{u} (Compound) causes {v} (Side Effect)",
"Cardiac disorder"
],
[
"Cardiac disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Vardenafil"
],
[
"Vardenafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Leflunomide"
]
]
] | Montelukast (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Leflunomide (Compound)
Montelukast (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Leflunomide (Compound)
Montelukast may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide
Montelukast may cause a moderate interaction that could exacerbate diseases when taken with Etravirine and Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide
Montelukast may cause a moderate interaction that could exacerbate diseases when taken with Voriconazole and Voriconazole may lead to a major life threatening interaction when taken with Leflunomide
Montelukast may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may lead to a major life threatening interaction when taken with Leflunomide
Montelukast may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin may lead to a major life threatening interaction when taken with Leflunomide
Montelukast (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Losartan (Compound) and Losartan may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide
Montelukast (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Vardenafil (Compound) and Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide |
DB00381 | DB12332 | 376 | 1,619 | [
"DDInter79",
"DDInter1626"
] | Amlodipine | Rucaparib | Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called _dihydropyridine calcium channel blockers_. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial depression and cardiac conduction abnormalities than other calcium channel blockers. Amlodipine is commonly used in the treatment of high blood pressure and angina. Amlodipine has antioxidant properties and an ability to enhance the production of nitric oxide (NO), an important vasodilator that decreases blood pressure. The option for single daily dosing of amlodipine is an attractive feature of this drug [FDA label]. | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the genetically-mutated cancer cells that lack a DNA repair mechanism, rucaparib causes cancer cell death and reduces tumour growth.[A18745,A31354] Rucaparib was granted FDA Breakthrough Therapy designation in April 2015 and accelerated approval in December 2016. The drug was later approved by the European Commission in May 2018. It is currently used to treat recurrent ovarian and prostate cancer in adults.[L42155,L42185] | Moderate | 1 | [
[
[
376,
24,
1619
]
],
[
[
376,
24,
259
],
[
259,
24,
1619
]
],
[
[
376,
40,
84
],
[
84,
24,
1619
]
],
[
[
376,
63,
58
],
[
58,
24,
1619
]
],
[
[
376,
24,
159
],
[
159,
63,
1619
]
],
[
[
376,
25,
913
],
[
913,
24,
1619
]
],
[
[
376,
23,
578
],
[
578,
24,
1619
]
],
[
[
376,
1,
1081
],
[
1081,
24,
1619
]
],
[
[
376,
23,
466
],
[
466,
63,
1619
]
],
[
[
376,
25,
1166
],
[
1166,
25,
1619
]
]
] | [
[
[
"Amlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Amlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
],
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Amlodipine",
"{u} (Compound) resembles {v} (Compound)",
"Nisoldipine"
],
[
"Nisoldipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Amlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
],
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Amlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Amlodipine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Amlodipine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Amlodipine",
"{u} (Compound) resembles {v} (Compound)",
"Nicardipine"
],
[
"Nicardipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Amlodipine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Amlodipine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolasetron"
],
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
]
]
] | Amlodipine may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Amlodipine (Compound) resembles Nisoldipine (Compound) and Nisoldipine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Amlodipine may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Amlodipine may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Amlodipine may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Amlodipine may cause a minor interaction that can limit clinical effects when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Amlodipine (Compound) resembles Nicardipine (Compound) and Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Amlodipine may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Amlodipine may lead to a major life threatening interaction when taken with Dolasetron and Dolasetron may lead to a major life threatening interaction when taken with Rucaparib |
DB00396 | DB09038 | 989 | 1,450 | [
"DDInter1529",
"DDInter636"
] | Progesterone | Empagliflozin | Progesterone is a hormone that occurs naturally in females, and is essential for endometrial receptivity, embryo implantation, and the successful establishment of pregnancy. A low progesterone concentration or an insufficient response to progesterone can cause infertility and pregnancy loss. Progesterone is used in various contraceptive preparations to prevent ovulation and fertilization, as well as in other formulations to promote and support pregnancy. Please see [Medroxyprogesterone acetate], [Megestrol acetate], [Dydrogesterone] and [Hydroxyprogesterone] entries for information on various other forms of progesterone. Pharmaceutical progesterone is made from a plant source as a starting material and is chemically identical to progesterone of human ovarian origin [FDA label]. Progesterone is available in gelatinized capsule form, vaginal gel form, tablet form, vaginal insert form, and injection form, all used for various purposes [Label,F389 | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 diabetes mellitus. The first known inhibitor of SGLTs, phlorizin, was isolated from the bark of apple trees in 1835 and researched extensively into the 20th century, but was ultimately deemed inappropriate for clinical use given its lack of specificity and significant gastrointestinal side effects. Attempts at overcoming these limitations first saw the development of O-glucoside analogs of phlorizin (e.g. [remogliflozin etabonate]), but these molecules proved relatively pharmacokinetically unstable. The development of C-glucoside phlorizin analogs remedied the issues observed in the previous generation, and led to the FDA approval of [canagliflozin] in 2013 and both [dapagliflozin] and empagliflozin in 2014. As the most recently approved of the "flozin" drugs, empagliflozin carries the highest selectivity for SGLT2 over SGLT1 (approximately 2700-fold). Empagliflozin was further approved by the EMA in March 2022 and Health Canada in April 2022, making it the first and only approved treatment in Europe and Canada for adults with symptomatic chronic heart failure regardless of ejection fraction.[L40783,L13916] | Moderate | 1 | [
[
[
989,
24,
1450
]
],
[
[
989,
63,
1179
],
[
1179,
24,
1450
]
],
[
[
989,
40,
870
],
[
870,
24,
1450
]
],
[
[
989,
24,
1017
],
[
1017,
63,
1450
]
],
[
[
989,
1,
443
],
[
443,
24,
1450
]
],
[
[
989,
24,
850
],
[
850,
24,
1450
]
],
[
[
989,
63,
1179
],
[
1179,
23,
1103
],
[
1103,
23,
1450
]
],
[
[
989,
40,
870
],
[
870,
1,
1103
],
[
1103,
23,
1450
]
],
[
[
989,
24,
1017
],
[
1017,
63,
1028
],
[
1028,
24,
1450
]
],
[
[
989,
1,
443
],
[
443,
63,
1061
],
[
1061,
24,
1450
]
]
] | [
[
[
"Progesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Progesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin lispro"
],
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Progesterone",
"{u} (Compound) resembles {v} (Compound)",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Progesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Progesterone",
"{u} (Compound) resembles {v} (Compound)",
"Spironolactone"
],
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Progesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Progesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin lispro"
],
[
"Insulin lispro",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Empagliflozin"
]
],
[
[
"Progesterone",
"{u} (Compound) resembles {v} (Compound)",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Empagliflozin"
]
],
[
[
"Progesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Torasemide"
],
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Progesterone",
"{u} (Compound) resembles {v} (Compound)",
"Spironolactone"
],
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
]
] | Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Progesterone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Progesterone (Compound) resembles Spironolactone (Compound) and Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Empagliflozin
Progesterone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Empagliflozin
Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Torasemide and Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Progesterone (Compound) resembles Spironolactone (Compound) and Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin |
DB01208 | DB01592 | 945 | 1,596 | [
"DDInter1705",
"DDInter975"
] | Sparfloxacin | Iron | Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. | A metallic element found in certain minerals, in nearly all soils, and in mineral waters. It is an essential constituent of hemoglobin, cytochrome, and other components of respiratory enzyme systems. Its chief functions are in the transport of oxygen to tissue (hemoglobin) and in cellular oxidation mechanisms. Depletion of iron stores may result in iron-deficiency anemia. Iron is used to build up the blood in anemia. | Moderate | 1 | [
[
[
945,
24,
1596
]
],
[
[
945,
21,
29276
],
[
29276,
60,
1596
]
],
[
[
945,
24,
1193
],
[
1193,
62,
1596
]
],
[
[
945,
63,
1096
],
[
1096,
23,
1596
]
],
[
[
945,
40,
1539
],
[
1539,
24,
1596
]
],
[
[
945,
25,
1383
],
[
1383,
63,
1596
]
],
[
[
945,
24,
1475
],
[
1475,
63,
1596
]
],
[
[
945,
24,
1283
],
[
1283,
24,
1596
]
],
[
[
945,
21,
29276
],
[
29276,
60,
1096
],
[
1096,
23,
1596
]
],
[
[
945,
21,
28876
],
[
28876,
60,
1215
],
[
1215,
24,
1596
]
]
] | [
[
[
"Sparfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron"
]
],
[
[
"Sparfloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Haemoglobin"
],
[
"Haemoglobin",
"{u} (Side Effect) is caused by {v} (Compound)",
"Iron"
]
],
[
[
"Sparfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Iron"
]
],
[
[
"Sparfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Iron"
]
],
[
[
"Sparfloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Ofloxacin"
],
[
"Ofloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron"
]
],
[
[
"Sparfloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sodium sulfate"
],
[
"Sodium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron"
]
],
[
[
"Sparfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium citrate"
],
[
"Sodium citrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron"
]
],
[
[
"Sparfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium oxide"
],
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron"
]
],
[
[
"Sparfloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Haemoglobin"
],
[
"Haemoglobin",
"{u} (Side Effect) is caused by {v} (Compound)",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Iron"
]
],
[
[
"Sparfloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Anaphylactoid reaction"
],
[
"Anaphylactoid reaction",
"{u} (Side Effect) is caused by {v} (Compound)",
"Lansoprazole"
],
[
"Lansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron"
]
]
] | Sparfloxacin (Compound) causes Haemoglobin (Side Effect) and Haemoglobin (Side Effect) is caused by Iron (Compound)
Sparfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Iron
Sparfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Iron
Sparfloxacin (Compound) resembles Ofloxacin (Compound) and Ofloxacin may cause a moderate interaction that could exacerbate diseases when taken with Iron
Sparfloxacin may lead to a major life threatening interaction when taken with Sodium sulfate and Sodium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Iron
Sparfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Sodium citrate and Sodium citrate may cause a moderate interaction that could exacerbate diseases when taken with Iron
Sparfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide and Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Iron
Sparfloxacin (Compound) causes Haemoglobin (Side Effect) and Haemoglobin (Side Effect) is caused by Mycophenolic acid (Compound) and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Iron
Sparfloxacin (Compound) causes Anaphylactoid reaction (Side Effect) and Anaphylactoid reaction (Side Effect) is caused by Lansoprazole (Compound) and Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Iron |
DB00682 | DB01066 | 126 | 1,462 | [
"DDInter1951",
"DDInter316"
] | Warfarin | Cefditoren | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors. | Cefditoren is an oral third-generation cephalosporin. It is commonly marketed under the trade name Spectracef by Cornerstone BioPharma. | Moderate | 1 | [
[
[
126,
24,
1462
]
],
[
[
126,
24,
1403
],
[
1403,
40,
1462
]
],
[
[
126,
24,
1392
],
[
1392,
1,
1462
]
],
[
[
126,
63,
149
],
[
149,
40,
1462
]
],
[
[
126,
63,
778
],
[
778,
1,
1462
]
],
[
[
126,
63,
837
],
[
837,
24,
1462
]
],
[
[
126,
24,
660
],
[
660,
24,
1462
]
],
[
[
126,
24,
379
],
[
379,
63,
1462
]
],
[
[
126,
24,
1403
],
[
1403,
1,
665
],
[
665,
40,
1462
]
],
[
[
126,
24,
665
],
[
665,
40,
1403
],
[
1403,
40,
1462
]
]
] | [
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefditoren"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefepime"
],
[
"Cefepime",
"{u} (Compound) resembles {v} (Compound)",
"Cefditoren"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefadroxil"
],
[
"Cefadroxil",
"{u} (Compound) resembles {v} (Compound)",
"Cefditoren"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ceftazidime"
],
[
"Ceftazidime",
"{u} (Compound) resembles {v} (Compound)",
"Cefditoren"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefixime"
],
[
"Cefixime",
"{u} (Compound) resembles {v} (Compound)",
"Cefditoren"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pantoprazole"
],
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefditoren"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esomeprazole"
],
[
"Esomeprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefditoren"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rabeprazole"
],
[
"Rabeprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefditoren"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefepime"
],
[
"Cefepime",
"{u} (Compound) resembles {v} (Compound)",
"Cefuroxime"
],
[
"Cefuroxime",
"{u} (Compound) resembles {v} (Compound)",
"Cefditoren"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefuroxime"
],
[
"Cefuroxime",
"{u} (Compound) resembles {v} (Compound)",
"Cefepime"
],
[
"Cefepime",
"{u} (Compound) resembles {v} (Compound)",
"Cefditoren"
]
]
] | Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Cefepime and Cefepime (Compound) resembles Cefditoren (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Cefadroxil and Cefadroxil (Compound) resembles Cefditoren (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Ceftazidime and Ceftazidime (Compound) resembles Cefditoren (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Cefixime and Cefixime (Compound) resembles Cefditoren (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Pantoprazole and Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Cefditoren
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole and Esomeprazole may cause a moderate interaction that could exacerbate diseases when taken with Cefditoren
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Rabeprazole and Rabeprazole may cause a moderate interaction that could exacerbate diseases when taken with Cefditoren
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Cefepime and Cefepime (Compound) resembles Cefuroxime (Compound) and Cefuroxime (Compound) resembles Cefditoren (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Cefuroxime and Cefuroxime (Compound) resembles Cefepime (Compound) and Cefepime (Compound) resembles Cefditoren (Compound) |
DB00372 | DB00988 | 999 | 817 | [
"DDInter1793",
"DDInter584"
] | Thiethylperazine | Dopamine | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | One of the catecholamine neurotransmitters in the brain. It is derived from tyrosine and is the precursor to norepinephrine and epinephrine. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (receptors, dopamine) mediate its action. | Moderate | 1 | [
[
[
999,
24,
817
]
],
[
[
999,
24,
584
],
[
584,
1,
817
]
],
[
[
999,
24,
874
],
[
874,
40,
817
]
],
[
[
999,
25,
1311
],
[
1311,
62,
817
]
],
[
[
999,
24,
433
],
[
433,
63,
817
]
],
[
[
999,
24,
473
],
[
473,
24,
817
]
],
[
[
999,
63,
73
],
[
73,
24,
817
]
],
[
[
999,
24,
1053
],
[
1053,
64,
817
]
],
[
[
999,
24,
247
],
[
247,
76,
817
]
],
[
[
999,
24,
584
],
[
584,
40,
1551
],
[
1551,
1,
817
]
]
] | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dopamine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levonordefrin"
],
[
"Levonordefrin",
"{u} (Compound) resembles {v} (Compound)",
"Dopamine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epinephrine"
],
[
"Epinephrine",
"{u} (Compound) resembles {v} (Compound)",
"Dopamine"
]
],
[
[
"Thiethylperazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dopamine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
],
[
"Ertugliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dopamine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
],
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dopamine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentermine"
],
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dopamine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dopamine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iobenguane"
],
[
"Iobenguane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Dopamine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levonordefrin"
],
[
"Levonordefrin",
"{u} (Compound) resembles {v} (Compound)",
"Methyldopa"
],
[
"Methyldopa",
"{u} (Compound) resembles {v} (Compound)",
"Dopamine"
]
]
] | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Levonordefrin and Levonordefrin (Compound) resembles Dopamine (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine (Compound) resembles Dopamine (Compound)
Thiethylperazine may lead to a major life threatening interaction when taken with Metoclopramide and Metoclopramide may cause a minor interaction that can limit clinical effects when taken with Dopamine
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin and Ertugliflozin may cause a moderate interaction that could exacerbate diseases when taken with Dopamine
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Dopamine
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Dopamine
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine may lead to a major life threatening interaction when taken with Dopamine
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Iobenguane may cause a moderate interaction that could exacerbate diseases when taken with Dopamine and Iobenguane may lead to a major life threatening interaction when taken with Dopamine
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Levonordefrin and Levonordefrin (Compound) resembles Methyldopa (Compound) and Methyldopa (Compound) resembles Dopamine (Compound) |
DB00087 | DB11601 | 599 | 1,270 | [
"DDInter41",
"DDInter1889"
] | Alemtuzumab | Tuberculin purified protein derivative | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant regions, and complementarity-determining regions from a murine (rat) monoclonal antibody (Campath-1G). Alemtuzumab is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin. Alemtuzumab was approved by the FDA in 2001. It is marketed as LEMTRADA for multiple sclerosis (MS) treatment and CAMPTAH for B-cell chronic lymphocytic leukemia (B-CLL). The dose of alemtuzumab used for B-CLL is | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycobacterium tuberculosis* through early diagnosis and appropriate therapeutic intervention. The purified protein fraction is isolated from culture media filtrates of a human strain of Mycobacterium tuberculosis. It is included in the World Health Organization's List of Essential Medicines. | Moderate | 1 | [
[
[
599,
24,
1270
]
],
[
[
599,
24,
350
],
[
350,
24,
1270
]
],
[
[
599,
63,
550
],
[
550,
24,
1270
]
],
[
[
599,
25,
1064
],
[
1064,
24,
1270
]
],
[
[
599,
24,
119
],
[
119,
63,
1270
]
],
[
[
599,
25,
1259
],
[
1259,
63,
1270
]
],
[
[
599,
24,
350
],
[
350,
63,
1531
],
[
1531,
24,
1270
]
],
[
[
599,
63,
550
],
[
550,
24,
1531
],
[
1531,
24,
1270
]
],
[
[
599,
24,
1531
],
[
1531,
24,
350
],
[
350,
24,
1270
]
],
[
[
599,
25,
1064
],
[
1064,
25,
350
],
[
350,
24,
1270
]
]
] | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
],
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab"
],
[
"Trastuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Alemtuzumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
],
[
"Talazoparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Alemtuzumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
],
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
],
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab"
],
[
"Trastuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
],
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
],
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
],
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Alemtuzumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Carfilzomib"
],
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
]
] | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab and Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Alemtuzumab may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib and Talazoparib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Alemtuzumab may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab and Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Alemtuzumab may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative |
DB00539 | DB01142 | 11 | 1,264 | [
"DDInter1837",
"DDInter593"
] | Toremifene | Doxepin | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has estrogenic (agonist) activity on the cardiovascular system and on bone tissue and it has weak estrogenic effects on uterine tissue, however, it also has antiestrogenic (estrogen-antagonist) activity on breast tissue. | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepressant but it is commonly associated with the class since it shares a lot of properties with members of the drug family including [amitriptyline], [clomipramine], [desipramine], [imipramine], [nortriptyline], [protriptyline] and [trimipramine]. Doxepin was developed by Pfizer and FDA approved in 1969 as an antidepressant. However, in 2010 it was approved for the treatment of insomnia. The latter indication was presented by Pernix Therapeutics. | Major | 2 | [
[
[
11,
25,
1264
]
],
[
[
11,
64,
508
],
[
508,
24,
1264
]
],
[
[
11,
25,
401
],
[
401,
24,
1264
]
],
[
[
11,
1,
1594
],
[
1594,
24,
1264
]
],
[
[
11,
24,
1335
],
[
1335,
24,
1264
]
],
[
[
11,
1,
11296
],
[
11296,
40,
1264
]
],
[
[
11,
1,
649
],
[
649,
63,
1264
]
],
[
[
11,
6,
4973
],
[
4973,
45,
1264
]
],
[
[
11,
7,
6952
],
[
6952,
46,
1264
]
],
[
[
11,
21,
28898
],
[
28898,
60,
1264
]
]
] | [
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxepin"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Promazine"
],
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Toremifene",
"{u} (Compound) resembles {v} (Compound)",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxcarbazepine"
],
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Toremifene",
"{u} (Compound) resembles {v} (Compound)",
"Bromodiphenhydramine"
],
[
"Bromodiphenhydramine",
"{u} (Compound) resembles {v} (Compound)",
"Doxepin"
]
],
[
[
"Toremifene",
"{u} (Compound) resembles {v} (Compound)",
"Clofedanol"
],
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Toremifene",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Doxepin"
]
],
[
[
"Toremifene",
"{u} (Compound) upregulates {v} (Gene)",
"MCOLN1"
],
[
"MCOLN1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Doxepin"
]
],
[
[
"Toremifene",
"{u} (Compound) causes {v} (Side Effect)",
"Constipation"
],
[
"Constipation",
"{u} (Side Effect) is caused by {v} (Compound)",
"Doxepin"
]
]
] | Toremifene may lead to a major life threatening interaction when taken with Promazine and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Toremifene may lead to a major life threatening interaction when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Toremifene (Compound) resembles Doxylamine (Compound) and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine and Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Toremifene (Compound) resembles Bromodiphenhydramine (Compound) and Bromodiphenhydramine (Compound) resembles Doxepin (Compound)
Toremifene (Compound) resembles Clofedanol (Compound) and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Toremifene (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Doxepin (Compound)
Toremifene (Compound) upregulates MCOLN1 (Gene) and MCOLN1 (Gene) is upregulated by Doxepin (Compound)
Toremifene (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Doxepin (Compound) |
DB00532 | DB06282 | 208 | 516 | [
"DDInter1152",
"DDInter1053"
] | Mephenytoin | Levocetirizine | Mephenytoin is used for the treatment of refractory partial epilepsy. Mephenytoin is a solid. This compound belongs to the phenylhydantoins. These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. Mephenytoin is known to target sodium channel protein type 5 subunit alpha. Cytochrome P450 2C19, Cytochrome P450 2C8, Cytochrome P450 2C9, Cytochrome P450 2B6, Cytochrome P450 1A2, and Cytochrome P450 2D6 are known to metabolize mephenytoin. Mephenytoin is a hydantoin-derivative anticonvulsant used to control various partial seizures. Mephenytoin and oxazolidinedione derivatives are associated with higher incid | Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine. Levocetirizine was granted FDA approval in 1995. | Moderate | 1 | [
[
[
208,
24,
516
]
],
[
[
208,
63,
1031
],
[
1031,
23,
516
]
],
[
[
208,
63,
701
],
[
701,
24,
516
]
],
[
[
208,
24,
407
],
[
407,
63,
516
]
],
[
[
208,
24,
1219
],
[
1219,
24,
516
]
],
[
[
208,
63,
1031
],
[
1031,
24,
697
],
[
697,
24,
516
]
],
[
[
208,
63,
701
],
[
701,
23,
771
],
[
771,
62,
516
]
],
[
[
208,
63,
1614
],
[
1614,
63,
701
],
[
701,
24,
516
]
],
[
[
208,
24,
407
],
[
407,
63,
701
],
[
701,
24,
516
]
],
[
[
208,
24,
1219
],
[
1219,
23,
771
],
[
771,
62,
516
]
]
] | [
[
[
"Mephenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Mephenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophylline"
],
[
"Theophylline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Levocetirizine"
]
],
[
[
"Mephenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Mephenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Mephenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azatadine"
],
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Mephenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophylline"
],
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Mephenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
],
[
"Hyaluronidase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Levocetirizine"
]
],
[
[
"Mephenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
],
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Mephenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Mephenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azatadine"
],
[
"Azatadine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
],
[
"Hyaluronidase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Levocetirizine"
]
]
] | Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a minor interaction that can limit clinical effects when taken with Levocetirizine
Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Azatadine and Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital and Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase and Hyaluronidase may cause a minor interaction that can limit clinical effects when taken with Levocetirizine
Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Azatadine and Azatadine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase and Hyaluronidase may cause a minor interaction that can limit clinical effects when taken with Levocetirizine |
DB09079 | DB11952 | 1,496 | 800 | [
"DDInter1296",
"DDInter612"
] | Nintedanib | Duvelisib | Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC).[L8453,L8459] It was first approved for use in the United States in 2014. Within the spectrum of idiopathic pulmonary fibrosis treatment options, nintedanib is currently one of only two disease-modifying therapies available and indicated for the condition (the other being [Pirfenidone]) and as such is used as a first-line treatment following diagnosis to slow down the progressive loss of lung function. As a chemotherapeutic agent for NSCLC, nintedanib, in combination with [Docetaxel], is reserved for patients who have tried and failed first-line chemotherapeutic options. | Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed that this agent is a potent inhibitor of both forms. Duvelisib was developed by Verastem, Inc and FDA approved on September 24, 2018. | Moderate | 1 | [
[
[
1496,
24,
800
]
],
[
[
1496,
63,
663
],
[
663,
24,
800
]
],
[
[
1496,
24,
124
],
[
124,
63,
800
]
],
[
[
1496,
25,
1017
],
[
1017,
63,
800
]
],
[
[
1496,
24,
1613
],
[
1613,
24,
800
]
],
[
[
1496,
64,
1220
],
[
1220,
24,
800
]
],
[
[
1496,
63,
609
],
[
609,
25,
800
]
],
[
[
1496,
24,
927
],
[
927,
25,
800
]
],
[
[
1496,
64,
1377
],
[
1377,
25,
800
]
],
[
[
1496,
63,
663
],
[
663,
24,
466
],
[
466,
62,
800
]
]
] | [
[
[
"Nintedanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
]
],
[
[
"Nintedanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
]
],
[
[
"Nintedanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
],
[
"Glasdegib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
]
],
[
[
"Nintedanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
]
],
[
[
"Nintedanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
],
[
"Peginterferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
]
],
[
[
"Nintedanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
]
],
[
[
"Nintedanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Duvelisib"
]
],
[
[
"Nintedanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Duvelisib"
]
],
[
[
"Nintedanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Duvelisib"
]
],
[
[
"Nintedanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Duvelisib"
]
]
] | Nintedanib may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Nintedanib may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Nintedanib may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Nintedanib may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Nintedanib may lead to a major life threatening interaction when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Nintedanib may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Duvelisib
Nintedanib may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may lead to a major life threatening interaction when taken with Duvelisib
Nintedanib may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Duvelisib
Nintedanib may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Duvelisib |
DB00334 | DB00938 | 867 | 455 | [
"DDInter1326",
"DDInter1635"
] | Olanzapine | Salmeterol | Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug interactions. Olanzapine very closely resembles [clozapine] and only differs by two additional methyl groups and the absence of a chloride moiety. It was discovered by scientists at Eli Lilly and approved to be marketed in the US in 1996. | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salmeterol was first described in the literature in 1988. Salmeterol's structure is similar to salbutamol's with an aralkyloxy-alkyl substitution on the amine. Salmeterol was granted FDA approval on 4 February 1994. | Moderate | 1 | [
[
[
867,
24,
455
]
],
[
[
867,
24,
688
],
[
688,
63,
455
]
],
[
[
867,
6,
8374
],
[
8374,
45,
455
]
],
[
[
867,
24,
1144
],
[
1144,
24,
455
]
],
[
[
867,
63,
600
],
[
600,
24,
455
]
],
[
[
867,
1,
87
],
[
87,
24,
455
]
],
[
[
867,
1,
623
],
[
623,
63,
455
]
],
[
[
867,
24,
877
],
[
877,
64,
455
]
],
[
[
867,
24,
688
],
[
688,
64,
1523
],
[
1523,
25,
455
]
],
[
[
867,
6,
8374
],
[
8374,
45,
688
],
[
688,
63,
455
]
]
] | [
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Olanzapine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Salmeterol"
]
],
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Olanzapine",
"{u} (Compound) resembles {v} (Compound)",
"Amoxapine"
],
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Olanzapine",
"{u} (Compound) resembles {v} (Compound)",
"Quetiapine"
],
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
],
[
"Macimorelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Salmeterol"
]
],
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
[
"Salbutamol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Labetalol"
],
[
"Labetalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Salmeterol"
]
],
[
[
"Olanzapine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Salbutamol"
],
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
]
] | Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Olanzapine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Salmeterol (Compound)
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Olanzapine (Compound) resembles Amoxapine (Compound) and Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Olanzapine (Compound) resembles Quetiapine (Compound) and Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin and Macimorelin may lead to a major life threatening interaction when taken with Salmeterol
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may lead to a major life threatening interaction when taken with Labetalol and Labetalol may lead to a major life threatening interaction when taken with Salmeterol
Olanzapine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Salbutamol (Compound) and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol |
DB00295 | DB00575 | 475 | 1,020 | [
"DDInter1244",
"DDInter412"
] | Morphine | Clonidine | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [fentanyl], [methadone], [hydrocodone], [hydromorphone], [meperidine], and [oxycodone]. Morphine was granted FDA approval in 1941. | Clonidine is an imidazole derivate that acts as an agonist of alpha-2 adrenoceptors. This activity is useful for the treatment of hypertension, severe pain, and ADHD.[L7237,L7240,L7243,L7246] Clonidine was granted FDA approval on 3 September 1974. | Moderate | 1 | [
[
[
475,
24,
1020
]
],
[
[
475,
24,
1617
],
[
1617,
40,
1020
]
],
[
[
475,
25,
876
],
[
876,
40,
1020
]
],
[
[
475,
6,
8374
],
[
8374,
45,
1020
]
],
[
[
475,
21,
28810
],
[
28810,
60,
1020
]
],
[
[
475,
24,
1311
],
[
1311,
63,
1020
]
],
[
[
475,
63,
701
],
[
701,
24,
1020
]
],
[
[
475,
24,
128
],
[
128,
24,
1020
]
],
[
[
475,
25,
593
],
[
593,
63,
1020
]
],
[
[
475,
24,
1264
],
[
1264,
64,
1020
]
]
] | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clonidine"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apraclonidine"
],
[
"Apraclonidine",
"{u} (Compound) resembles {v} (Compound)",
"Clonidine"
]
],
[
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tizanidine"
],
[
"Tizanidine",
"{u} (Compound) resembles {v} (Compound)",
"Clonidine"
]
],
[
[
"Morphine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Clonidine"
]
],
[
[
"Morphine",
"{u} (Compound) causes {v} (Side Effect)",
"Gastrointestinal pain"
],
[
"Gastrointestinal pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Clonidine"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clonidine"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clonidine"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
],
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clonidine"
]
],
[
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clonidine"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clonidine"
]
]
] | Morphine may cause a moderate interaction that could exacerbate diseases when taken with Apraclonidine and Apraclonidine (Compound) resembles Clonidine (Compound)
Morphine may lead to a major life threatening interaction when taken with Tizanidine and Tizanidine (Compound) resembles Clonidine (Compound)
Morphine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Clonidine (Compound)
Morphine (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by Clonidine (Compound)
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Clonidine
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Clonidine
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Clonidine
Morphine may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Clonidine
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may lead to a major life threatening interaction when taken with Clonidine |
DB00872 | DB08865 | 1,080 | 1,593 | [
"DDInter438",
"DDInter448"
] | Conivaptan | Crizotinib | Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement. Crizotinib was the first-in-class drug used to treat ALK-positive tumors. Second- and third-generation ALK-tyrosine kinase-inhibitors have overcome many of the pharmacodynamic and genetic resistance mechanisms crizotinib is prone to. Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used to detect ALK and ROS1 rearrangements. | Major | 2 | [
[
[
1080,
25,
1593
]
],
[
[
1080,
6,
8374
],
[
8374,
45,
1593
]
],
[
[
1080,
21,
28792
],
[
28792,
60,
1593
]
],
[
[
1080,
25,
283
],
[
283,
62,
1593
]
],
[
[
1080,
24,
466
],
[
466,
62,
1593
]
],
[
[
1080,
63,
883
],
[
883,
24,
1593
]
],
[
[
1080,
25,
1409
],
[
1409,
24,
1593
]
],
[
[
1080,
24,
710
],
[
710,
63,
1593
]
],
[
[
1080,
24,
309
],
[
309,
24,
1593
]
],
[
[
1080,
1,
165
],
[
165,
24,
1593
]
]
] | [
[
[
"Conivaptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
],
[
[
"Conivaptan",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Crizotinib"
]
],
[
[
"Conivaptan",
"{u} (Compound) causes {v} (Side Effect)",
"Gastrointestinal disorder"
],
[
"Gastrointestinal disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Crizotinib"
]
],
[
[
"Conivaptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Crizotinib"
]
],
[
[
"Conivaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Crizotinib"
]
],
[
[
"Conivaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
],
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Conivaptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
],
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Conivaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
],
[
"Binimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Conivaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
],
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Conivaptan",
"{u} (Compound) resembles {v} (Compound)",
"Tolvaptan"
],
[
"Tolvaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
]
] | Conivaptan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Conivaptan (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Crizotinib (Compound)
Conivaptan may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Crizotinib
Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Crizotinib
Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Conivaptan may lead to a major life threatening interaction when taken with Apixaban and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib and Binimetinib may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone and Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Conivaptan (Compound) resembles Tolvaptan (Compound) and Tolvaptan may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib |
DB04868 | DB10989 | 478 | 496 | [
"DDInter1293",
"DDInter858"
] | Nilotinib | Hepatitis A Vaccine | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor used as a first-line treatment for CML. | Hepatitis A viral infection can lead to significant morbidity and mortality, with signs and symptoms that include anorexia, nausea, vomiting, and liver failure. Known by several trade names, such as Havrix and Twinrix, the Hepatitis A vaccine has been formulated for immunization against hepatitis A virus (HAV) infection and safely confers strong protection against the disease caused by infection with this virus.[A199185,L12756] In the US, the approved vaccine is inactivated while live Hepatitis A vaccines are currently available in other countries. | Moderate | 1 | [
[
[
478,
24,
496
]
],
[
[
478,
63,
4
],
[
4,
24,
496
]
],
[
[
478,
24,
850
],
[
850,
24,
496
]
],
[
[
478,
24,
738
],
[
738,
63,
496
]
],
[
[
478,
64,
77
],
[
77,
24,
496
]
],
[
[
478,
74,
1419
],
[
1419,
24,
496
]
],
[
[
478,
25,
976
],
[
976,
24,
496
]
],
[
[
478,
25,
676
],
[
676,
63,
496
]
],
[
[
478,
63,
4
],
[
4,
24,
1093
],
[
1093,
63,
496
]
],
[
[
478,
24,
850
],
[
850,
63,
4
],
[
4,
24,
496
]
]
] | [
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idarubicin"
],
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Nilotinib",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
],
[
"Ixekizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
]
] | Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Nilotinib may lead to a major life threatening interaction when taken with Idarubicin and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Nilotinib (Compound) resembles Imatinib (Compound) and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Nilotinib may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Nilotinib may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab and Ixekizumab may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine |
DB00213 | DB00436 | 837 | 323 | [
"DDInter1388",
"DDInter179"
] | Pantoprazole | Bendroflumethiazide | Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome. It can also be found in quadruple regimens for the treatment of _H. pylori_ infections along with other antibiotics including [amoxicillin], [clarithromycin], and [metronidazole], for example. Its efficacy is considered similar to other medications within the PPI class including [omeprazole], [esomeprazole], [lansoprazole], [dexlansoprazole], and [rabeprazole]. Pantoprazole exerts its stomach acid-suppressing effects by preventing the final step in gastric acid production by covalently binding to sulfhydryl groups | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810) | Moderate | 1 | [
[
[
837,
24,
323
]
],
[
[
837,
24,
1014
],
[
1014,
1,
323
]
],
[
[
837,
21,
28766
],
[
28766,
60,
323
]
],
[
[
837,
24,
126
],
[
126,
62,
323
]
],
[
[
837,
24,
1287
],
[
1287,
63,
323
]
],
[
[
837,
1,
660
],
[
660,
63,
323
]
],
[
[
837,
25,
663
],
[
663,
63,
323
]
],
[
[
837,
24,
1014
],
[
1014,
40,
504
],
[
504,
1,
323
]
],
[
[
837,
24,
504
],
[
504,
1,
1014
],
[
1014,
1,
323
]
],
[
[
837,
21,
28766
],
[
28766,
60,
504
],
[
504,
1,
323
]
]
] | [
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bendroflumethiazide"
]
],
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzthiazide"
],
[
"Benzthiazide",
"{u} (Compound) resembles {v} (Compound)",
"Bendroflumethiazide"
]
],
[
[
"Pantoprazole",
"{u} (Compound) causes {v} (Side Effect)",
"Hypotension"
],
[
"Hypotension",
"{u} (Side Effect) is caused by {v} (Compound)",
"Bendroflumethiazide"
]
],
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bendroflumethiazide"
]
],
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amphotericin B"
],
[
"Amphotericin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bendroflumethiazide"
]
],
[
[
"Pantoprazole",
"{u} (Compound) resembles {v} (Compound)",
"Esomeprazole"
],
[
"Esomeprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bendroflumethiazide"
]
],
[
[
"Pantoprazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bendroflumethiazide"
]
],
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzthiazide"
],
[
"Benzthiazide",
"{u} (Compound) resembles {v} (Compound)",
"Hydrochlorothiazide"
],
[
"Hydrochlorothiazide",
"{u} (Compound) resembles {v} (Compound)",
"Bendroflumethiazide"
]
],
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrochlorothiazide"
],
[
"Hydrochlorothiazide",
"{u} (Compound) resembles {v} (Compound)",
"Benzthiazide"
],
[
"Benzthiazide",
"{u} (Compound) resembles {v} (Compound)",
"Bendroflumethiazide"
]
],
[
[
"Pantoprazole",
"{u} (Compound) causes {v} (Side Effect)",
"Hypotension"
],
[
"Hypotension",
"{u} (Side Effect) is caused by {v} (Compound)",
"Hydrochlorothiazide"
],
[
"Hydrochlorothiazide",
"{u} (Compound) resembles {v} (Compound)",
"Bendroflumethiazide"
]
]
] | Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Benzthiazide and Benzthiazide (Compound) resembles Bendroflumethiazide (Compound)
Pantoprazole (Compound) causes Hypotension (Side Effect) and Hypotension (Side Effect) is caused by Bendroflumethiazide (Compound)
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Bendroflumethiazide
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Amphotericin B and Amphotericin B may cause a moderate interaction that could exacerbate diseases when taken with Bendroflumethiazide
Pantoprazole (Compound) resembles Esomeprazole (Compound) and Esomeprazole may cause a moderate interaction that could exacerbate diseases when taken with Bendroflumethiazide
Pantoprazole may lead to a major life threatening interaction when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Bendroflumethiazide
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Benzthiazide and Benzthiazide (Compound) resembles Hydrochlorothiazide (Compound) and Hydrochlorothiazide (Compound) resembles Bendroflumethiazide (Compound)
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Hydrochlorothiazide and Hydrochlorothiazide (Compound) resembles Benzthiazide (Compound) and Benzthiazide (Compound) resembles Bendroflumethiazide (Compound)
Pantoprazole (Compound) causes Hypotension (Side Effect) and Hypotension (Side Effect) is caused by Hydrochlorothiazide (Compound) and Hydrochlorothiazide (Compound) resembles Bendroflumethiazide (Compound) |
DB04948 | DB12332 | 1,084 | 1,619 | [
"DDInter1083",
"DDInter1626"
] | Lofexidine | Rucaparib | Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hypertension than clonidine. Lofexidine was then repurposed for the treatment of opioid withdrawal, as it was seen to be more economical and have fewer side effects than clonidine. Lofexidine was developed by US Woldmeds LLC and it was approved by the FDA on May 16, 2018. | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the genetically-mutated cancer cells that lack a DNA repair mechanism, rucaparib causes cancer cell death and reduces tumour growth.[A18745,A31354] Rucaparib was granted FDA Breakthrough Therapy designation in April 2015 and accelerated approval in December 2016. The drug was later approved by the European Commission in May 2018. It is currently used to treat recurrent ovarian and prostate cancer in adults.[L42155,L42185] | Moderate | 1 | [
[
[
1084,
24,
1619
]
],
[
[
1084,
63,
222
],
[
222,
23,
1619
]
],
[
[
1084,
62,
112
],
[
112,
23,
1619
]
],
[
[
1084,
24,
1662
],
[
1662,
24,
1619
]
],
[
[
1084,
63,
888
],
[
888,
24,
1619
]
],
[
[
1084,
64,
1166
],
[
1166,
25,
1619
]
],
[
[
1084,
25,
1593
],
[
1593,
25,
1619
]
],
[
[
1084,
24,
976
],
[
976,
25,
1619
]
],
[
[
1084,
25,
982
],
[
982,
64,
1619
]
],
[
[
1084,
63,
222
],
[
222,
63,
1407
],
[
1407,
24,
1619
]
]
] | [
[
[
"Lofexidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Lofexidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rucaparib"
]
],
[
[
"Lofexidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rucaparib"
]
],
[
[
"Lofexidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
],
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Lofexidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Lofexidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolasetron"
],
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
]
],
[
[
"Lofexidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
]
],
[
[
"Lofexidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
]
],
[
[
"Lofexidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
]
],
[
[
"Lofexidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eszopiclone"
],
[
"Eszopiclone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
]
] | Lofexidine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Lofexidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Lofexidine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Lofexidine may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Lofexidine may lead to a major life threatening interaction when taken with Dolasetron and Dolasetron may lead to a major life threatening interaction when taken with Rucaparib
Lofexidine may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may lead to a major life threatening interaction when taken with Rucaparib
Lofexidine may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitinib may lead to a major life threatening interaction when taken with Rucaparib
Lofexidine may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Rucaparib
Lofexidine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Eszopiclone and Eszopiclone may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib |
DB00619 | DB00745 | 1,419 | 307 | [
"DDInter909",
"DDInter1236"
] | Imatinib | Modafinil | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy".. The discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient. Imatinib was approved on February 1st,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751] | Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron activation is associated with psychoactivation and euphoria. The exact mechanism of action is unclear, although in vitro studies have shown it to inhibit the reuptake of dopamine by binding to the dopamine reuptake pump, and lead to an increase in extracellular dopamine. Modafinil activates glutamatergic circuits while inhibiting GABA. | Minor | 0 | [
[
[
1419,
23,
307
]
],
[
[
1419,
25,
704
],
[
704,
40,
307
]
],
[
[
1419,
64,
362
],
[
362,
40,
307
]
],
[
[
1419,
63,
847
],
[
847,
40,
307
]
],
[
[
1419,
24,
998
],
[
998,
40,
307
]
],
[
[
1419,
6,
7950
],
[
7950,
45,
307
]
],
[
[
1419,
21,
28898
],
[
28898,
60,
307
]
],
[
[
1419,
63,
450
],
[
450,
23,
307
]
],
[
[
1419,
24,
1557
],
[
1557,
23,
307
]
],
[
[
1419,
24,
1250
],
[
1250,
62,
307
]
]
] | [
[
[
"Imatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
]
],
[
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fentanyl"
],
[
"Fentanyl",
"{u} (Compound) resembles {v} (Compound)",
"Modafinil"
]
],
[
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} (Compound) resembles {v} (Compound)",
"Modafinil"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atomoxetine"
],
[
"Atomoxetine",
"{u} (Compound) resembles {v} (Compound)",
"Modafinil"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylbutazone"
],
[
"Phenylbutazone",
"{u} (Compound) resembles {v} (Compound)",
"Modafinil"
]
],
[
[
"Imatinib",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Modafinil"
]
],
[
[
"Imatinib",
"{u} (Compound) causes {v} (Side Effect)",
"Constipation"
],
[
"Constipation",
"{u} (Side Effect) is caused by {v} (Compound)",
"Modafinil"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Astemizole"
],
[
"Astemizole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
],
[
"Pazopanib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
]
]
] | Imatinib may lead to a major life threatening interaction when taken with Fentanyl and Fentanyl (Compound) resembles Modafinil (Compound)
Imatinib may lead to a major life threatening interaction when taken with Phenytoin and Phenytoin (Compound) resembles Modafinil (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Atomoxetine and Atomoxetine (Compound) resembles Modafinil (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Phenylbutazone and Phenylbutazone (Compound) resembles Modafinil (Compound)
Imatinib (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Modafinil (Compound)
Imatinib (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Modafinil (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Cyclophosphamide and Cyclophosphamide may cause a minor interaction that can limit clinical effects when taken with Modafinil
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Astemizole and Astemizole may cause a minor interaction that can limit clinical effects when taken with Modafinil
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may cause a minor interaction that can limit clinical effects when taken with Modafinil |
DB00279 | DB01357 | 1,152 | 890 | [
"DDInter1074",
"DDInter1160"
] | Liothyronine | Mestranol | Liothyronine is a thyroidal hormone T3 which is normally produced by the thyroid gland in a ratio 4:1 when compared with T4: T3. Liothyronine is the active form of thyroxine which is composed in a basic chemical structure by a tyrosine with bound iodine. The exogenous liothyronine product was developed by King Pharmaceuticals and FDA approved in 1956. | The 3-methyl ether of ethinyl estradiol. It must be demethylated to be biologically active. It is used as the estrogen component of many combination ORAL contraceptives. | Moderate | 1 | [
[
[
1152,
24,
890
]
],
[
[
1152,
24,
35
],
[
35,
40,
890
]
],
[
[
1152,
24,
559
],
[
559,
1,
890
]
],
[
[
1152,
24,
1264
],
[
1264,
23,
890
]
],
[
[
1152,
63,
1324
],
[
1324,
24,
890
]
],
[
[
1152,
24,
126
],
[
126,
24,
890
]
],
[
[
1152,
1,
542
],
[
542,
24,
890
]
],
[
[
1152,
24,
35
],
[
35,
40,
1197
],
[
1197,
40,
890
]
],
[
[
1152,
24,
380
],
[
380,
1,
1417
],
[
1417,
40,
890
]
],
[
[
1152,
24,
1264
],
[
1264,
23,
35
],
[
35,
40,
890
]
]
] | [
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mestranol"
]
],
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinestrol"
],
[
"Quinestrol",
"{u} (Compound) resembles {v} (Compound)",
"Mestranol"
]
],
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estrone"
],
[
"Estrone",
"{u} (Compound) resembles {v} (Compound)",
"Mestranol"
]
],
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mestranol"
]
],
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mestranol"
]
],
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mestranol"
]
],
[
[
"Liothyronine",
"{u} (Compound) resembles {v} (Compound)",
"Levothyroxine"
],
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mestranol"
]
],
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinestrol"
],
[
"Quinestrol",
"{u} (Compound) resembles {v} (Compound)",
"Norethisterone"
],
[
"Norethisterone",
"{u} (Compound) resembles {v} (Compound)",
"Mestranol"
]
],
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Conjugated estrogens"
],
[
"Conjugated estrogens",
"{u} (Compound) resembles {v} (Compound)",
"Estramustine"
],
[
"Estramustine",
"{u} (Compound) resembles {v} (Compound)",
"Mestranol"
]
],
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Quinestrol"
],
[
"Quinestrol",
"{u} (Compound) resembles {v} (Compound)",
"Mestranol"
]
]
] | Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Quinestrol and Quinestrol (Compound) resembles Mestranol (Compound)
Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Estrone and Estrone (Compound) resembles Mestranol (Compound)
Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a minor interaction that can limit clinical effects when taken with Mestranol
Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Mestranol
Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Mestranol
Liothyronine (Compound) resembles Levothyroxine (Compound) and Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Mestranol
Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Quinestrol and Quinestrol (Compound) resembles Norethisterone (Compound) and Norethisterone (Compound) resembles Mestranol (Compound)
Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Conjugated estrogens and Conjugated estrogens (Compound) resembles Estramustine (Compound) and Estramustine (Compound) resembles Mestranol (Compound)
Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a minor interaction that can limit clinical effects when taken with Quinestrol and Quinestrol (Compound) resembles Mestranol (Compound) |
DB00694 | DB11988 | 51 | 270 | [
"DDInter485",
"DDInter1321"
] | Daunorubicin | Ocrelizumab | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-humanized CD20 antibodies such as [rituximab], ocrelizumab is expected to be less immunogenic with repeated infusions, improving the benefit-to-risk profile for patients with MS.[A18875,A251745] MS is a chronic, inflammatory, autoimmune disease of the central nervous system that leads to neurological disabilities and a significantly reduced quality of life. Most patients with MS experience episodes of relapses with worsening function, followed by recovery periods or remissions. Primary progressive multiple sclerosis (PPMS) accounts for 10-15% of the overall population of patients with MS, and leads to the gradual worsening of neurologic disability from symptom onset, often without early relapses or remissions . Developed by Genentech/Roche, ocrelizumab was approved by the FDA in March 2017 under the market name Ocrevus for intravenous injection. It was later approved by Health Canada in August 2017, making the drug the first available treatment for PPMS in both the US and Canada. In clinical trials of patients with relapsing forms of MS, treatment with ocrelizumab resulted in reduced relapse rates and reduced worsening of disability compared to [interferon beta-1a]. In phase 3 clinical trials of patients with PPMS, treatment with ocrelizumab led to lower clinical and MRI progression rates compared to placebo. | Moderate | 1 | [
[
[
51,
24,
270
]
],
[
[
51,
63,
1461
],
[
1461,
23,
270
]
],
[
[
51,
63,
134
],
[
134,
24,
270
]
],
[
[
51,
24,
1491
],
[
1491,
24,
270
]
],
[
[
51,
24,
287
],
[
287,
63,
270
]
],
[
[
51,
25,
770
],
[
770,
24,
270
]
],
[
[
51,
64,
550
],
[
550,
24,
270
]
],
[
[
51,
74,
322
],
[
322,
24,
270
]
],
[
[
51,
35,
77
],
[
77,
24,
270
]
],
[
[
51,
25,
962
],
[
962,
25,
270
]
]
] | [
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
],
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
],
[
"Diroximel fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Daunorubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Daunorubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trastuzumab"
],
[
"Trastuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Daunorubicin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Daunorubicin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
],
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Daunorubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
],
[
"Bacillus calmette-guerin substrain tice live antigen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ocrelizumab"
]
]
] | Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ocrelizumab
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate and Diroximel fumarate may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Daunorubicin may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Daunorubicin may lead to a major life threatening interaction when taken with Trastuzumab and Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Daunorubicin (Compound) resembles Epirubicin (Compound) and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Daunorubicin (Compound) resembles Idarubicin (Compound) and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Daunorubicin may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen and Bacillus calmette-guerin substrain tice live antigen may lead to a major life threatening interaction when taken with Ocrelizumab |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.